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Abstract 
Developing neurones require a dynamic cytoskeleton for newly forming processes to 
respond to guidance cues. The Rho GTPases, including Rac1, are very important in 
cytoskeleton remodelling. A GTPase activating protein (GAP) for Rac1, α2-chimaerin, 
participates in  Semaphorin 3A (Sema 3A) and ephrin/EphA4 growth cone collapse 
pathways, and the SH2 domain is essential, suggesting phosphotyrosine interactions are 
involved. The activation of α2-chimaerin in collapse pathways may be through 
diacylglycerol binding to the cysteine rich C1 domain or via phosphotyrosine signalling. 
This investigation explores the interactions of α2-chimaerin and the role of tyrosine 
phosphorylation in retraction signalling pathways.  
The Src family tyrosine kinase, Fyn, is involved in Sema 3A and ephrin A1/EphA4 
signalling. Results showed that Fyn can bind to the GAP domain of α2-chimaerin and can 
phosphorylate α2-chimaerin activated by phorbol 12-myristate 13-acetate, Sema 3A or 
ephrin A1. Fyn was found to phosphorylate tyrosines 143 and 303 of α2-chimaerin. Over-
expression of α2-chimaerin led to increased axon number in hippocampal neurones. 
Selected point mutations of α2-chimaerin were sufficient to affect axon branching in 
developing hippocampal neurones. 
In COS-7 cells, the receptor EphA4 interacted with α2-chimaerin GAP domain when un-
stimulated and with the SH2 domain when stimulated with the ligand ephrin A1. In N1E-
115 cells permanently expressing EphA4, α2-chimaerin shRNA inhibited ephrin A1-
induced cell rounding. The SH2 and C1 domains of α2-chimaerin were both necessary 
for ephrin A1/EphA4 cell rounding. 
 4 
Another partner of α2-chimaerin is adaptor protein Nck1. The α2-chimaerin Nck1 
binding region has been mapped and the binding may be sufficient to activate α2-
chimaerin, allowing other partners to interact. A novel α2-chimaerin interacting protein 
Vps28, a component of the endosomal sorting complex required for transport-I, has been 
investigated in endocytosis using monoclonal antibodies and shRNA. These results 
together suggest an important regulatory role for α2-chimaerin and its partners in axonal 
guidance pathways. 
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1.0 Introduction 
 
In brain development, neuronal cells originate from proliferative layers of progenitor 
cells from which they migrate to their final positions and differentiate, acquiring distinct 
neuronal identities and connections (Donahoo and Richards, 2009; Kwan et. al., 2012). 
As neurogenesis progresses, neurones are generated sequentially and migration occurs in 
an inside-first, outside-last manner. Mechanisms regulating neuronal migration include 
cell-cell interactions and cytsokeletal dynamics. The actin and microtubule cytoskeleton, 
the cellular scaffolding, forms dynamic structures allowing individual neurone subtypes 
to differentiate and develop complex morphology. Neurones form a highly ordered 
network of connectivity in the adult central and peripheral nervous system, supported by 
non-neuronal glial cells, including oligodendrocytes, astrocytes and Schwann cells. 
Developing axons and dendrites respond to specific guidance signals. Attractive and 
repulsive signalling molecules are displayed by neighbouring cells, secreted soluble 
factors or in the extracellular matrix. Their various membrane receptors activate 
intracellular signalling pathways, transmitting the external guidance stimulus to proteins 
that reorganise the cytoskeleton. Intracellular signalling pathways involve multiple 
proteins including the Rho GTPase family of proteins, which act as molecular switches. 
Rac1 is a member and like the rest of the RhoGTPase family its interactions and 
functions are tightly regulated by GTPase activating proteins (GAPs) and Guanine-
nucleotide exchange factors (GEFs). The Rho GTPases act via a range of effector 
proteins playing a pivotal role in coordinating dynamic changes in the actin cytoskeleton.  
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This study investigates α2-chimaerin, a neuronal GAP specific for Rac1 which enhances 
intrinsic Rac GTPase activity, thereby down-regulating Rac1. GAPs are themselves 
tightly regulated multi-domain signalling proteins. This study aims to investigate α2-
chimaerin regulation and interactions with partner proteins that contribute to the complex 
orchestration of repulsive guidance pathways in developing neurones. 
 
1.1 The Cytoskeleton 
 
The cytoskeleton comprises three major components; actin filaments, microtubules and 
intermediate filaments and is crucial in many dynamic cell processes. These include cell 
motility, cell polarity, cell division, intracellular trafficking and endocytosis (Pollard and 
Cooper, 2009).  
 
1.1.1 Actin Filaments 
Actin assembly provides a force for re-shaping cells and cell movement. Monomeric 
globular (G-actin) polymerises to form filamentous actin (F-actin). Actin filaments are 
polar structures with a slow growing pointed end and a fast growing barbed end and are 
mainly cross-linked into aggregates and bundles. During polymerisation ATP-actin joins 
the barbed end of a filament, the ATP molecule is hydrolysed causing a conformational 
change and trapping ADP inside the actin monomer (Pollard et. al., 2000). Although ATP 
bound to actin stabilises the molecule, it is not required for polymerisation as such, but 
seems to indicate filament age and initiate processes for depolymerisation (Pollard and 
Borisy, 2003).  
Treadmilling, first described by Wegner in 1976, occurs as ATP-bound actin joins 
filaments at the barbed end and ADP-bound actin dissociates from the pointed end at the 
 22 
same rate, due to ATP-actin and ADP-actin having the same kinetic constant (Frederick 
et. al., 2008). Treadmilling is a slow process that has been visualised by fluorescence 
microscopy (Fujiwara et. al., 2002) and therefore other factors, such as actin binding 
proteins, are required to regulate polymerisation and accelerate the process in migrating 
cells (Pollard and Borisy, 2003).  
At the leading edge of migrating cells, the barbed ends of actin filaments drive 
lamellipodia (sheet-like) and filopodia (rod-like) extensions. Actin filaments found in 
lamellipodia are short and highly branched. In contrast, filopodia consist of longer, un-
branched, unipolar, parallel bundles of actin filaments (Le Clainche and Carlier, 2008). 
Protrusion of the leading edge is driven by the lamellipodium and the lamella (Svitkina 
and Borisy, 1999). Fluorescence speckle microscopy studies have shown these two 
distinct but overlapping actin systems at work, with the lamellipodium as fast but short-
lived speckles and the lamella as slow-moving, longer-lived speckles (Ponti et. al., 2004; 
Iwasa and Mullins, 2007). The formation of lamellipodia and filopodia in the same area 
of the cell may be explained by two different nucleation mechanisms involving the 
Arp2/3 complex and formins, creating two actin networks (Le Clainche and Carlier, 
2008). 
The Arp2/3 complex comprises seven proteins, actin-related Arp2 and Arp3 and ARPC1-
5 (Machesky et. al., 1994). In its purified form Arp2/3 cross-links the pointed end of one 
actin filament to the side of another filament at a 70 degree Y-branch angle (Mullins et. 
al., 1998). Like actin, Arp2 and Arp3 bind to ATP, causing conformational changes to 
the Arp2/3 complex (Goley et. al., 2004; Zencheck et. al., 2009). 
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The Arp2/3 complex is a weak actin nucleator, but it can be activated by nucleotide 
binding and interactions with nucleation promoting factors (NPFs), such as the WASp 
(Wiskott-Aldrich Syndrome protein)/Scar family, of which there are five members, 
WASp, N-WASP (Neural-Wiskott-Aldrich Syndrome Protein) and Scar/WAVE (WASP 
family verprolin homologous protein) proteins 1-3 (Higgs, 2001). The majority of 
mammalian NPFs, including the WASp/Scar family, activate the Arp2/3 complex 
through a VCA domain. This consists of a WASP-homology-2 or verprolin homology 
domain which binds G-actin, a central region, and an acidic region which interacts with 
the Arp2/3 complex (Campellone and Welch, 2010). Other domains of N-WASP interact 
directly with Cdc42 (via the CRIB domain/GTPase binding domain (GBD)) (Aspenstrom 
et. al., 1996), Phosphatidylinositol Phosphate2 (PIP2) (to the basic region) (Miki et. al., 
1996) and Src Homology (SH)3 domain proteins including Nck (via the proline rich 
region) (Rivero-Lezcano et. al., 1995). N-WASP is auto-inhibited through association of 
GBD with VCA unless activated by multiple inputs, including Cdc42 (Padrick and 
Rosen, 2010). WAVE acts downstream of Rac1, stimulating the Arp2/3 complex (Miki 
et. al., 1998). WAVE proteins are constitutively part of a complex with PIR121 (also 
known as Sra1 or CYFIP2), Nck associated protein 1, Abelson (Abl) interacting protein 
and HSPC300 (Innocenti et. al., 2004), in which inhibition of WAVE by PIR121 is 
relieved by active Rac, and WAVE is also phosphorylated (Chen et. al., 2010).  
In contrast to the Arp2/3 complex, other actin nucleators produce linear filaments, the 
most studied of these being the formins. The formins contain conserved formin-
homology domains FH1 and FH2 and alternatively from the Arp2/3 complex, catalyse 
polymerisation of filaments at the barbed end. It has been suggested that formins promote 
 24 
polymerisation by stabilising spontaneously formed actin dimers/trimers (Pring et. al., 
2003). More recent additions to identified nucleators involved in actin monomer 
recruitment to filaments include Spire, Cordon bleu and Leiomodin (Chesarone and 
Goode, 2009).  
Rho-family GTPases are extremely important in actin dynamics, acting through their 
many effector proteins which include NPFs and kinases, and they play a key role in NPF 
regulation (Section 1.3). Early studies showed Rho is responsible for the formation of 
stress fibres and focal adhesions, Rac for lamellipodia and ruffles (Ridley et. al., 1992; 
Ridley and Hall, 1992), and Cdc42 for formation of filopodia (Nobes and Hall, 1995; 
Kozma et. al., 1995). The cellular activities of the RhoGTPases are spatially and 
temporally co-ordinated. Recently, a live-cell study of RhoA, Rac and Cdc42 activation 
suggests Rho acts transiently to initiate protrusive events with sequential activation of 
Cdc42 and Rac (Machacek et. al., 2009). 
 
1.1.2 Actin-Binding Proteins 
In addition to the Arp2/3 complex, formins and the newer actin nucleators, there are 
hundreds of other actin-binding proteins, with functions involved in forming, stabilising 
and depolymerising actin structures (Dominguez, 2009). Amongst these are Actin-
depolymerisation factor (ADF) and cofilin, which are involved in severing actin filaments 
and the rapid turnover of actin filament barbed ends that drive forward the leading edge 
of cells (Carlier et. al., 1999). Profilin is an actin monomer binding protein which 
enhances the exchange of ADP to ATP and the rate of actin treadmilling (Yarmola and 
Bubb, 2006). Gelsolin and Capping Protein work together to regulate the barbed end of 
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actin filaments (Barkalow et. al., 1996). Cross-linking proteins, such as tropomyosin, 
strengthen actin filaments by binding along the length of a filament. Fimbrin and α-
actinin bundle filaments and spectrin attaches the sides of filaments to the plasma 
membrane (Uribe and Jay, 2009). Myosins I, V and VI are motor proteins implicated in 
movement of vesicles in the actin cortex (Eichler et. al., 2006; Buss and Kendrick-Jones, 
2008; Kim and Flavell, 2008). Focal contacts, points of cell attachment and signalling 
complexes, are controlled by the integrin family of proteins, including talin and vinculin, 
which also associates with α-actinin. Tyrosine kinases Src and focal adhesion kinase 
(FAK) are involved in focal contact formation (Section 1.3.4). 
 
1.1.3 Microtubules 
Microtubules are made up of GTP-binding α- and β-tubulin heterodimers that form 
polarised helical structures, which can be stabilised by the pointed end joining a 
microtubule organising centre (MTOC) (Desai and Mitchison, 1997). Microtubules play a 
major role in cell polarisation. In hippocampal neurones, microtubules in axons are 
arranged in a uniform polarity with the barbed end directed towards the growth cone, 
whereas microtubules in dendrites contain a mixed orientation of polarity (Baas et. al., 
1988). Axons also contain more stable acetylated microtubules, whilst dendritic 
microtubules are less stable and more dynamic (Witte and Bradke, 2008). In developing 
neurones, microtubules stabilize in one neurite which then goes on to become the axon 
(Witte et. al., 2008). 
Microtubule-associated proteins (MAPs) are important in microtubule dynamics and in 
mediating microtubule interactions. There are two major classes of MAPs; high 
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molecular weight proteins of 100-200 kDa, MAP-1 and MAP-2, and Tau proteins, which 
have molecular weights of around 60 kDa. Both classes of protein contain a microtubule 
binding domain and a domain which links microtubules to other cell components. 
Neuronal MAPs bind to microtubules and crosslink adjacent tubulin subunits to stabilise 
the structures and promote the polymerisation phase (Desai and Mitchison, 1997). Tau is 
mainly located in axons with the more stable microtubules and MAP-2 is associated with 
dendritric microtubules (Mandelkow and Mandelkow, 1995). A further class of 
microtubule associated protein are collapsin response mediator proteins (CRMP1-5). 
These dihydropyrimidinase related proteins promote axon outgrowth and play a role in 
microtubule stability (Inagaki et. al, 2001). CRMP-2 C-terminal is phosphorylated by 
Cyclin dependent kinase (Cdk) 5 and Glycogen Synthase Kinase (GSK)-3β (Brown et. 
al., 2004; Uchida et. al., 2005). The interaction of CRMP-2 with microtubules is 
dynamically regulated through phosphorylation (Lin et. al., 2011) similarly to Tau 
(Mandelkow and Mandelkow, 2012). CRMP-2 is an α2-chimaerin binding partner 
(Brown et. al., 2004). 
  
1.1.4 Intermediate Filaments 
In contrast to globular actin and tubulin monomers, intermediate filament (IF) proteins 
are apolar and highly elongated polymers of fibrous proteins. IFs provide mechanical 
strength and stability to the cell by cross linking to each other, to microtubules and to 
actin via plectin or spectrins, helping to protect cells against mechanical stresses 
(Svitkina et. al., 1996). IFs differ between cell types, for example, the main IF in 
astrocytes is glial fibrillary acidic protein (Liem and Messing, 2009). Neuronal cell IFs 
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consist of three proteins, NF (neurofilament)-L, which provides the backbone of the 
neurofilament for NF-M and NF-H (Fuchs and Cleveland, 1998), and α-internexin 
(Fliegner et. al., 1990; Kaplan et. al., 1990). Septins are a family of filament forming 
GTP-binding proteins, which bind to membranes, actin and microtubules to stabilise cells 
and participate in cellular processes involving the cytoskeleton (Silverman-Gavrila and 
Silverman-Gavrila, 2008). 
 
1.2 Protein Phosphorylation and Signal Transduction 
Post-translational protein modifications provide transient regulation of protein-protein 
interactions in signal transduction. Phosphorylation is the commonest modification, 
causing conformational changes, activation or deactivation and regulating or promoting 
binding sites (Ubersax and Ferrell, 2007). There are several hundred kinases which 
phosphorylate tyrosine or serine and threonine residues (Chico et. al., 2009). 
 
1.2.1 Receptor Tyrosine Kinases 
Receptor tyrosine kinases (RTKs) are an important class of receptor for guidance 
molecules and extracellular ligands involved in the development of the nervous system. 
There are several hundred RTKs encoded in the human genome. The Trk family are 
receptors for nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) and 
neurotrophins (NTs). NGF is required for the survival and differentiation of sympathetic 
neurones (Levi-Montalcini, 1987). BDNF is important for support of dendritic structure 
and neuronal plasticity (Martinowich et. al., 2003; Jiang et. al., 2008). NTs are growth 
factors which are vital in neuronal network formation and plasticity (Huang and 
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Reichardt, 2003). The Eph family of receptors, which are receptors for ephrins, are 
discussed in Section 1.4.2.  RTKs and their respective ligands are crucial in the 
development and regulation of neurones. 
RTKs such as Trks, are membrane bound proteins with typically three domains; an 
extracellular glycosylated ligand binding receptor domain, a transmembrane domain 
comprising a single transmembrane α-helix and an intracellular domain that includes an 
intrinsic tyrosine kinase domain (Hubbard, 2002). Following ligand binding, RTKs 
dimerise and autophosphorylate, initiating intracellular signalling cascades. 
Autophosphorylated tyrosines act as high affinity binding sites for intracellular signalling 
proteins, which usually contain single or combinations of phosphotyrosine binding 
(PTB), Src homology (SH) 2 and SH3 domains (Pawson, 2002). Recruitment and 
tyrosine phosphorylation may activate intracellular signalling proteins, for example 
phospholipase Cγ (PLCγ), which catalyses hydrolysis of phosphatidylinositol (4, 5) 
bisphosphate with formation of inositol (1,4,5) triphosphate (IP3) and diacylglycerol 
(DAG) (Segal, 2003). RTK activity is limited by protein tyrosine phosphatases (Östman 
and Böhmer, 2001) and endocytic trafficking (Wiley and Burke, 2001). 
 
1.2.2 Non-Receptor Tyrosine Kinases 
Non-receptor tyrosine kinases include the Src, Abl and Janus families of kinases. In the 
nervous system, Abl kinases are involved in regulating neuronal morphogenesis, 
controlling cytoskeletal dynamics in neurones and regulating synaptic structure and 
function (Moresco and Koleske, 2003). The Janus family are involved in JAK-STAT 
(Janus kinase - signal transducer and activator of transcription proteins) signalling, 
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downstream of cytokines in the immune system, and transmit stress signals from the 
plasma membrane to the nucleus (Boengler et. al., 2008). The Janus family of non-
receptor tyrosine kinases consists of four members- JAK1, 2 and 3 and Tyk2. Their 
domain structure consists of a FERM (F for 4.1 protein, E for ezrin, R for radixin and M 
for moesin) domain, thought to be important in localisation of the protein, an SH2-like 
domain, which lacks the phosphotyrosine binding of conventional SH2 domains, a 
kinase-like domain and a protein tyrosine kinase domain (Wilks, 2008). 
The most studied non-receptor tyrosine kinases are the Src family kinases (SFKs) which 
play a fundamental role in cell adhesion, morphology and motility (Roskoski, 2004), as 
well as in proliferation and differentiation in the development of neurones (Kalia et. al., 
2004). There are eight members, comprising Src, Fyn (Section 1.2.3), Yes, Lck, Lyn, 
Blk, Fgr, Hck, and three SFK related kinases Srm, Frk and Brk. SFKs function in diverse 
signalling pathways including the semaphorin (sema) 3A and ephrin/Eph collapse 
pathways (Sasaski et. al., 2002; Liu et. al., 2004; Shi et. al., 2007). SFKs are also 
associated with various downstream targets including PI3-kinase, PLC, FAK and p190 
rhoGAP (Frame, 2004; Ingley, 2008). 
 
1.2.3 Fyn in Axonal Guidance 
Fyn tyrosine kinase, a member of the Src family, comprises an N-terminal (SH4) domain 
containing acylation sites, a unique region, SH3 and SH2 domains, an SH1/kinase 
domain and a C-terminal regulatory tail (Martin, 2001). The most N-terminal glycine can 
be myristoylated, occurring co-translationally on free polysomes. This acylation anchors 
Fyn to the plasma membrane (Resh, 1998). Palmitoylation can occur on the most N-
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terminal cysteine, which may target Fyn to lipid raft microdomains and directs the 
remaining SH4 region away from the membrane, possibly for Fyn interaction with target 
proteins (Rawat and Nagaraj, 2010). Fyn is held in an inactive closed conformation by 
intramolecular binding of SH2 to a phosphorylated tyrosine (Y531) in the C-terminal 
regulatory domain and SH3 with the linker region between SH2 and SH1. 
Dephosphorylation of the regulatory tyrosine or binding of SH2 or SH3 domains by 
external ligands alters Fyn conformation to an open ‘active’ state. Additionally, 
intermolecular autophosphorylation of tyrosine 420 in the SH1/kinase domain stabilises 
the active state (Roskoski, 2004). It is well recognised that Fyn is important in axon-glial 
signal transduction and processes needed for oligodendrocyte maturation and CNS 
myelination (Krämer-Albers and White, 2011). Fyn tyrosine kinase has been shown to be 
involved in the sema 3A, ephrin-Eph and netrin-1 neuronal signalling pathways (Sasaki 
et. al., 2002; Liu et. al., 2004; Shi et. al., 2007; Zhou et. al., 2008) and is essential for 
normal brain development (Goto et. al., 2008). In the sema 3A pathway Fyn 
phosphorylates Cdk5 Y15, activating Cdk5, mediating growth cone collapse and axonal 
guidance (Sasaski et. al., 2002), and plays a role in dendritic spine maturation (Morita et. 
al., 2006). Fyn has been shown to phosphorylate CRMP-2 (Uchida et. al., 2009), a 
component of the sema 3A pathway (Goshima et. al., 1995), required for sema 3A 
induced growth cone retraction (Brown et al 2004; Uchida et. al., 2009). Figure 1.1 
shows a representation of Fyn in sema 3A signalling. Several GAPs have been reported 
to be regulated by Fyn phosphorylation. Fyn phosphorylates p190 RhoGAP in the 
regulation of oligodendrocyte differentiation (Wolf et. al., 2001), Fyn phosphorylation of 
p250RhoGAP enhances its GAP activity (Taniguchi et. al., 2003), and in contrast, 
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TCGAP activity is suppressed by Fyn phosphorylation of its GAP domain (Liu et. al., 
2006).  
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Figure 1.1: Fyn in sema 3A signalling A representation of Fyn in 
the sema 3A pathway. The ligand sema 3A binds to the receptor 
complex of neuropilin 1 (NP1) and Plexin A1, which transmits the 
signal across the plasma membrane. Fyn binds plexin, which 
phophorylates Cdk5 at Y15, downstream signalling through Rac 
leads to cytoskeletal remodelling. (Adapted from Sasaki et. al., 
2002.) 
 
1.2.4 Cdk5 in Neurones 
Cdk5 is one of a large family of proline-directed serine/threonine kinases and has a 
fundamental role in neurones; during development in neuronal positioning and migration 
in establishing cortical layers, in synapse formation and axonal patterning, as well as 
regulating membrane dynamics and intracellular trafficking (Smith and Tsai, 2002). Cdks 
are generally reliant on a cyclin for their activation; Cdk5 is an exception and is activated 
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by two partners, p35 and p39. Although not activated by cyclins, Cdk5 does have the 
ability to bind to cyclin D (Xiong et. al., 1997). 
Calpain is known to cleave Cdk5 activator p35 to a constitutively active form, p25, 
causing hyperactivity of Cdk5. This can result in hyperphosphorylation of Cdk5 
substrates such as tau, MAPs and neurofilaments, which leads to neuronal cell death and 
has been implicated in Alzheimer’s disease (Kesavapany et. al., 2004). Cdk5 is also 
thought to play a role in the early stages of memory formation and in learning (Angelo et. 
al., 2006). Cdk5 acts downstream of EphA4 in ephexin dependent retraction of dendritic 
spines (Fu et. al., 2007), and plays a role in sema 3A signalling (Sasaki et. al., 2002). 
Cdk5 and p35 interact with the C-terminal of α2-chimaerin (Qi et. al., 2004; Brown et. 
al., 2004). 
 
1.2.5 Serine/Threonine Kinases, PKA, PKC and CamK11 
Three other well characterised serine/threonine kinases enriched in the brain and involved 
in receptor and ion channel modulation, neurotransmitter synthesis and release, and 
synaptic strength and plasticity (among other functions) are Cyclic AMP-dependent 
protein kinase A (PKA); calcium/phospholipid-dependent protein kinase C (PKC) 
(Section 1.2.6); and calcium/calmodulin-dependent kinase II (CaMKII). Each of these 
kinases becomes active when their respective secondary messengers displace an 
autoinhibitory domain, freeing the catalytic subunit/domain to phosphorylate specific 
protein substrates (Domańska-Janik, 1996). 
PKA is a tetramer formed of two regulatory subunits containing two cAMP binding sites 
and two catalytic subunits. When cAMP binds to the regulatory subunits, the 
 33 
homodimeric regulatory core is released from the catalytic subunits thus activating them 
(Dai et. al., 2009). The cAMP/PKA pathway plays a major role in regulating the 
corticotrophin releasing factor gene in hypothalamic neurones, which controls the stress 
response (Suda et. al., 1985; Seasholtz et. al., 1988; Spengler et. al., 1992). 
CaMKII kinases are large multimeric enzymes, derived from four genes, producing six-
twelve kinase subunits each. The α and β genes are neuronal isoforms, whereas the γ and 
δ genes are more broadly expressed. Calmodulin binds to the regulatory domain of 
CaMKII and activates the kinase by allowing ATP and protein substrates to bind to the 
catalytic region. Calmodulin binding is further assisted by the autophosphorylation of a 
threonine residue in the autoinhibitory domain. After calmodulin dissociation, CaMKII is 
still active, subsequent autophosphorylation of different residues is required for kinase 
deactivation (Domańska-Janik, 1996). CamKII is enriched in postsynaptic densities of 
excitatory synapses and is associated with long-term potentiation (Fukunaga et. al., 1993; 
Lledo et. al., 1995; Barria et. al., 1997). 
 
1.2.6 PKC Family and C1 Domain in Regulation 
The PKC super-family of serine/threonine kinases play a vital role in signal transduction 
pathways and are regulated by lipids in a manner similar to chimaerins. PKCs 
phosphorylate a wide range of substrates implicated in neurotransmitter release, cell 
proliferation, synaptic remodelling and gene expression (Ron and Kazanietz, 1999; 
Amadio et. al., 2006). PKCs have four conserved domains, C1-4, and five variable 
regions V1-5. C1 is the cysteine-rich, DAG binding domain additionally found in 
chimaerins and several other proteins, they also specifically bind phosphatidylserine 
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(Kheifets and Mochly-Rosen, 2007; Johnson et. al., 2000). C1 domains are important in 
PKC regulation, they are involved in recruiting proteins to membranes and have a 
conserved motif HX12CX13-14CX2CX4HX2CX7C, where X is any amino acid (Hommel et. 
al., 1994). C2 domains are most well known as calcium sensors and phosphatidylserine-
binding domains (Cho and Stahelin, 2006). The ATP-binding C3 domain and the 
substrate-binding C4 domain form the catalytic region (Amadio et. al., 2006). 
PKCs are split into three subfamilies based on the N-terminal regulatory domain 
structures, which dictate the different cofactors of PKC isoenzymes (Newton, 2001). 
There are ten PKC family members with four conventional PKCs, containing a C1 and a 
C2 domain, which require DAG, calcium and phosphatidylserine as their cofactors. Four 
novel PKCs also have C1 and C2 domains, although the C2 domain lacks calcium 
binding, they require DAG and phosphatidylserine as cofactors. There are two atypical 
PKCs that have an atypical C1 domain, lacking DAG binding and do not have a C2 
domain, they only require phosphatidylserine as a cofactor (Newton, 2003). Atypical 
PKCs contain an additional protein-protein interaction domain, Phox and Bem1 (PB1), 
which interacts with other PB1 domain containing scaffolding proteins (Steinberg, 2008). 
N-terminal to PKC C1 domain sits an autoinhibitory/pseudosubstrate domain, which 
maintains PKC in an inactive conformation. The sequence of the autoinhibitory domain 
resembles a PKC substrate; but contains an alanine instead of a serine/threonine 
phosphoacceptor site (Steinberg, 2008). Activation is also related to translocation of 
PKCs to different intracellular sites and subsequent serine/threonine phosphorylation of 
downstream substrates (Amadio et. al., 2006). 
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For conventional PKCs, signals that increase intracellular calcium and DAG result in 
calcium binding the C2 domain, anchoring PKC to the plasma membrane (Nalefski and 
Newton, 2001; Schaefer et. al., 2001). However, this does not activate PKC, activation 
occurs when DAG binds the C1 domain, the pseudosubstrate is released and downstream 
binding and signalling takes place (Nishizuka, 1995; Toker, 1998; Newton, 2001). 
Hydrolysis of phosphatidylinositol-(4,5)-bisphosphate by PLC produces DAG and 
inositol-1, 4, 5-trisphosphate (IP3). IP3 stimulates the release of calcium from intracellular 
stores. Conventional PKCs are recruited to the membrane and the calcium ions bridge the 
C2 domain to phosphatidylserine. PKC is activated at the membrane by DAG binding the 
C1 domain. The exposed surface of phorbol ester (DAG)-bound C1 domains is 
hydrophobic and buried in the lipid bilayer of the membrane (Corbalán-García and 
Gómez-Fernández, 2006). The hydrophobic pocket that binds DAG or phorbol esters is 
formed by a zinc finger coordinating with cysteine and histidine residues and their 
hydrophobic side chains (Hurley et. al., 1997).  
The crystal structure of PKCβ11 revealed a two-step activation of its autoinhibited 
conformation. The active site is accessible to the substrate, but the ATP-binding side 
chain of the conserved NFD motif is displaced, preventing full activation. The C1B 
domain holds the NFD helix in a less active conformation, which is reversed by 
membrane binding (Leonard et. al., 2011).  
Several other proteins contain a C1 domain, demonstrating an important role for DAG in 
diverse signalling pathways. In addition to PKCs and chimaerins, other C1 domain 
containing proteins include PKD, DAG kinases, the exchange factors RasGRPs, munc 13 
and myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) (Brose and 
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Rosenmund, 2002; Tan et. al., 2001). The mechanism of DAG binding to the C1 domain 
will differ between proteins and some C1 domains (such as in atypical PKCs and Raf) are 
non-functional in phorbol ester binding (Colón-González and Kazanietz, 2006; Hall et. 
al., 2005).  
 
1.2.7 Protein Phosphatases 
Protein phosphatatases are important in reversing the action of a kinase by removing the 
phosphate group. As with kinases, there are receptor and non-receptor tyrosine 
phosphatases and phosphatases that dephosphorylate tyrosines or serines and threonines. 
Protein tyrosine phosphatases have been linked to cell adhesion receptors, growth factor 
receptors and also to ion/neurotransmitter-gated channels (Arregui et. al., 2000). 
Receptor protein tyrosine phosphatases have significant roles in axonal guidance, 
involving target recognition, as inhibitory guidance cues and in synapse formation 
(Ensslen-Craig and Brady-Kalnay, 2004). Protein phosphatase 1 (PP1) and PP2A are 
families of the most abundant serine/threonine phosphatases (Virshup and Shenolikar, 
2009). Defective PP2A expression has been associated with the phospho-Tau pathology 
seen in Alzheimer’s disease (Sontag et. al., 2004). 
 
 
 
 
 
 
 37 
1.3 GTPase Superfamily - Rho GTPases 
Monomeric G proteins or small GTP-binding proteins with molecular weights between 
20 and 40 kDa make up a superfamily with more than one hundred members classified 
into at least five families; Ras, Rho, Rab, Arf and Ran. The GTPases act like molecular 
switches, when bound to GTP they are ‘on’ and in an active state and engage with 
effector proteins, and when bound to GDP they are ‘off’ (inactive). Regulation of 
GTPases switching between the active and inactive states is tightly controlled by other 
proteins, which also contribute to specificity as described below. This study involves the 
Rho family of GTPases, which are involved in cytoskeletal reorganisation and gene 
expression (Takai et. al., 2001). The most studied members of the Rho GTPase family are 
RhoA, Rac1 and Cdc42. Rho GTPases are vital in controlling signalling pathways 
affecting the actin cytoskeleton (Schmandke et. al., 2007), and crucial in neuronal 
migration and axonal guidance (Kawachi and Hoshino, 2008). RhoGTPases contain a C-
terminal CAAX box which is modified posttranslationally by geranylgeranylation 
increasing hydrophobicity and membrane association (Sebti and Der, 2003). 
 
1.3.1 Rho GTPase Regulation 
1.3.1.1 Guanine-nucleotide Exchange Factors 
GEFs act by displacing a GDP molecule from the GTPase enabling exchange for a GTP 
molecule, thereby activating the GTPase. GEFs are themselves tightly regulated by 
specific upstream signals, determining the activation of a GTPase (Rittinger, 2009). Some 
GEFs are specific for one GTPase, whereas others have broader substrate specificity 
(Takai et. al., 2001). Identified Rho GEFs contain a Dbl-homology (DH) domain and a 
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pleckstrin homology (PH) domain in tandem, or alternatively, an unrelated domain 
identified in DOCK (dedicator of cytokinesis) proteins, which activates Rac (or Cdc42) 
(Bos et. al., 2007). 
 
1.3.1.2 Guanine-nucleotide Dissociation Inhibitors (GDIs) 
GDIs have wide substrate specificity and maintain GTPases in their inactive state by 
inhibiting the exchange of GDP for GTP by preventing GDP dissociation, and influence 
cellular location by maintaining the GTPase in the cytosol (Sasaki and Takai, 1998). 
RhoGDI binding masks the C-terminal membrane targeting CAAX moiety (Michaelson 
et. al., 2001). 
 
1.3.1.3 GTPase Activating Proteins 
GAPs stimulate intrinsic GTPase activity by hydrolysing GTP to GDP and inorganic 
phosphate and switching the GTPase to the inactive state.  There are more than 70 Rho 
GAPs in eukaryotes (Bernards, 2003), outnumbering the Rho GTPases which they 
regulate, as with GEFs. GAPs have multiple domains and may provide specificity via 
selective tissue expression, GTPase specificity, regulation of different signalling 
pathways and/or acting as recognition modules (Tcherkezian and Lamarche-Vane, 2007). 
GAPs, like the GEFs can have a single substrate or a range of substrates. Rho GAPs are 
involved in a wide variety of cellular functions, for example, MgcRacGAP is involved in 
cytokinesis by varying its location throughout cell cycle progression (Hirose et. al., 2001; 
Kitamura et. al., 2001) and p190 RhoGAP is important in neuronal differentiation, where 
it facilitates axon stability and branching (Billuart et. al., 2001). Overexpression 
promotes neuritogenesis and p190RhoGAP, regulated by Src, acts downstream of cell 
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adhesion molecules (Brouns et. al., 2001). P190RhoGAPs, comprising p190B RhoGAP 
(ARHGAP5) and p190A RhoGAP (ARHGAP35), are important in antagonizing RhoA 
activity in various cell functions including cytokinesis (Mikawa et. al., 2008). Inhibition 
of RhoA via Arg and p190RhoGAP promotes dendritic spine maturation (Sfakianos et. 
al., 2007). In the hippocampus, the Rac GAP family consisting of the breakpoint cluster 
region gene product (BCR) and Abr (active Bcr-related) have been implicated in 
excitatory synapse regulation, where mice lacking BCR or Abr showed a decrease in the 
maintenance (but not induction) of long term potentiation (Oh et. al., 2010). Chimaerins 
Rac GAPs are discussed later (Section 1.5). 
 
GEFs and GAPs are multi-domain proteins, which in addition to the conserved catalytic 
Rho GAP or GEF domain, contain various other domains. These include SH3, SH2, 
BAR, C1 and PH domains which combine additional functions to GEF and GAP proteins 
such as localisation targeting and scaffolding (Tolias et. al., 2011). The regulation of 
GEFs and GAPs is tightly controlled and includes protein-protein or protein-lipid 
interactions, second messenger binding, post-translational modifications and 
autoregulation (Jacobs and Hall, 2005). Effects of regulation may consist of translocation 
to the location of the GTPase, release of an auto inhibited state and/or allosteric changes 
in the catalytic domain (Bos et. al., 2007). Figure 1.2 shows Rho GTPase cycle 
regulation.  
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Figure 1.2: Rho GTPase regulation Rho GTPases act like 
molecular switches, being inactive when bound to GDP and activated 
when bound to GTP, associating with their effectors to induce 
changes on the actin cytoskeleton. GAPs inactivate Rho GTPases by 
hydrolysing GTP molecules to GDP and GEFs activate Rho GTPases 
by exchanging GDP molecules for GTP. 
 
 
1.3.2 Rho GTPase Regulation of the Actin Cytoskeleton 
Downstream of extracellular signals RhoA, Rac1 and Cdc42 coordinate reorganisation of 
the cytoskeleton, which is important in many cell processes including; cell growth, 
membrane trafficking, development, axon guidance, axon extension, cell shape changes, 
motility, adhesion and cytokinesis. The Rho GTPases are involved in these processes 
either directly or indirectly by regulation of the cytoskeleton and altering gene expression 
(Takai et. al., 2001). Figure 1.3 is a summary diagram of the main RhoGTPases, their 
effector proteins and how they affect cell processes. 
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Figure 1.3: Rho GTPases in cell processes (adapted from Iden and 
Collard, 2008) A summary diagram showing Rho GTPase involvement 
in multiple cell processes, particularly in the organisation of the 
cytoskeleton. The most well studied Rho GTPases are RhoA, Rac1 and 
Cdc42, some of their main effector proteins (light blue) are shown in the 
diagram. 
 
 
1.3.3 Morphological Effects of Rho Proteins 
The role of RhoA in the reorganisation of the actin cytoskeleton was first shown in Swiss 
3T3 fibroblastic cells. RhoA is essential for the formation of stress fibers and focal 
adhesions induced by LPA (Ridley and Hall, 1992). RhoA promotes focal adhesions and 
stress fibres leading to a contractile cell phenotype acting through its effectors Rho-
kinase (ROCK) and diaphanous (mDia), which are essential in this process. ROCK 
phosphorylation of the regulatory serine 19 of MLC2 (Vicente-Manzanares et. al., 2009) 
and of myosin phosphatase (i.e. the myosin-binding subunit MBS or MYPT1 of myosin 
phosphatase) promotes increased contractility (Leung et. al., 1996; Matsui et. al., 1996; 
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Nakano et. al., 1999; Watanabe et. al., 1999). ROCK also phosphorylates and activates 
LIM kinase, which subsequently phosphorylates cofilin, resulting in actin filament 
stabilisation (Maekawa et. al., 1999). RhoA and ROCK activity are required in migrating 
cells for the regulation of tail retraction (Pertz et. al., 2006).  
Rac1 stimulates lamellipodia formation and membrane ruffles in response to growth 
factors such as Platelet Derived Growth Factor (PDGF) (Ridley et. al., 1992). A later 
response is the formation of actin stress fibres; the growth factor signals through Rac1 to 
stimulate a Rho-dependant response (Ridley et. al., 1992), a first indication of the inter-
dependence/cross-talk in GTPase signalling. During lamellipodia extension, Rac1 
regulates actin polymerisation by activating actin polymerising proteins including the 
Arp2/3 complex through WAVE proteins. Rac1 may also increase the availability of 
actin monomers through regulation of cofilin or by removing capping proteins (Heasman 
and Ridley, 2008). In hippocampal neurones, increased dynamics of dendrites and 
dendritic branches induced by N-Methyl-D-Aspartic acid (NMDA), is accompanied by 
endogenous Rac activation and inhibited by the expression of dominant negative Rac1 
(Henle et. al., 2006). Rac1 has also been shown to regulate growth cone collapse or 
expansion in response to different extracellular ligands (Jin and Strittmatter, 1997; Kuhn 
et. al., 1999; Vastrik et. al., 1999; Shekarabi et. al., 2005). 
Cdc42 produces peripheral actin microspikes and filopodia formation in response to the 
growth factor bradykinin (Nobes and Hall, 1995; Kozma et. al., 1995). Cdc42 is involved 
in yeast budding, epithelial polarity, migratory polarity and fate specification in cell 
division. Downstream targets for Cdc42 in the formation of filopodia include mDia 
(Mellor, 2010), members of the formin family and insulin receptor substrate (IRS) p53 
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(Govind et. al., 2001; Krugmann et. al., 2001). LIM kinase is also activated downstream 
of Cdc42 and p21 Activated Kinase (PAK), which stimulates phosphorylation and 
inactivates cofilin (Heasman and Ridley, 2008).  
 
1.3.4 Cell Adhesion and Rho 
RhoA and ROCK are involved in the formation of focal adhesions and stress fibres 
leading to contractility (Dhawan and Helfman, 2004). ROCK is also regulated 
downstream of integrin signalling in cell migration (White et. al., 2007). Integrins are a 
large family of cell adhesion receptors that mediate cell matrix adhesion and transduce 
cell signals (Hynes, 2009). The αβ1 integrins form focal adhesions comprised of a 
complex of proteins that associate with the cytoskeleton (Schober et. al., 2007). Integrins 
lack enzymatic activity and therefore rely on a variety of proteins such as FAK to 
function (Hynes, 2002). A FAK-Src complex is important in integrin regulation of the 
Rho GTPases in cell adhesion (Huveneers and Danen, 2009).  
.  
1.3.5 GTPases in Endocytosis and Vesicle Transport 
Endocytosis and vesicle trafficking involves small GTPases of the Rab family, of which 
there are more than 60 members, localised to different membrane compartments (Pfeffer 
and Aivazian, 2004). Rab 5 is a marker of early endosomes, Rab7 is present in late 
endosomes and lysosomes and Rab11 in Golgi and recycling endosomes (Hutagalung and 
Novick, 2011). Rabs function through effector proteins to achieve specificity (Grosshans 
et. al., 2006). In vesicle trafficking, Rabs can recruit as effectors GAPs and GEFs for 
upstream and downstream signalling (Hutagalung and Novick, 2011). Some Rab 
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effectors are able to recognise more than one Rab protein, such as Rabaptin5, which 
interacts with Rab4 and Rab5, connecting endocytosis and recycling (Vitale et. al., 1998). 
Rho GTPase regulation of the actin cytoskeleton is also important in endocytosis. 
Expression of dominant active mutations of Rho and Rac in different cell types affects 
endocytosis of different types of receptors (Takai et. al., 2001). RhoD and RhoB have 
been shown to localise to early and late endosomes respectively (Murphy et. al., 2001; 
Adamson et. al., 1992) further implicating the Rho GTPases as having an important role 
in endocytosis. Rac1 has been shown to drive endocytosis of the plasma membrane in 
response to ephrin A2 and sema 3A, causing growth cone collapse (Jurney et. al., 2002). 
Cells require vesicle transport for a variety of functions, including establishing and 
maintaining cell polarity, by transporting proteins to distinct cellular locations. The 
transport of vesicles has four different stages, vesicle formation, intracellular transport 
(which involves myosins, kinesins and dyneins (Mallik and Gross, 2004)), vesicle 
tethering and membrane fusion (involving the SNARE proteins (Chen and Scheller, 
2001)). The Rab proteins and Rab effectors play a critical role in all four stages of vesicle 
transport, all of which are highly regulated and not fully understood (Grosshans et. al., 
2006). The Rho GTPases are also important in vesicle transport, and associate with the 
exocyst complex, an octameric complex that tethers secretory vesicles to the plasma 
membrane prior to fusion. The Rho GTPases are involved in cell polarity and membrane 
transport regulation and have been associated in playing a role in downstream vesicle 
fusion (Wu et. al., 2008). 
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1.3.6 Rho GTPases in Neurones 
In differentiating neurones, RhoA, Rac1 and Cdc42 have distinct and overlapping roles. 
Temporal and spatial differences, or GEFs and GAPs responding differently to upstream 
signals, provide specificity in cell function of Rho GTPases (Lowery and Van Vactor, 
2009). Rho mediates ROCK activation and translocation to the membrane where they 
phosphorylate specific substrates in cell contractility mentioned above (Section 1.3.3/4) 
(Leung et. al., 1996; Matsui et. al., 1996). A major brain substrate of ROCK is CRMP-2, 
which is phosphorylated at threonine 555 (Arimura et. al., 2000). CRMP-2 is involved in 
growth cone collapse via the sema 3A pathway (Goshima et. al, 1995) and neuronal 
polarity and axonal outgrowth (Inagaki et. al, 2001). 
Rac1 regulates a major effector, the PAK serine/threonine kinases, of which there are six 
known members. PAK1 and PAK3 are highly enriched in neurones and induce the 
formation of dendritic spines (Zhang et. al., 2005). The PAK N-terminal auto-inhibitory 
domain prevents the activity of the C-terminal kinase domain. Association of the auto-
inhibitory domain of PAK with Rac1-GTP or Cdc42-GTP disrupts the auto-inhibition 
(Manser et. al., 1994). Cdc42 is able to activate Rac1 and PAKs 1-3 and therefore, 
distinguishing between which proteins Cdc42 and Rac1 activate is problematic (Bernard 
et. al., 1999). Rac1 also binds p35/Cdk5 a serine/threonine kinase (Nikolic et. al., 1998), 
which is involved in neurite outgrowth during neuronal differentiation (Nikolic et. al., 
1996). 
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1.3.7 Adaptor Proteins-Nck 
Nck1 and 2 are adaptor proteins containing three SH3 domains followed by a C-terminal 
SH2 domain. Nck couples phosphotyrosine signalling to proteins that regulate the actin 
cytoskeleton. Nck SH2 domain interacts with active tyrosine phosphorylated RTKs, such 
as PDGF receptor, epidermal growth factor (EGF) and ephrins, and the SH3 domains 
bind to proteins that regulate the cytoskeleton, such as, N-WASP. Nck can activate N-
WASP, by binding to the polyproline region (Tomasevic et. al., 2007). Rac and Cdc42 
GTPases also promote Arp2/3 association with WASP family members and actin 
polymerization regulators of the cytoskeleton (Bladt et. al., 2003). 
Nck also associates with G-protein coupled receptor kinase-interacting protein 1 (GIT-1), 
an Arf-GAP (Frese et. al., 2006). Activation of the adaptor protein Nck, results in the 
membrane localisation of the serine/threonine kinase PAK (Lu et. al., 1997; Sells et. al., 
1997). Nck interacts with PAK1 through the second SH3 domain and regulates 
membrane localisation and kinase activity synergistically with Cdc42. Activated PAK1 
phosphorylates LIM kinase which subsequently phosphorylates and inhibits cofilin 
affecting actin organisation. PAK1 also has a scaffolding function, binding the SH3 
domain of a Cdc42-GEF PIX, and Rac1 (Bladt et. al., 2003). Nck2 has been implicated in 
integrin signalling (Section 1.3.4), binding the LIM4 domain of PINCH through its third 
SH3 domain (Tu et. al., 1998), and therefore linking integrin signalling through PAK to 
cytoskeleton rearrangement (Buday et. al., 2002). 
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1.4 Axonal Guidance 
Neurones are highly specialised and polarised cells, which receive and transmit signals 
through dendrites and an axon, which extend over long distances. During development, 
growing axons are directed to their targets by attractive and repellent guidance cues. The 
growth cone is situated at the growing tip of the axon and is a ‘spread-out’ and very 
dynamic structure, constantly lengthening and retracting filopodia in response to 
guidance cues. 
Neuronal growth cones express cell adhesion molecules which regulate adhesion to the 
extracellular matrix and to other cells, enabling the movement of the axon (Chisholm and 
Tessier-Lavigne, 1999). Molecular guidance cues include members of the semaphorin 
family, ephrins, netrins, slits, neurotrophins and neurotransmitters (Mortimer et. al., 
2007). Molecular guidance cues can be soluble, such as class 3 semaphorins, or cell 
membrane associated, such as other classes of semaphorins and ephrins.  
 
1.4.1 Semaphorin Signalling 
Semaphorins are widely expressed in the nervous system, the immune system and the 
heart and vascular system, affecting cell migration, branching of the vascular system and 
immune cell regulation (Kruger et. al., 2005). In the brain, semaphorins are mainly 
repulsive guidance molecules, but also elicit an attractive response in the axons of 
developing peripheral neurones (Wong et. al., 1999) and apical dendrites of cortical 
neurones (Polleux et. al., 2000). There are eight classes overall, classes 1 and 2 are 
invertebrate, 3-7 are vertebrate and 8 (or V) is virally encoded. Classes 1, 4, 5 and 6 are 
transmembrane proteins, class 7 is tethered to membranes via a GPI anchor and class 3 
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(as well as 2 and V) are secreted proteins. All contain a Sema domain at the N-terminal 
and a PSI (plexins, semaphorins and integrins) domain, (except for viral semaphorins, 
that do not contain a PSI domain). Sema domains are also found in the extracellular 
region of plexins (sema co-receptors) and in the RTKs Met and Ron (Gherardi et. al., 
2004). In addition to the Sema domain, plexins have three PSI domains and three IPT (Ig-
like, plexins and transcription factors) domains and in their intracellular region is a GAP 
homology region, which is split into two by a GTPase binding domain. There are nine 
mammalian plexins A1-4, B1-3, C1 and D1. Neuropilins-1 and -2 are transmembrane 
sema receptors with short cytoplasmic tails, which form complexes with plexin-As 
(Negishi et. al., 2005). Of class 3 soluble semaphorins, sema 3A is associated with 
neuropilin 1, sema 3F with neuropilin 2 and sema 3C with a neuropilin 1/2 heterodimer 
(Chisholm and Tessier-Lavigne, 1999).  
Sema 3A is the most studied, with neuropilin-1/plexin-A as its receptor complex. Rho 
GTPases are involved in this signalling pathway and cause a repulsive response. Growth 
cone collapse initiated by sema 3A signalling involves the Rho GTPase Rac1 (Jin and 
Strittmatter, 1997). Downstream from sema 3A ligand binding, signalling to microtubules 
and to actin may act simultaneously to alter the cytoskeleton and cause growth cone 
collapse (Goshima et. al., 1995; Aizawa et. al., 2001). 
Sema 3A binds neuropilin-1, making the cytoplasmic region of plexin-A1 available for 
Fes/Fps binding and phosphorylation, stimulating the repulsive response (Negishi et. al., 
2005). Fes/Fps tyrosine phosphorylates a CRMP-2/CRAM (CRMP-5) complex (Mitsui 
et. al., 2002). CRMP-2 was identified as an essential component of sema 3A signalling 
(Goshima et. al., 1995) and its interaction with microtubules is regulated by 
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phosphorylation (especially serine/threonine phosphorylation by Cdk5 and GSK3β) 
(Brown et. al., 2004; Yoshimura et. al., 2005). Cdk5 and GSK3β are also participants in 
sema 3A signalling (Sasaki et. al., 2002; Eickholt et. al., 2002) and their substrates 
include Tau and MAP, affecting the cytoskeleton.  
Fyn tyrosine kinase and Cdk5 serine/threonine kinase form an activity dependent 
complex that associates with the plexin-A cytoplasmic domain in response to sema 3A 
stimulation, Fyn phosphorylates Cdk5 (Sasaki et. al. 2002). Activated Cdk5 
phosphorylates CRMP-2 at serine 522 which primes for phosphorylation by the 
serine/threonine kinase GSK-3β at serine 518 and threonines 514 and 509. This 
phosphorylation cascade of CRMP-2 by Cdk5 and GSK-3β is essential for sema 3A 
growth cone collapse and neuronal polarity (Brown et. al., 2004; Yoshimura et. al., 
2005). CRMP-2 binds to tubulin heterodimers promoting microtubule assembly (Fukata 
et. al., 2002), but recently has been shown to stabilize microtubules from which it is 
released by phosphorylation (Lin et. al., 2011). Rho kinase phosphorylates CRMP-2 at 
threonine 555, this has been shown to reduce CRMP-2 binding of tubulin (Arimura et. 
al., 2000).  
Down regulation of sema 3A signalling at the growth cone may occur by endocytosis of 
neuropilin-1, and the cell adhesion molecule L1 has been implicated (Castellani et. al., 
2000). L1 is expressed along the axon shaft, but is preferentially expressed at the growth 
cone where it binds neuropilin-1 and is responsible for determining the attractive or 
repulsive response. After semaphorin binding, L1 controls endocytosis, thereby 
controlling the turnover of the neuropilin receptor (Castellani et. al., 2002). Sema 3A and 
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Fyn signalling has also been reported to influence dendrite branching in brain 
development (Morita et. al., 2006). 
 
1.4.2 Ephrin-Eph Signalling 
Eph-ephrin signalling regulates dendritic spine formation and is involved in many aspects 
of synaptogenesis, including presynaptic differentiation and neurotransmitter release 
(Klein, 2009). In vertebrates, the Eph family of receptors are the largest subfamily of 
RTKs.  Eph receptors are split into two subclasses based on sequence and ligand 
specificity; there are nine EphAs (EphA1-8 and EphA10) and five EphBs (EphB1-4 and 
EphB6). Their membrane-bound ligands, ephrins are also split into two subclasses, ephrin 
A1-5 and ephrin B1-3. Ephrin As are attached to the membrane via a GPI anchor, 
whereas, ephrin Bs have transmembrane domains. Figure 1.4 shows a diagrammatic 
representation of Eph receptors and their ligands. Mainly ephrin A ligands signal through 
the EphA receptors and ephrin B ligands signal through EphB receptors, although there 
are some exceptions, the most well characterised being the EphA4 receptor which can 
bind both A and B ephrins.  The large number of Eph receptors and ephrin ligands 
suggests, there may be some functional redundancies and/or some specific functions that 
are as yet unidentified (Murai and Pasquale, 2004). 
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Figure 1.4: Ephrin/Eph signalling Ephrin As are GPI-linked to the plasma 
membrane (PM), whereas ephrinBs are transmembrane proteins. Signalling can 
occur in either direction, forward from the ligand to the Eph receptor, or in 
reverse from the receptor to the ephrins.  
 
Although the Eph family are RTKs, they are quite unusual in the way that they function. 
The Eph-ephrin interaction requires a high order of ligand clustering for a signal to occur 
and the Eph-ephrins can signal bi-directionally; forward signalling from the ligand to the 
receptor, and reverse signalling from the Eph receptor to the ephrin ligand in the 
neighbouring cell. As Eph receptors and ephrin ligands can be expressed on the same cell 
surface, it is possible that cis interactions of the ligand and receptor on the same cell may 
also occur (Carvalho et. al., 2006). The ephrin-Eph signalling pathway and many other 
RTKs, recruit phosphotyrosine binding adaptor proteins containing SH2 and/or SH3 
domains, for example Nck and other proteins such as Phosphoinositide 3-Kinase (PI3K), 
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and signal downstream to RhoGTPases to remodel the actin cytoskeleton (Noren and 
Pasquale, 2004). 
In forward signalling, ephrin-Eph binding triggers large clusters of both receptors and 
ligands on the cell surface, causing auto-phosphorylation of two conserved tyrosines in 
the juxtamembrane region of Eph (Goldshmit et. al., 2006). The juxtamembrane domain 
of the Eph receptor is auto-inhibitory until tyrosine autophosphorylation occurs in 
response to ligand stimulation. Eph auto-phosphorylation then enhances kinase activity 
and provides a docking site to recruit SH2 domain containing proteins, such as SFKs 
(Ellis et. al., 1996; Zisch et. al., 1998), PLCγ and PI3K (Murai and Pasquale, 2004).  
The GEF, ephexin, provides a direct functional link between EphA receptors and Rho 
GTPases (Shamah et. al., 2001). Ephexin specifically binds EphA receptors in the 
absence of stimulation by ephrins. Upon activation by ephrins, EphA4 phosphorylates 
ephexin at tyrosine 87 and ephexin then activates RhoA and inhibits Cdc42 and Rac1, in 
turn, inhibiting PAK and PAK mediated events, promoting growth cone collapse (Huot, 
2004). Ephrin induced growth cone collapse or retraction requires Rho and ROCK and 
additionally, Cdc42 and MRCK signalling pathways (Groeger and Nobes, 2007). Ephrin 
A5 mediated collapse signals through Rho and ROCK and Rac is down regulated (Wahl 
et. al., 2000). 
Cdk5 is involved in the ephrin A induced signalling pathway (Cheng et. al., 2003). 
Activation of EphA4 leads to the recruitment and subsequent tyrosine phosphorylation of 
Cdk5, causing Cdk5 activation (Fu et. al., 2007). Active Cdk5 phosphorylates two actin 
cytoskeleton regulators, ephexin1 and WAVE-1, leading to the loss of dendritic spines, 
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and it was shown that phosphorylation of ephexin1 by Cdk5 is necessary for ephrin A1-
induced spine retraction (Fu and Ip, 2007). 
Reverse signalling has mainly been studied in the B class of Ephs and ephrins, the A 
class can also participate in reverse signalling, although the ephrin As do not have a 
transmembrane domain. Ephrin A can trigger intracellular signalling pathway activation 
through association with transmembrane proteins, such as p75 neurotrophin receptor and 
the TrkB receptor (Lim et. al., 2008; Marler et. al., 2008). Ephrin B reverse signalling 
may use a phosphotyrosine-independent docking mechanism rather than the intrinsic 
kinase domain used in forward signalling (Mäkinen et. al., 2005). Ephrin Bs take part in 
reverse signalling by recruiting PDZ-containing proteins to their C-terminal, PDZ-
binding domain, and these recruit serine/threonine kinases to transmit the signal (Torres 
et. al., 1998). Rho GTPases and Src family kinases are also involved in ephrin B reverse 
signalling (Egea and Kein, 2007). In neurones, ephrin B reverse signalling promotes the 
maturation of dendritic spines. This process involves the adaptor protein Nck2, GIT1 and 
β-PIX, an exchange factor for Rac (Zhang et. al., 2005; Segura et. al. 2007). 
Ligand-receptor complexes are endocytosed to suppress the Eph-ephrin signalling 
pathway. Internalisation of ephrin B/EphB complex and consequent cell retraction is a 
Rac1 dependent pathway (Marston et. al., 2003). A Rho-GEF Vav2, binds to the 
phosphorylated tyrosines in the juxtamembrane domain of activated EphA4 through its 
single SH2 domain and Vav2 knock out studies in mice have shown a defect in Eph 
endocytosis, suggesting that Vav2 plays a role. Moreover, the phosphorylation of Vav2 
promotes local Rac1-dependent endocytosis, which induces an ephrin-Eph repulsive 
response (Cowan et. al., 2005). Another possibility for Eph-ephrin signalling suppression 
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is the cleavage of the ephrin A ectodomain by A-Disintegrin-And-Metalloprotease 
(ADAM) 10. ADAM10 only cleaves ephrin As on the opposite cell surface (Janes et. al., 
2005). Alternatively, to deactivate Eph-ephrin signalling, the Eph receptor 
juxtamembrane tyrosines can be dephosphorylated by a phosphotyrosine specific protein 
phosphatase (PTP). Protein tyrosine phosphatase receptor type O (Ptpro) has been 
suggested for this as it is a PTP that dephosphorylates EphA and B receptors (Shintani et. 
al., 2006). 
Studies using knock out mice have shown that when EphA4 or ephrin B3 are absent, 
mice produce axons with guidance defects that inappropriately cross the spinal cord 
midline, resulting in mice with a rabbit-like hopping gate (Dottori et. al., 1998; Kullander 
et. al., 2001) showing an essential developmental role of ephrin B3/EphA4 signalling in 
correct axonal positioning in motor pathways.  
 
1.4.3 Netrins 
Netrins are soluble guidance factors which interact with cell membranes through 
negatively charged proteoglycans, and can act as an attractant or a repellent to growth 
cones depending upon which receptor they bind. Netrins signalling through a 
transmembrane receptor of the Deleted in Colorectal Cancer (DCC) family, with four 
immunoglobulin domains and six fibronectin type III repeats, cause an attractive 
response. A repulsive response occurs when netrins signal through transmembrane 
receptor of the UNC-5 family, containing two immunoglobulin domains and two 
thrombospondin repeats (Chisholm and Tessier-Lavigne, 1999). 
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1.4.4 Slits 
Slits are large proteins containing leucine rich and EGF-like repeats. Much of the work 
on the Slit family of proteins has been carried out in Drosophila. Slit proteins are midline 
repellents, which signal through a transmembrane receptor roundabout (Robo), they 
ensure that axons cross the midline only once. Axons expressing Robo are repelled by 
Slit at the midline, this works by Commissureless (Comm) keeping Robo down-regulated 
by acting as an endosomal sorting receptor (Keleman et. al., 2002) until the axon crosses 
the midline. Robo is then up-regulated thereby preventing the axon from crossing back 
(Chilton, 2006). No Comm has been found in vertebrates, however, vertebrates contain a 
third Robo receptor (rig-1/Robo 3) which appears to have the same function as Comm 
(Allen and Chilton, 2009). 
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1.5 Chimaerins 
1.5.1 Chimaerin Genes 
Chimaerin was first isolated as a novel neuronally-expressed sequence from a human 
brain cDNA library, related to PKC and BCR (Hall et. al., 1990). Chimaerins contain a 
cysteine rich, phospholipid-dependent phorbol ester binding C1 domain and were the first 
non-PKC phorbol ester receptors described (Ahmed et. al., 1990). There are two genes 
for chimaerin, α and β. The α- (n-) chimaerin gene (CHN1) maps to chromosome locus 
2q31.1 and the β-chimaerin gene (CHN2) to chromosome 7p15.3 (Hall et. al., 1993; 
Leung et. al., 1993; http://www.ncbi. nlm.nih.gov/gene). Each encodes two major splice 
variants, α1-, β1- and α2-, β2- (Figure 1.5).  
 
Figure 1.5: Chimaerin splice variants Two chimaerin genes, α and β, each encode two isoforms α1- and α2- 
and β1- and β2-chimaerin respectively. Chimaerins α2- and β2- contain an SH2 domain in addition to the C1 
and GAP domains present in all chimaerins. Amino acid numbers are shown and the position corresponding to 
the conserved alternative splice site is indicated (α2-chimaerin 184). 
 
The protein sequences of α2-chimaerin and β2-chimaerin SH2, C1 and GAP domains are 
highly similar, with 81.8%, 85.5% and 75% identity, respectively and there is greater 
sequence divergence in the SH2-C1 linker regions (39.1% identity) and N-terminals 
(66.7% identity). Between species α2-chimaerin is highly conserved; at the protein level 
sequence similarities are mouse 96%, chicken 95% and zebra fish 86.7% compared to 
human α2-chimaerin. 
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The rat embryonic nervous system expresses high levels of α2-chimaerin mRNA, 
whereas, α1-chimaerin mRNA is only detectable after embryonic day 16.5 (Hall et. al., 
2001) and increases in expression during development (Lim et. al., 1992). Adult rat 
neurones express α2-chimaerin mRNA in specific brain regions; the highest being the 
anterior olfactory nucleus, hippocampus, cortex and entorhinal cortex (Hall et. al., 2001). 
Additionally, α2-chimaerin is expressed in rat testis (Hall et. al., 1993). β1-Chimaerin is 
mainly expressed in testis (with a different expression pattern to α2-chimaerin), and is 
associated with spermatogenesis (Leung et. al., 1994). β2-Chimaerin is highly expressed 
in cerebellum and is also found in T-lymphocytes (Leung et. al., 1994; Siliceo et. al., 
2006). α2-Chimaerin expressed in mammalian cells is predominantly soluble, with only a 
fraction being membrane associated whilst α1-chimaerin is almost entirely membrane 
and cytoskeleton bound. A point mutation in the SH2 domain of α2-chimaerin was 
sufficient to produce an α1-chimaerin-like phenotype (Hall et. al., 2001). 
 
1.5.2 Chimaerins as RacGAPs 
Chimaerin was identified as a RhoGAP for Rac1 (Diekmann et. al., 1991; Manser et. al., 
1994), while its GAP domain is highly related to BCR C-terminal domain (Hall et. al., 
1990; Ahmed et. al., 1994). Similar GAP domains are present in the large RhoGAP 
superfamily (Bernards and Settleman, 2004). Chimaerins as RacGAPs play an important 
role in limiting/inhibiting Rac-dependent actin reorganisation and cell morphology. Early 
work in mammalian cells indicated that chimaerin expression can act in conjunction with 
Rac1 and Cdc42 to stimulate actin rearrangement, forming lamellipodia and filopodia, 
independently of GAP activity. This suggested that α-chimaerin may have morphological 
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functions in association with other proteins in addition to down regulating GTPases 
(Kozma et. al., 1996). In N1E-115 neuroblastoma cells, permanent expression of α2-
chimaerin generated neuritis, whereas permanent expression of α1-chimaerin produced 
microspikes and F-actin clusters but very few neurites (Hall et. al., 2001). The different 
morphology possibly reflects the differences in GAP activity and protein interactions of 
the two isoforms. The RacGAP activity of chimaerins is sensitive to phorbol ester/DAG, 
phosphatidylserine and phosphatidic acid via the C1 domain (Ahmed et. al., 1993; 
Ahmed et. al., 1994; Caloca et. al., 2003). 
 
1.5.3 Chimaerin C1 Domain  
Chimaerin C1 domain has approximately 40% homology with PKC isoenzyme C1 
domains and contains the necessary amino acid residues for phorbol ester binding and the 
hydrophobic residues required for membrane insertion (Caloca et. al., 2001). In in vitro 
studies, chimaerins, like PKC, bind DAG and phorbol esters with high affinity in a 
phosphatidylserine-dependent manner (Ahmed et. al., 1990; Caloca et. al., 1997; Areces 
et. al., 1994). Chimaerin C1 domain is important in regulating the localisation of 
chimaerins, as phorbol ester treatment induces translocation of chimaerins from the 
cytosol to membranes (Caloca et. al., 1999; Caloca et. al., 2001). The C1 domain 
mutation of β2-chimaerin C246 is sufficient to block phorbol ester/DAG binding and 
membrane translocation (Caloca et. al., 1999). Mutants with reduced affinity for phorbol 
esters, including P216 in α2-chimaerin (Colón-González et. al., 2008) and F215 in β2-
chimaerin (Siliceo et. al., 2006), have also been utilized to inhibit C1 domain function. 
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1.5.4 Chimaerin Structure 
The crystal structure of β2-chimaerin was resolved by Canagarajah et. al. in 2004, which 
revealed an inactive, closed conformation (Figure 1.6). The C1 domain has many 
intramolecular contacts throughout the protein. A helix of eight residues within the N-
terminal of β2-chimaerin lies against the membrane binding site and conceals the phorbol 
ester binding groove. The C1 domain also has contacts with the SH2 domain, the GAP 
domain and the SH2-C1 inter-domain linker and in all approximately 40% of the C1 
domain is buried. The SH2 domain appears to have a phosphotyrosine binding pocket of 
three arginine residues and a glutamine residue, however, unusually one of the arginine 
residue side chains is rotated away from the binding site. The Rac1 interacting surface of 
the C-terminal GAP domain is concealed by two proline residues in the N-terminal of β2-
chimaerin (Canagarajah et. al., 2004). This demonstrated a closed conformation of 
inactive chimaerin with hidden binding sites. Binding of phospholipids at the C1 domain 
involves dissociation of the tightly wound structure of chimaerin, unblocking the active 
site and activating chimaerin (Canagarajah et. al., 2004).  
      
A     B 
 
Figure 1.6 Structure of α2-chimaerin (A: α2-Chimaerin structure from 
http://www.ncbi.nlm.nih.gov/structure/, B: β2-Chimaerin structure adapted from 
Caraganajah et. al., 2004). A: Structure of α2-chimaerin demonstrating the 
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partially buried nature of the C1 domain. The C-terminal GAP domain is shown in 
green and brown, the C1 domain is purple, with the co-ordinated zinc shown as 
grey spheres, and the SH2 domain is blue. The extreme N-terminal (yellow N) and 
SH2-C1 linker contact the other domains. The phorbol ester binding site is shown 
in yellow (Phorbol Myristate Acetate (PMA)). B: Space filling diagram of β2-
chimaerin also showing the obscured nature of the C1 domain. The linker regions 
and the N-terminal are shown in yellow. 
 
 
1.5.5 Chimaerin Regulation – C1 Domain 
Chimaerins are more resistant to membrane translocation by phorbol esters than PKC 
(Caloca et. al., 1999; Caloca et. al., 2001; Colón-González et. al., 2008), possibly due to 
C1 domain occlusion by intramolecular interactions (Caraganajah et. al., 2004; Colón-
González et. al., 2008). This has also been demonstrated for MRCK (Tan et. al., 2001), 
where MRCK C1 domains are more resistant to DAG than PKC, similar to chimaerins 
(Choi et. al., 2008). Structural differences in the binding cleft or membrane binding 
regions of various C1 domains may also play a role in DAG signalling (Colón-González 
and Kazanietz, 2006).  
Interestingly it was reported that a series of β2-chimaerin mutants (L28A, I130A and 
I359A) that disrupt intramolecular interactions show enhanced translocation, increased 
binding to acid phospholipid vesicles and increased GAP activity (Caraganajah et. al., 
2004; Sosa et. al., 2009). Similarly, N-terminal single point mutations of L20A and 
I122A in α2-chimaerin, which were predicted to disrupt intramolecular interactions, were 
more sensitive to phorbol ester and translocation, and I122A showed enhanced RacGAP 
activity compared to wild type α2-chimaerin (Colón-González et. al., 2008).   
Response to different phorbol esters affects the location of β2-chimaerin and PKCα, 
suggesting that DAG signalling regulates their cellular location. This may also involve 
protein-protein interaction mechanisms (Caloca et. al., 2001). Chimaerin isoforms may 
 61 
localise to the golgi apparatus through their C1 domain interaction with the endoplasmic 
reticulum and golgi protein P23/Tmp21. This indicates that the C1 domain interacts with 
both proteins and lipids (Wang and Kazanietz, 2002; Wang and Kazanietz, 2010). 
Phorbol esters also promote the association of β2-chimaerin with Rac1 (Caloca et. al., 
2001) and increase stability of α1-chimaerin (Marland et. al., 2011). 
 
 
1.5.6 SH2 Domain Interactions  
Chimaerins α2- and β2- contain an N-terminal SH2 domain in addition to C1 and GAP 
domains (Hall et. al., 1993; Leung et. al., 1994). SH2 domains specifically recognise 
phosphotyrosine containing proteins and are present in a wide spectrum of proteins 
including GTPase regulatory proteins like vav and RasGAP, adaptor proteins such as Nck 
and Grb2, and the phospholipid signalling protein PLCγ (Pawson et. al., 2001), as well as 
SFKs. The SH2 domains of α2- and β2-chimaerin are atypical in that they contain a 
glutamic acid residue in the place of the conserved tryptophan residue at the N-terminal 
end of SH2 domains. This substitution in mutated Src SH2 resulted in altered 
phosphotyrosine binding (Bibbins et. al., 1993), possibly indicating that chimaerin 
phosphotyrosine binding may be different to that of conventional SH2 domains. 
However, the essential arginine residues required for phosphotyrosine-binding are 
conserved in chimaerins (Hall et. al., 1993; Leung et. al., 1994). The role of α2- and β2-
chimaerin SH2 domains is still unclear, and a phosphotyrosine-dependent target has not 
been unequivocally identified. Although α2-chimaerin interacts with the RTK EphA4, 
whether this is a phosphotyrosine-dependent SH2 interaction is not established (see 
below). The α2-chimaerin SH2 domain interacts with other proteins, such as CRMP-2, 
however, the interaction may not require phosphotyrosine binding (Brown et. al., 2004). 
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Over-expression of mutations in the SH2 domain of conserved arginines (R73 and R56), 
which abolish phosphotyrosine interactions (Waksman et. al., 1993; Hall et. al., 2001) 
did not prevent CRMP-2 binding to the α2-chimaerin SH2 domain (Brown et. al., 2004). 
 
The roles of chimaerin phosphorylation are currently under investigation and studies have 
been emerging over the last few years, during the course of this project (Kai et. al., 2007; 
Siliceo and Mérida, 2009; Griner et. al., 2010). Over-expressed β2-chimaerin in COS 
cells was reported to be phosphorylated by PKCδ at serine169 when stimulated by PMA 
or EGF. In addition, endogenous β2-chimaerin was phosphorylated in cerebellar granule 
neurones in response to BDNF (Griner et. al., 2010). An S169A mutant of β2-chimaerin 
was reported to be more sensitive to C1 mediated translocation from the cytosol to the 
membrane, with an enhanced effect on Rac-GTP in EGF treated COS cells (without 
altering intrinsic in vitro Rac-GAP activity). S196 phosphorylated β2-chimaerin detected 
by a phospho-antibody was soluble and not in the particulate fraction (membrane 
associated). Phosphorylation of β2-chimaerin S169 by PKCδ leads to its retention in the 
cytosol and restricts relocalisation and activation (Griner et. al., 2010). S169 in β2-
chimaerin lies in the SH2-C1 linker region, which in contrast to the C1 domain is not 
well conserved between α and β-chimaerins. In fact, the sequence divergence in this 
region could underlie differences in the regulation of α2- and β2-chimaerin. 
Tyrosine phosphorylation of β2-chimaerin Y21 in EGF-treated COS cells by SFKs was 
reported to have negative regulatory effects on its RacGAP activity (Kai et. al., 2007). 
Y21F (but not Y153F, a mutant that did not show reduced phosphorylation) showed 
significantly increased GAP activity towards RacGTP (Kai et. al., 2007). However, 
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tyrosine phosphorylation of β2-chimaerin by Lck in T-cells was mapped to Y153 which 
negatively regulated β2-chimaerin membrane stabilisation, leading to its decreased 
RacGAP activity (Siliceo and Mérida, 2009). 
 
1.5.7 Chimaerins in Cell Signalling 
 
β2-Chimaerin can function downstream of EGFR, which activates pathways leading to 
DAG generation and Rac activation. Fluorescent resonance energy transfer studies were 
used to show that translocation of β2-chimaerin mediated by EGF causes its association 
with Rac1 at the plasma membrane (Wang et. al., 2006). β2-Chimaerin has also been 
implicated as a tumour suppressor in breast cancer, inhibiting cancer cell proliferation 
and metastasis (Menna et. al., 2003; Yang et. al., 2005). In addition, chimaerins have a 
role in the immune system, where their catalytic activity is important in T-cell receptor 
inhibition and also in inhibition of Vav1-dependant stimulation of the transcription factor 
NF-AT (Caloca et. al., 2008), which is vital for T-cell activation and differentiation 
(Serfling et. al., 2000). β2-Chimaerin has also been shown to be important in regulating 
adhesion and chemotaxis of T cells and can localise at the immune synapse (Siliceo et. 
al., 2006).  
 
α2-Chimaerin is implicated in Sema 3A growth cone collapse through Rac1 (as described 
in section 1.4.1), with its SH2 and GAP domains being essential (Brown et. al., 2004). 
Activation of α2-chimaerin by PMA induces growth cone collapse and activated α2-
chimaerin interacts with CRMP-2 through its SH2 domain, and p35/Cdk5 via the GAP 
domain (Brown et. al., 2004; Qi et. al., 2004). CRMP-2 phosphorylation by Cdk5, which 
primes for phosphorylation by GSK3β, is required for growth cone collapse (Brown et. 
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al., 2004; Uchida et. al., 2005). It was demonstrated that both α2-chimaerin and CRMP-2 
can bind the sema 3A co-receptor neuropilin1/plexin-A1 (Brown et. al., 2004), further 
implicating them in this pathway. 
 
During the course of this study, EphA4 axonal growth cone collapse was shown to 
involve α2-chimaerin (Wegmeyer, et. al., 2007; Beg et. al., 2007; Iwasato et. al., 2007; 
Shi et. al., 2007). Chimaerin gene deletion mutant mice display similar phenotypes to that 
of ephrin B3-/- (Yokoyama et. al., 2001; Kullander et. al., 2001) and EphA4-/- mice 
(Dottori et. al., 1998). Axon development is inappropriately targeted, resulting in defects 
in the spinal cord central pattern generator and locomotor function (Wegmeyer, et. al., 
2007; Beg et. al., 2007; Iwasato et. al., 2007).  
EphA4 can bind to α2-chimaerin and mediates ephrin A1/EphA4 and ephrin B3/EphA4 
forward signalling. Active EphA4 stimulated increased tyrosine phosphorylation of α2-
chimaerin and was reported to enhance α2-chimaerin’s GAP activity for Rac1, 
inactivating Rac1 and inhibiting growth cone extension in motor circuit formation 
(Iwasato et. al., 2007; Shi et. al., 2007). However, Src-family kinase activity (inhibited 
by PP2) was also required in the pathway (Shi et. al., 2007).  Whether chimaerin binds 
EphA4 via a tyrosine phosphorylation dependent interaction is not entirely clear. Two 
groups reported that there were two EphA4 binding sites in chimaerin (Beg et. al., 2007; 
Wegmeyer, et. al., 2007), and a further study reported an EphA4 interaction with the C-
terminal of both α1- and α2-chimaerin (Iwasato et. al., 2007). β2-Chimaerin has also 
been shown to bind to EphA4 and EphA2 and inactivate Rac1 following ephrin A1 
treatment (Wegmeyer, et. al., 2007; Iwasato et. al., 2007; Shi et. al., 2007; Takeuchi et. 
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al., 2009). Ephrin A1 induces suppression of cell migration and knock down of β2-
chimaerin abolished this effect (Takeuchi et. al., 2009). EphA4 has been shown via 
peptide array to directly phosphorylate α2-chimaerin in vitro at tyrosines 21, 125, 143, 
333 and 357 (Warner et. al., 2008). 
The adaptor proteins Nck1 and Nck2, were also shown to interact with Eph receptors, 
including EphA4 (Holland et. al., 1997; Bisson et. al., 2007). Furthermore, α2-chimaerin 
(but not α1-chimaerin) was shown to bind Nck1 and Nck2 in a phosphotyrosine 
independent manner. This interaction requires the α2-chimaerin SH2 domain containing 
N-terminal (amino acids 1-183) and one of the three SH3 domains of Nck (Wegmeyer et. 
al., 2007). These studies suggest a role for Rac1, chimaerins, Nck proteins and tyrosine 
phosphorylation in ephrin/EphA4 growth cone collapse.  
 
1.5.8 Other Functions of α2-Chimaerin 
Mutations in the human CHN1 gene are involved in Duane’s retraction syndrome, a 
congenital eye movement disorder caused by an inability of ocular motor neurones to 
effectively innervate their target muscles (Miyake et. al., 2008). These mutations in the 
coding region, including the recently reported Y148F mutation (Miyake et. al., 2011), 
increased the RacGAP activity in vitro and are suggested to influence chimaerin structure 
as described (Caraganajah et. al., 2004; Colón-González et. al., 2008; Sosa et. al., 2009).  
In addition to its vital role in the development of ocular motor axons and locomotor 
circuits, α2-chimaerin is involved in cell migration. Knock down of the zebra fish CHN1 
gene homologue resulted in severe abnormalities, with defects in cell adhesion and 
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migration, indicating a key role for α2-(/β2-) chimaerin in early development (Leskow et. 
al., 2006).  
Recently, α2-chimaerin in mice was shown to control neuronal migration and functioning 
of the cerebral cortex with the involvement of CRMP-2 (Ip et. al., 2011). In utero 
suppression of α2-chimaerin arrested neuronal migration at the multipolar stage, with an 
accumulation of neurones in the subcortical region. As a result, mice with migration 
defects showed an imbalance between excitation and inhibition in local cortical circuitry 
and evidence of susceptibility to epileptic seizures (Ip et. al., 2011).  
α1-Chimaerin has a role in the regulation of synaptic activity in adult neurones. The C-
terminal interacts with the NR2A subunit of NMDA receptors and over expression of α1-
chimarin in hippocampal neurones inhibits spine formation and prunes existing spines 
(Van de Ven et. al., 2005). Stimulation of phospholipase Cβ in hippocampal neurones 
recruits α1-chimaerin to the membrane and pruning of dendrites on α1-chimaerin 
expression required both DAG binding and an active GAP domain (Buttery et. al., 2006).  
Literature points to a vital role for chimaerins in the developing nervous system and adult 
brain, in diverse signalling pathways. However, the proteins interacting with chimaerin in 
axonal guidance and its regulation in these signalling pathways have not yet been 
determined. 
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1.6 Aims of This Study 
The aim of this study is to investigate α2-chimaerin and interacting partners in neuronal 
signalling pathways. As described above, α2-chimaerin can be activated by phorbol 
esters/DAG, but also contains an SH2 domain which indicated probable participation in 
phosphotyrosine regulation. Chimaerin is tightly regulated by its auto-inhibited structure 
and a key question is how α2-chimaerin is activated in neuronal guidance pathways, 
could it be via DAG or phosphotyrosine signalling or both? This investigation aims to 
discover the tyrosine kinases and residues involved in the tyrosine phosphorylation of α2-
chimaerin. It will also try to establish what effects tyrosine phosphorylation of α2-
chimaerin may have on neuronal development and in the sema 3A and ephrin A1/EphA4 
pathways in which α2-chimaerin is now known to play a role. 
 The second part of this study aims to investigate new and established α2-chimaerin 
partner proteins in these pathways, particularly SH2 domain associated partners. Novel 
interacting partners have emerged during the course of this study, some discovered in our 
laboratory by a yeast two-hybrid screen. As a direct result of this study (and others’ 
work), α2-chimaerin has been shown to interact with a receptor, a tyrosine kinase and an 
adaptor protein, as well as a novel partner for α2-chimaerin involved in protein 
trafficking and degradation. How α2-chimaerin interacts with these partners and what 
functions may occur as a result of the interaction will be examined. 
Ultimately the study aims to bring a greater understanding of the signalling pathways that 
involve α2-chimaerin and its interacting partners. 
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2.1 Materials 
2.1.1 General Laboratory Reagents 
Water was obtained from an ELGA Maxima SC purification system, which was 
autoclaved to sterilise before use. General laboratory chemicals were obtained from 
Sigma-Aldrich or BDH.  
 
2.1.2 Oligomer Synthesis and cDNA Sequencing Service 
Oligonucleotides were custom synthesized by Sigma-Aldrich and cDNA sequencing was 
carried out by Cogenics. 
 
2.1.3 Reagents for DNA Methods 
Agarose was obtained from Sigma. 50x Tris-acetate-EDTA (TAE) was from Millipore. 
DNA restriction enzymes were from Invitrogen, Stratagene, Promega or New England 
Biolabs. The DNA markers Hae III-digested x174 and Hind III-digested bacteriophage 
were from Invitrogen. The site-directed mutagenesis kit was from Stratagene. Mini and 
Maxi prep DNA kits for DNA purification were from Qiagen.  
 
2.1.4 Reagents for Bacterial Methods 
E. coli XL1-blue CaCl2 competent cells were obtained from Stratagene. Tryptone was 
from BD Biosciences. Yeast extract and agarose were from DIFCO. 
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2.1.5 cDNA Constructs 
Plexin-A1 and Neuropilin 1 vectors, pcDNA3, were kindly provided by S. M. Strittmatter 
(Yale, USA). Fyn and K299M Fyn, pCMV5, vectors were kindly provided by M. Resh, 
(Sloan-Kettering, Hong Kong). EphA4 and Kinase Dead EphA4, pcDNA3, were kindly 
provided by N. Y. Ip (Hong Kong). Mammalian vectors used were pXJ40 with GFP, Flag 
and HA tags adjacent to the polylinker (E. Manser, GSK-IMCB Singapore), pXJ40-
8xHIS-precission-SBP and pBIOTIN-8HIS (pGEX-T4). PsiSTRIKE vectors with GFP, 
or including Neomycin or Hygromycin resistance genes were from Promega. 
 
2.1.6 Reagents for Protein Biochemistry Methods 
Triton X-100 and -mercaptoethanol were from BDH. Inhibitors DTT, sodium vanadate, 
PMSF and sodium fluoride were from Sigma. Protease inhibitor cocktail tablets were 
obtained from Roche. FLAG and HA conjugated agarose beads were from Sigma. 
TEMED was from Bio-Rad. Bis-acrylamide was from Severn Biotech. SeeBlue plus2 
Pre-Stained Standard Protein markers were from Invitrogen. PVDF was from Perkin-
Elmer. ECL hyperfilm and ECL solutions were from Amersham Healthcare. Developer 
and fixer solutions were from Kodak. 
 
2.1.7 Reagents for Cell Biology Methods 
DMEM, OptiMEM, Neurobasal Medium, B-27, Hanks Buffered Saline Solution, trypsin, 
antibiotic/antimycotic and Foetal Bovine Serum (FBS) and for transfections 
Lipofectamine and Lipofectamine 2000, were all obtained from Invitrogen. G418 was 
from Calbiochem. Disposable plastic-ware supplies were from Greiner. Nucleofector and 
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solution for electroporation of primary cells were from Amaxa. Slides and coverslips 
were from BDH. Laminin was obtained from ICN, Poly-D-Lysine was from Sigma. 
Bovine Serum Albumin was from Jackson Laboratories. TRITC Phalloidin was from 
Sigma. Slide mountant was from DAKO. 
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2.1.8 Antibodies 
Antibody Dilution for 
immunoblotting 
Dilution for cell 
immunostaining 
Donor 
Animal 
Company 
Primary Antibodies     
α2-Chimaerin 1:2000 1:100 Rabbit In House 
FLAG 1:2000 1:100 Rabbit Sigma 
HA 1:2000  Rabbit Bethyl Laboratories 
Fyn 1:250  Mouse R and D Systems 
EphA4 1:200  Rabbbit Santa Cruz 
4G10 1:1000  Mouse Upstate/Millipore 
PY20 1:1000  Mouse Signal Transduction 
Vps28 1:250 1:20 Mouse In House 
Nck1 1:1000  Rabbit Epitomics 
Tau  1:100 Mouse Chemicon 
Secondary 
Antibodies 
    
Mouse HRP 1:1000  Rabbit DAKO 
Rabbit HRP 1:1000  Swine DAKO 
Trueblot HRP 1:1000  Mouse eBioscience 
Trueblot HRP 1:1000  Rabbit eBioscience 
Rabbit Cy5  1:100 Donkey Jackson Laboratories 
Mouse FITC  1:100 Donkey Jackson Laboratories 
Table 2.1: Table of Antibodies Table of antibodies, dilutions used for immunoblotting and 
immunostaining and supplier. 
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2.2 Methods 
2.3 Bacterial Methods 
2.3.1 Solutions for Bacterial Growth 
 LB Media- 1 % Tryptone, 1 % NaCl, 0.5 % Yeast Extract, in ddH2O, sterilised by 
autoclave. 
 LB Agar- 1.5 % agarose in LB media, sterilised by autoclave. 
 Ampicillin- was added at 100 µg/ml prior to use when antibiotic selection was 
required. 
 
2.3.2 Production of CaCl2 Competent Bacteria 
A single E. coli XL-1 Blue competent cell colony was picked from an agar plate using a 
sterile toothpick and grown in 100 ml of LB media at 37 °C for approximately 3 hours 
until the absorbance at 600 nm measured 0.35. The bacteria were cooled on ice for 10 
minutes, pelleted at 2,700 g for 10 minutes at 4 °C and the supernatant removed. The 
pellet was resuspended in 30 ml of ice-cold 50 mM CaCl2 for 5-10 minutes, pelleted at 
2,700 g for 10 minutes at 4 °C and the supernatant removed. The pellet was resuspended 
in 2 ml of 15 % glycerol in 50 mM CaCl2 and aliquots frozen at -80 °C. 
 
2.3.3 Transformation of Competent Bacteria 
Competent XL-1 Blue or CaCl2 (as described above) competent cells were thawed from -
80 °C on ice. For commercial XL-1 Blue cells only, 1.7µl of β-mercaptoethanol was 
added to 100µl of bacteria and incubated on ice for 10 minutes. For transformation, 5 µg 
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of DNA was added to 100µl of bacteria, for re-transformation 1 µg of DNA was added to 
10-50 µl of bacteria and this was incubated on ice for 30 minutes. The bacteria were heat 
shocked by heating them to 42 oC  for 30 or 90 seconds, for commercial XL-1 Blue and 
CaCl2 (described above) cells respectively and returned to ice for 2 minutes. For 
transformations (but not re-transformations) 1 ml of LB media was added to the bacteria 
for 1 hour, agitating at 37 oC. The bacteria were pelleted in a bench top centrifuge, 900 µl 
of the supernatant was removed, and the pellet re-suspended in the remaining 100µl of 
LB media. The bacteria were streaked onto an agar plate containing ampicillin and 
incubated overnight at 37 oC. 
 
2.3.4 Growing Bacterial Cultures for DNA Preparation 
 
Using a sterile toothpick, a single bacterial colony was taken off the agar plate and placed 
into 5 ml for mini-preparations or 250 ml for maxi-preparations of LB media 
supplemented with 100 µg/ml ampicillin. This was incubated overnight at 37 oC with 
agitation. The culture was centrifuged at 3,000 rpm for 10 minutes at 4 oC. The bacterial 
pellets for maxi-preparation only were washed by re-suspention in 50 ml of PBS and 
transferred to 50 ml falcon tubes, which were centrifuged at 3,000 rpm for 10 minutes at 
4 oC. Supernatants were removed and the bacterial pellets were ready for DNA extraction, 
or stored at -20 oC and the DNA extracted at a later date. 
 
2.3.5 Isolation of Plasmid DNA 
Plasmid DNA was extracted from the bacterial pellets using Mini or Maxi kits from 
Qiagen as directed by the manufacturer’s instructions. Briefly, the bacterial pellets were 
re-suspended and then lysed, the lysate was passed through a filter to remove genomic 
 75 
DNA and cellular debris. The plasmid DNA was passed through a Qiagen column which 
it bound, the DNA was washed and then eluted. Despite the kit insert indicating DNA 
clean up should no longer be necessary, it was found in our laboratory that the stability of 
DNA was enhanced and therefore DNA was cleaned up by phenol chloroform extraction 
and ethanol precipitation (See section 2.4.2). 
 
2.3.6 Quantification of DNA Quality and Concentration 
10 µl of DNA was added to 1 ml of EB buffer (10 mM Tris/HCl, pH 8.5, Qiagen) and 
mixed well. The absorption of this solution was then measured by spectrophotometer at 
two wavelengths, 260 nm (DNA absorption peak) and 280 nm (protein absorption peak), 
against a blank sample of EB buffer. A ratio of the A260:A280 gave an indication of the 
samples purity, with a 1.8 reading considered desirable. DNA concentration was 
determined by the following equation (derived from an absorbance at 260 nm of 1 being 
equal to ~50 µg/ml of DNA in TE buffer (Sambrook and Russell, 2001));  
DNA concentration (µg/ml) = Absorbance at 260 nm x 50 (the extinction coefficient) x 
1/1000 (dilution factor) x 1 (the path length). 
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2.4 DNA Methods 
2.4.1 DNA Solutions 
 6x DNA Gel Loading Buffer- 30% glycerol, 0.25% Bromophenol blue, in 1x 
Tris-Acetate-EDTA (TAE) Buffer.  
 1% Agarose Gel- 1 g Agarose, 1x TAE Buffer 100 ml, warmed in microwave 
until the agarose dissolved, when cool, 6 µg of EtBr was added and the gel was 
poured and left to set.  
 TE Buffer- 10 mM Tris-Cl pH 7.5, 1 mM EDTA in ddH2O. 
 
 
2.4.2 Phenol/Chloroform Extraction and Ethanol Precipitation 
An equal volume of phenol chloroform was added to DNA and vortexed until white, the 
mix was centrifuged at 14,000 rpm for 4 minutes. The top aqueous layer (containing the 
DNA) was carefully removed so as not to disturb the interface. The above step was then 
repeated. Two volumes of 100 % ethanol and 0.1 volumes of 3 M Na Acetate pH 5.2 was 
added to the DNA and mixed gently. This was placed on dry ice for 5-10 minutes and 
centrifuged at 14,000 rpm for 10 minutes. The supernatant was removed and the pellet 
washed in 200 µl of 70 % ethanol and centrifuged at 14,000 rpm for 5 minutes. All liquid 
was removed and the pellet dried. The pellet was resuspended in an appropriate amount 
of TE buffer. 
 
2.4.3 DNA Electrophoresis 
1 % agarose gels were placed into an electrophoresis tank and covered with 1x TAE 
buffer. DNA markers were loaded to give size indication and DNA samples were 
 77 
prepared by adding 6x loading buffer and then loaded into the wells. The gel was run at 
100 Volts for 40-50 minutes. DNA was visualized via an ultra violet light box and 
pictures were taken using a Kodak EDAS 290 camera and Kodak Molecular Imaging 
Software. 
 
2.4.4 Polymerase Chain Reaction (PCR) 
PCR was used for site directed mutagenesis reactions and to amplify cDNA fragments to 
be cloned into different vectors. PCR reactions were set up as follows; 
 
For Amplification;     For Site Directed Mutagenesis; 
5 µl 10x Reaction Buffer     5 µl 10x Reaction Buffer 
3 µl MgCl2      10 ng Template DNA 
125 ng Primer 1     125 ng Primer 1 
125 ng Primer 2     125 ng Primer 2 
1 µl of dNTP Mix     1 µl of dNTP Mix 
0.5 µg Template DNA    3 µl QuikSolution  
Made up to 50 µl with ddH2O   Made up to 50 µl with ddH2O 
0.5 µl Taq Polymerase (5µg/µl)             1 µl PfuTurbo DNA polymerase 
 
Samples were mixed and placed into the thermal cycler for PCR with a program set as 
follows; 
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   94°C  1 minute  Initialisation 
   94°C  45 seconds  Denaturation 
28 Cycles  50-60 °C 30 seconds  Annealing (Dependent on sequence) 
   72°C  2 minutes  Elongation 
   72°C  5 minutes  Final Elongation 
    7°C  Indefinitely 
A sample of 10 µl was checked for product by DNA gel electrophoresis. 
 
2.4.5 Site Directed Mutagenesis 
For all site directed mutagenesis, the QuikChange XL Site-Directed Mutagenesis Kit 
from Stratagene was used. Several sites were mutated in α2-chimaerin. Cysteine 239 was 
mutated to abolish DAG binding as published for β2-chimaerin (Canagarajah et. al, 
2004). Previous members of the laboratory had shown that α2-chimaerin can be tyrosine 
phosphorylated In Vitro towards the N-terminal region. A phosphorylation prediction 
website NETPhos was used to find the most likely tyrosine sites and the highest scoring 
tyrosines. These included Y70, 143, 148, 157 and 303. Tyrosine 303 was chosen to be 
mutated as it resides next to the essential arginine residue for GAP activity. Once the sites 
had been chosen, oligos were designed to incorporate the change of amino acid. Cysteine 
was mutated to alanine to prevent DAG binding and tyrosines were mutated to 
phenylalanine so that they can no longer be phosphorylated. The designed oligos are 
shown below; 
- Wild type: 5’CAGGGAGTGAAATGTGCAGATTGTGGTTTGAATGTTCATAAGCAG 3’ 
C239A Primer 1: 5’ CAGGGAGTGAAATGTGCAGATGCTGGTTTGAATGTTCATAAGCAG 3’ 
C239A Primer 2: 5’ CTGCTTATGAACATTCAAACCAGCATCTGCACATTTCACTCCCTG 3’ 
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- Wild Type: 5’ GGTCTTAATTCTGAAGGACTATACCGAGTATCAGGATTTAGTGAC 3’ 
Y303F Primer 1: 5’ GGTCTTAATTCTGAAGGACTATTCCGAGTATCAGGATTTAGTGAC 3’ 
Y303F Primer 2: 5’ GTCACTAAATCCTGATACTCGGAATAGTCCTTCAGAATTAAGACC 3’ 
 
- Wild Type: 5’ GTGGCTGAGGGGAGCTACCTCATCCGGGAGAGC 3’ 
Y70F Primer 1: 5’ GTGGCTGAGGGGAGCTTCCTCATCCGGGAGAGC 3’ 
Y70F Primer 1: 5’ GCTCTCCCGGATGAGGAAGCTCCCCTCAGCCAC 3’ 
 
- Wild Type: 5’ CAAGATGACGATAAACCCAATTATTGAGCACGTAGGATACACAACC 3’ 
Y143F Primer 1: 5’ CAAGATGACGATAAACCCAATTTTTGAGCACGTAGGATACACAACC 3’ 
Y143F Primer 1: 5’ GGTTGTGTATCCTACGTGCTCAAAAATTGGGTTTATCGTCATCTTG 3’ 
 
- Wild Type: 5’ CCAATTTATGAGCACGTAGGATACACAACCTTAAACAGAGAGCC 3’ 
Y148F Primer 1: 5’ CCAATTTATGAGCACGTAGGATTCACAACCTTAAACAGAGAGCC 3’ 
Y148F Primer 1: 5’ GGCTCTCTGTTTAAGGTTGTGAATCCTACGTGCTCATAAATTGG 3’ 
 
- Wild Type: 5’ CTTAAACAGAGAGCCAGCATACAAAAAACATATGCCAGTC 3’ 
Y157F Primer 1: 5’ CTTAAACAGAGAGCCAGCATTCAAAAAACATATGCCAGTC 3’ 
Y157F Primer 1: 5’ GACTGGCATATGTTTTTTGAATGCTGGCTCTCTGTTTAAG 3’ 
 
The oligos were used in a PCR reaction as described above.  
To eliminate template plasmid, 1 µl of Dpn1 restriction enzyme was added to the PCR 
mutagenesis product and this was incubated at 37 °C. After 2 hours this was transformed 
into competent bacteria and colonies were grown for mini-preparation as described in 
sections 2.3.3 and 2.3.4. DNA from the mini-preparations was sent for sequencing. A 
clone containing the mutation was re-transformed and DNA purified by maxi-preparation 
ready for transient transfections into mammalian cells. 
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2.4.6 Cloning of shRNA Sequences 
ShRNA oligos were designed using Promega’s shRNA design tool, to predict the most 
likely sequences to cause knock down, three sequences were chosen to test. A scrambled 
sequence was also chosen to act as a negative control. Oligos were from Sigma Genosys. 
Oligos include an upstream ACC overhang; a loop, TTCAAGAGA; a U6 termination 
sequence, TTTTT; and a downstream overhang and Pst1 partial site, C on the 5’-3’ oligo 
and GACGT on the 3’-5’ oligo. Oligos are as follows; 
ShRNA oligos for α2-chimaerin; 
Oligos for sequence 1:  
5’ACCGACGATAAACCCAATTTATTTCAAGAGAATAAATTGGGTTTATCGTCTTTTTC 3’ 
5’ TGCAGAAAAAGACGATAAACCCAATTTATTCTCTTGAAATAAATTGGGTTTATCGT 3’ 
Oligos for sequence 2:  
5’ ACCGGCCCTGACCCTGTTTGATTTCAAGAGAATCAAACAGGGTCAGGGCCTTTTTC 3’ 
5’ TGCAGAAAAAGGCCCTGACCCTGTTTGATTCTCTTGAAATCAAACAGGGTCAGGGC 3’ 
Oligos for sequence 3:  
5’ ACCGGATACACAACCTTAAACATTCAAGAGATGTTTAAGGTTGTGTATCCTTTTTC 3’ 
5’ TGCAGAAAAAGGATACACAACCTTAAACATCTCTTGAATGTTTAAGGTTGTGTATC 3’ 
Scrambled Sequence: 
5’ ACCGCTCTGACCAAATAAATTATTCAAGAGATAATTTATTTGGTCAGAGCTTTTTC 3’ 
5’ TGCAGAAAAAGCTCTGACCAAATAAATTATCTCTTGAATAATTTATTTGGTCAGAG 3’ 
 
ShRNA oligos for Vps28; 
Oligos for sequence 1:  
5’ ACCGGATATCACCCACAATAAATTCAAGAGATTTATTGTGGGTGATATCCTTTTTC 3’ 
5’ TGCAGAAAAAGGATATCACCCACAATAAATCTCTTGAATTTATTGTGGGTGATATC 3’ 
 
Oligos for sequence 2:  
5’ ACCGAGCTGTATGAGGAAGTAATTCAAGAGATTACTTCCTCATACAGCTCTTTTTC 3’ 
5’ TGCAGAAAAAGAGCTGTATGAGGAAGTAATCTCTTGAATTACTTCCTCATACAGCT 3’ 
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Oligos for sequence 3:  
5’ ACCGGCTCCTGGTCCAGTACAAATTCAAGAGATTTGTACTGGACCAGGAGCTTTTTC 3’ 
5’ TGCAGAAAAAGCTCCTGGTCCAGTACAAATCTCTTGAATTTGTACTGGACCAGGAG 3’ 
 
 
The system used was siSTRIKE U6 Hairpin Cloning System from Promega, which 
included linearised psiSTRIKE vectors containing the U6 promoter. This study used 
psiSTRIKE vectors encoding either neomycin resistance or hygromycin resistance. 
Oligonucleotides were diluted into nuclease free water to a concentration of 1 µg/µl. 
Annealing reactions were set up as follows; 
- Oligonucleotide A    2 µl 
- Oligonucleotide B    2 µl 
- Oligo Annealing Buffer  46 µl  (60 mM Tris-Hcl (pH 7.5), 500 mM NaCl, 60 mM 
MgCl2, 10 mM DTT.)         
This mix was heated to 90°C for 3 minutes and then placed into a water bath at 37°C for 
15 minutes. The annealed hairpin oligonucleotides were further diluted by adding 5 µl to 
45 µl of nuclease free water.  Ligations were set up as shown below; 
- 2x rapid ligation buffer (vortexed before use) 5 µl 
- psiSTRIKE vector (50 µg/ml)   1 µl 
- Annealed oligonucleotides    1 µl 
- Nuclease free water     2 µl 
- T4 DNA ligase     1 µl 
The ligation mixture was mixed by pipetting and incubated at room temperature for 2 
hours. Transformation of competent bacteria was performed and colonies grown for mini-
preparation as described in sections 2.3.3 and 2.3.4.  
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To screen for the insert, DNA was digested by Pst 1, a site incorporated into the vectors 
to allow screening for an insert. After Pst1 digestion, samples were checked by DNA 
electrophoresis and imaged via uv light and a Polaroid camera. Most samples contained 
the insert and therefore, one of each of the clones containing the shRNA insert sequence 
was picked to analyse. These were re-transformed, as described in sections 2.3.3 and 
2.3.4, to ensure a clean colony and the DNA maxi-prepared ready for transient 
transfection into mammalian cells.  
 
2.4.7 Cloning into Tap-Tag Vectors 
The vectors pXJ40-8xHIS-precission-SBP and pBIOTIN-8HIS (pGEX-T4) were 
obtained from E. Manser, GSK-IMCB Singapore. These dual tagged His-Biotin tagged 
vectors enable proteins to be purified onto Nickel beads and subsequently purified via 
streptavidin to investigate endogenous partner proteins. Oligos were designed to amplify 
α2-chimaerin and the N-terminal region of α2-chimaerin including the SH2 domain 
(amino acids 1-137). Oligos included a stop codon TAG, a restriction site for cloning into 
the vector (Xho1 and Pst1 for the pXJ40 vector or EcoR1 and Sal1 for the pGEX vector) 
and an enzyme seat GACGTC. Oligos were designed as follows; 
 
- pXJ40-8xHIS-precission-SBP 
Forward Primer (including Xho1 restriction site) 
5’ GAC GTC CTC GAG ATG GCC CTG ACC CTG TTT G 3’ 
Reverse Primer (including Pst1 restriction site) 
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For full length α2-chimaerin:  
5’GA CGT CCT GCA GAT TTA AAA TAA AAT GTC TTC GTT TTT G 3’ 
For 1-137 α2-chimaerin: 
5’ GA CGT CCT GCA GGT CTA CAT CTT GGC AAT GTA TTC TGC TGC 3’ 
  
- pBIOTIN-8HIS (pGEX-T4) 
Forward Primer (including EcoR1 restriction site) 
5’ GAC GTC GAA TTC ATG GCC CTG ACC CTG TTT G 3’ 
Reverse Primer (including Sal1 restriction site) 
For full length α2-chimaerin:  
5’ GAC GTC GTC GAC AAA TAA AAT GTC TTC GTT TTT G 3’ 
For 1-137 α2-chimaerin: 
5’ GAC GTC GTC GAC CAT CTT GGC AAT GTA TTC 3’ 
 
The oligos were used in a PCR reaction for amplification as described previously. Once 
the PCR conditions (particularly the annealing temperature) had been established, a large 
scale PCR was set up and the product visualised via DNA gel electrophoresis and an 
ultra-violet light box. The product was cut out of the agarose gel and extracted and 
cleaned up using the QIAquick Gel Extraction Kit (from Qiagen) according to the 
manufacturer’s instructions. Digests were set up as follows; 
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48 µl DNA 
6 µl Enzyme 
10 µl Appropriate Enzyme Buffer 
1 µl BSA if required (or add 1 µl to the ddH2O added) 
35 µl ddH2O 
 
Both the vectors and the inserts required double digests, which were done sequentially 
with overnight incubations at 37 °C. Between each digest the enzymes were stopped from 
functioning and the DNA purified using the QIAquick Gel Extraction Kit. After the 
second digestion, the vectors were dephosphorylated. To 100 µl of vector digest, 13 µl of 
10x buffer and 11 µl of 1:100 diluted alkaline phosphatase enzyme was added and 
incubated for 30 minutes at 37 °C.  After this time, another 11 µl of 1:100 diluted alkaline 
phosphatase enzyme was added and again incubated for 30 minutes at 37 °C. 
Vectors and insert sizes were checked via DNA electrophoresis before ligation. Ligations 
were set up as follows; 
 
0.5 µl of Vector DNA 
16.5 µl of Insert DNA (or ddH2O for vector control) 
2 µl of 10x T4 DNA Ligase Buffer 
1 µl of Ligase Enzyme 
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The vector and insert DNA was denatured at 65 °C for 5 minutes, cooled on ice and the 
condensation centrifuged down. The buffer and enzyme were added, mixed on ice and 
incubated at 16 °C overnight. Ligation mixes were transformed as described in section 
2.3.3 and E. coli colonies grown and the DNA purified by mini-preparation (Qiagen). 
The products were digested with the same enzymes used to clone the inserts, to check 
that the product contained the insert of the correct size. Once this was established and 
confirmed by DNA sequencing, the insert containing clone was retransformed and 
purified by maxi-preparation, ready for transient transfection into mammalian cells. 
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2.5 Protein Biochemistry Methods 
2.5.1 Protein Expression Solutions 
 12% SDS Polyacrylamide Gel Electrophoresis (PAGE) gel- Deionised water 
10.2 ml, 30% Acrylamide stock solution 12 ml, 1.5 M TrisHCl pH 8.8 7.5 ml, 20 
% SDS 150 µl, 10 % APS 150 µl, TEMED 20 µl.  
 4% SDS stack- Deionised water 6.15 ml, 30% Acrylamide stock solution 1.34 
ml, 0.5 M TrisHCl pH 6.8 2.5 ml, 20 % SDS 50 µl, 10 % APS 50 µl, TEMED 10 
µl.  
 4x Protein Sample Buffer- 200 mM TrisHCl pH 6.8, 8 % SDS, 40 % glycerol, 
400 mM  β-mercaptoethanol and 0.4 % Bromophenol blue made up in ddH2O.  
 10x Tris-Glycine Running Buffer- Tris Base 30 g, Glycine 144 g, SDS 10 g, 
make up to 1 L with ddH2O.  
 10x Western Transfer Buffer- 48 mM Tris Base, 39 mM Glycine, 1.3 mM SDS, 
and make up to 1 L with ddH2O. To use, make 1x Transfer buffer as follows; 100 
ml 10x Transfer buffer, 200 ml Methanol and 700 ml ddH2O. 
 PBS-Tween- 1 x PBS 1 L, Tween 0.1 %.  
  Blocking Buffer- 5 % Marvel (powdered milk) in PBS-Tween. 
 Coomassie Stain- Coomassie Brilliant Blue R250  0.5 g, Methanol:Water (1:1) 
25 ml, Glacial acetic acid 50 ml, filter through Whatman filter paper. 
 Destain- Methanol 450 ml, Glacial Acetic Acid 100 ml and Deionised Water 450 
ml. 
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2.5.2 Analysis of Proteins by Polyacrylamide Gel Electrophoresis 
(PAGE) 
Protein gels were made using a 12 % SDS separating gel, topped by a 4 % SDS stack. 10 
µl of SeeBlue Pre-stained protein markers were loaded onto the gel to give an indication 
of protein size, once bands are identified. 4x Protein Sample Buffer was added to 
samples, which were heated at 95 °C for 10 minutes and 20 µl loaded onto the gel. Gels 
were run at 170 V for one hour. 
 
2.5.3 Transferring Proteins to Polyvinylidene Difluoride (PVDF) 
Membranes 
The protein was transferred from the polyacrylamide gel onto PVDF membrane using a 
Trans-blot semi-dry-transfer blotter (Biorad). The PVDF membrane was soaked in 
methanol and then as with the gels and blotting paper, soaked in 1x transfer buffer prior 
to being placed into the Trans-blot semi-dry-transfer blotter. Four pieces of 3 mm blotting 
paper were placed either side of the gel and membrane and any air bubbles rolled out. 
The Trans-blot semi-dry-transfer blotter was run at 22 V for 36minutes. 
 
2.5.4 Coomassie Staining of Proteins 
PVDF membranes were stained with coomassie stain for 5 minutes and placed in destain 
twice for ten minutes each. Proteins may be visualised in this way and background was 
reduced when PVDF membranes were subsequently used for immunodetection. 
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2.5.5 Immunodetection of Proteins Immobilised on PVDF Membranes 
After de-staining, PVDF membranes were thoroughly washed with PBS. Membranes 
were placed in blocking buffer over night at 4 ˚C or for an hour at room temperature. 
Primary antibodies were added at the appropriate dilution (see antibody table) in 1 % 
Marvel in PBS-Tween and incubated over night at 4 ˚C or for two hours at room 
temperature. Membranes were washed five times with PBS-Tween and then incubated 
with secondary antibodies conjugated to Horse Radish Peroxidase (HRP) (for dilutions 
see antibody table, 2.1.8) also in 1 % marvel in PBS-Tween for one hour at room 
temperature. Membranes were washed five times with PBS-Tween before being 
incubated with ECL reagent for two minutes before being developed onto light sensitive 
film for detection. 
For re-blotting, membranes were incubated in 1x Re-Blot Plus Strong Antibody Striping 
Solution (from Millipore) for 30 minutes at room temperature, thoroughly washed with 
PBS and then blocked as described above. 
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2.6 Cell Biology Methods 
2.6.1 Cell Solutions 
 Growth Media- DMEM, 10 % FCS and 1 % Antibiotic/antimycotic. 
 Freezing Solution- 10 % DMSO and 90 % FCS. 
 Plating Media- OptiMEM, 10 % FCS, 20 mM Glucose and 1 % Antibiotic/ 
antimycotic. 
 NB plus Media- Neurobasal media, 1:50 dilution of B-27 supplement, 0.5 mM L-
glutamine, 1 mM Sodium Pyruvate, 0.06 mg/ml Cysteine and 1 % Antibiotic/ 
antimycotic. 
 EB Lysis Buffer- 20 mM TrisHCl pH 7.4, 5 mM EDTA, 150 mM NaCl, 10 % 
glycerol and 1 % triton-X100 made up in ddH2O. 
 N1E-115 Lysis Buffer- 25 mM HEPES pH 7.5, 0.3 M NaCl, 1 mM MgCl, 1 mM 
EGTA, 20 mM p-glycerophosphate, 5 % glycerol and 1 % triton-X100 made up 
in ddH2O. 
 Inhibitors- 0.1 mM Sodium Vanadate, 10 mM Sodium Flouride, 5 mM DTT, 1x 
Protein inhibitor cocktail and 1 mM PMSF. 
 
2.6.2 Recovery of Cells from Frozen Stocks 
Vials of frozen cells were thawed from liquid nitrogen quickly in a 37 ˚C water bath. 
Cells were placed into pre-warmed media and centrifuged at 800 rpm for 5 minutes. The 
supernatant was removed and the cell pellet re-suspended in fresh media and plated onto 
Nunc coated dishes. 
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2.6.3 Freezing Down Cell Stocks 
Cells were removed from the plate by pipetting or by trypsin treatment and centrifuged at 
800 rpm for 5 minutes. Supernatant was removed and the pellet was resuspended in 1.5 
ml of freezing solution and placed into a Cryovial. Cells were frozen down slowly to -20 
˚C and then to -80 °C over night before being placed into liquid nitrogen for storage. 
 
2.6.4 Cell Maintenance 
Three main cell types were used in this study, all cell types were maintained in incubators 
at 37 °C with 5 % CO2. 
COS-7 cells, derived from monkey kidney cells, were kept in media as listed above. To 
maintain the cells at the required density or to plate them for transfection, they were 
washed with PBS and treated with trypsin to detach them from the dish. The cells were 
centrifuged at 800 rpm for 5 minutes, the supernatant removed and the cells resuspended 
in media and distributed as required into dishes. 
Mouse neuroblastoma N1E-115 cells were kept in media as above and maintained by 
never allowing them to become fully confluent. As loosely adherent cells, they do not 
require trypsin and can be pipetted off the dishes when required to plate them for 
transfection or for maintenance. N1E-115 cell lines permanently expressing receptors 
neuropilin-1, neuropilin-1/Plexin-A1 or Eph A4 were made during this study. These all 
had a neomycin selection gene encoded in their vectors to allow for selection of cells 
expressing the relevant receptor and were cultured in 4-800 µg/ml of the antibiotic G418.  
 91 
The third cell type used were primary neuronal cells, hippocampal and cortical neurones 
isolated from E18 rat brains. These were isolated as described in section 2.6.11 and 
maintained by replacing half of their NB plus media every 2-3 days.  
 
2.6.5 Preparation of Coverslips 
Glass coverslips (24 x 24, thickness 1) were treated with 40 % HCl, 60 % ethanol for 10 
minutes and washed thoroughly with water. Coverslips were placed out individually to 
dry on blotting paper, packaged into foil and baked overnight in an oven. 
Coverslips were coated for use for 1 hour with 10 µg/ml laminin for N1E-115 
neuroblastoma cells, or 30 µg/ml Poly-D-Lysine (in ddH2O) plus 2 µg/ml laminin (in 
PBS) for primary neurones. Coverslips were washed three times with water and allowed 
to dry before adding media and cells to them. 
 
2.6.6 Transient Transfection of Cells 
Cells were plated at around 70 % confluency. A DNA mix of 1 ml of DMEM, 2-5 µg of 
DNA and 15 µl of lipofectamine or lipofectamine 2000 (for Cos-7 and N1E-115 cells 
respectively) was made and left at room temperature for 45 minutes. Cells were serum 
starved in DMEM for this time and then the DNA mix was added for 4 hours. After this 
time, the media was replaced with the cell type’s normal growth medium for 16 hours 
before harvesting.  
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2.6.7 Cell Treatments  
- Phorbol 12-myristate 13-acetate (PMA) 
PMA stock solution was made at 1 mM in DMSO and added to cells at 1 µM for 1 hour 
at 37 ˚C. 
- Semaphorin 3A 
Kindly given by Britta Eickholt (Eickholt, et. al., 2002), Sema 3A-Fc enriched 
supernatent was added to cells at a 1:50 dilution for 10 minutes at 37 ˚C. 
- Ephrin A1 
Ephrin A1 (R&D Systems) (100 µg/ml stock in PBS) was clustered with goat-anti-human 
IgG at a 1:4.5 ratio for 1 hour at room temperature, before being added to cells at 5 µg/ml 
for 10 minutes at 37 ˚C.  
- PP2/PP3 
The Src family kinase inhibitor PP2 (Sigma) and its inactive analogue PP3 were added to 
cells at 20 µM for 1 hour at 37 ˚C.      
- Pervanadate 
Pervandate is a phosphatase inhibitor. A pervanadate stock was made; 593 µl PBS, 60 µl 
200 mM Na3VO4, 1 µl 30 % w/w H2O2, and left at room temperature for 5 minutes. A 20 
mg/ml catalase stock was made; with an equal volume of ddH2O and 0.1 M PPB and 0.01 
g of catalase added per 500 µl. 0.6 g of the catalase stock was added to the pervanadate 
stock and left at room temperature for 5 minutes. This was added to cells at a 1:200 
dilution for 20 minutes at 37 ˚C. 
 
 
 93 
2.6.8 Affinity Purification of Proteins (by pull down assay) 
Dishes containing COS-7 cells expressing tagged proteins were placed on ice, media was 
removed and the cells washed with PBS. 500 µl of EB lysis buffer with inhibitors freshly 
added was added to the dish and incubated for 5 minutes on ice. Cells were scraped off 
the dish and pipetted into eppendorf tubes. The samples were sonicated in a sonicator 
ultrasonic processor (Heat Systems) at level 6 for 5 minutes and incubated on ice for 30 
minutes. Samples were pelleted in a 4 ˚C centrifuge at 14,000 g for 20 minutes.  
Dishes containing N1E-115 cells expressing tagged proteins were placed on ice, media 
was removed and 500 µl of N1E-115 lysis buffer with inhibitors freshly added was added 
to the dish. Cells were scraped off the dish and pipetted into eppendorf tubes. The 
samples were incubated on ice for 15 minutes, and then pelleted at 4 ˚C at 14,000 g for 15 
minutes.  
Following centrifugation, for both COS-7 and N1E-115 neuroblastoma cells, a 100 µl 
supernatant sample was collected, 4x protein sample buffer was added and these were 
frozen at -20 ˚C. The rest of the supernatant was transferred to a new tube and incubated 
with 30 µl of the appropriate affinity beads (FLAG or HA antibody) for 3 hours at 4 ˚C 
on a rotary shaker. Beads were washed 5 times in EB lysis buffer (COS-7 cells) or N1E-
115 lysis buffer (N1E-115 cells) with the inhibitors freshly added and after the final wash 
beads were pelleted, all supernatant removed and 4x protein sample buffer added. 
Samples were frozen for later analysis by SDS-PAGE. 
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2.6.9 Immunoprecipitations 
To immunoprecipitate α2-chimaerin, cells were lysed as described in protein pull downs. 
1 µg of rabbit IgG and 20 µl of rabbit True-blot or protein A/G beads were added to pre-
clear the supernatant for 30 minutes at 4 °C. Beads were pelleted in a 4 °C centrifuge and 
the supernatant moved to a new tube. α2-Chimaerin antibody was added to the 
supernatant for an hour at 4 °C. A fresh 20 µl of beads was added and the tube rotated at 
4 °C for ~ 3 hours. Beads were washed 4x with PBS and after the last wash, the 
supernatant removed and sample buffer added. Samples were then frozen for later 
analysis by SDS-PAGE. 
 
2.6.10 His-Biotin-Tandem Affinity Purification from Brain Extracts 
To pull down α2-chimaerin using the His-Biotin vector tags, BL-21 cells were 
transformed with α2-chimaerin His-Biotin onto an agar plate and incubated at 37 °C 
overnight. Around 30 of the colonies were inoculated into 400 ml of LB media 
supplemented with ampicillin and grown at 37 °C until an absorbance of OD600 = 1 was 
achieved. IPTG 0.25 mg/ml and D-Biotin 1 µg/ml was added for a further 3 h of agitation 
at room temperature. Cells were centrifuged for 10 minutes at 6000 rpm at 4 °C. The 
pellet was stored overnight at -80 °C. 
The following day, the pellet was thawed on ice and subsequently resuspended in 40 ml 
of cold bacteria cell lysis buffer (50 mM Tris (pH 8.0), 0.5 % Triton X-100, 0.5 mM 
MgCl2, 10 mM Imidazole and PBS. Protease inhibitors were added before use). For 5 
minutes. Cells were sonicated twice for a total of 1 minute each, with 20 seconds of 
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sonication and 20 seconds pause. Cells were centrifuged at 40,000 rpm, 4 °C for 30 
minutes. 
The supernatant was loaded onto a nickel column (GE Healthcare), washed twice with a 
column volume of cold washing buffer (PBS, 25 mM Tris (pH 7.5) and 0.1 % Triton X-
100) and 20 mM Imidazole. The His-tagged fusion protein was eluted with 50 mM 
Tris.Cl (pH 8.5), 100 mM NaCl and 250 mM Imidazole.  
The eluted protein was passed through a streptavidin binding column (from IBA) and 
washed three times with cold washing buffer and 0.1 µg/ml of Biotin to block non-
specific sites. Previously prepared synaptosomal membrane fractions of rat brain extract 
was passed through the column twice and subsequently washed three times with cold 
washing buffer. The interactions were eluted with desthiobiotin, then 1 % SDS sample 
buffer at 37 °C and subsequently 2 % SDS sample buffer at 37 °C. Samples were 
analysed via SDS-PAGE.  
 
2.6.11 Neuronal Preparation 
The hippocampus or cortices were dissected from E18 rat brains, all tissue was kept in ice 
cold Hanks buffered saline solution (HBSS). Once dissected, the tissue was suspended in 
2 ml of HBSS, 0.2 µg/ml of DNase 1 and 1x trypsin and incubated at 37 ˚C for 15 
minutes. This mix was removed and the tissue washed three times with 1 ml of plating 
media. The last wash was removed and a fresh 1 ml of plating media added. Using two 
glass Pasteur pipettes which had their holes reduced in diameter (one more than the other) 
by holding them in a flame, the tissue was dissociated by passing them first through the 
larger and then the smaller pipettes until a homogeneous cell suspension without tissue 
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particles was obtained. 9 ml of plating media was added and the cells counted and 
centrifuged for a few minutes at 2-300 rpm. Cells were resuspended in plating media and 
plated at around 200,000 cells per coverslip, media was replaced with NB plus media 
after 2-3 hours, or if cells were to be transfected by electroporation, cells were treated as 
described below (Section 2.6.12). 
 
2.6.12 Electroporation of Neuronal Cells 
After centrifugation, the cell pellet was resuspended in 100 µl of rat neuron nucleofector 
solution (Amaxa) per transfection reaction, with 1-2 million cells per reaction. 2 µg of 
DNA was put into the electroporation cuvettes and 100 µl of the resuspended cells added 
to it. Cuvettes were put into the Nucleofector II and run on programme 0-003 a 
programme designed for primary rat hippocampal neurones. 100 µl of plating media was 
added to the cuvettes to dilute the Nucleofector solution and the whole mix was removed 
from the cuvette with a sterile plastic pipette and the cells plated onto coverslips in 
plating media. After 2-3 hours the plating media was changed to NB plus media. 
 
2.6.13 Cell Immunostaining 
Cells were fixed in 4 % paraformaldehyde (PFA) in PBS for 10 minutes. This was 
washed off with two 10 minute PBS washes. Cells were permeabilised in 0.2 % triton in 
PBS for 7.5 minutes and blocked in 3 % BSA in PBS for 15 minutes. Primary antibodies 
were added at the appropriate dilution (see antibody table, section 2.1.8) in 1 % BSA in 
PBS. The coverslips were covered with parafilm, to prevent drying out, and dishes 
wrapped in foil before being placed in a 37 ˚C incubator for a 2 hour incubation. Cells 
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were washed 3 times for 10 minutes each in PBS. Secondary antibodies were added at the 
appropriate dilution (see antibody table, section 2.1.8) and Phalloidin was added at 1:100 
in 1 % BSA in PBS. Again the coverslips were covered with parafilm and the dishes 
wrapped in foil for a one hour incubation at 37 ˚C. Cells were washed three times for 10 
minutes each in PBS. The coverslips were dried and then mounted onto slides and 
analysed by microscopy. 
 
2.6.14 Microscopy 
Cells were visualized using an Zeiss Axioplan or Zeiss LSM 510 confocal microscope. 
Using FITC (488 nm), TRITC (568 nm) and Cy5 (633 nm) excitation channels. 
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Chapter 3.0: 
Results I: 
Mechanisms of α2-Chimaerin Activation and Tyrosine 
Phosphorylation by Fyn 
 
 
 
 99 
3.1 Mechanisms of α2-Chimaerin Activation 
Axons and dendrites of developing neurones follow attractive and repulsive guidance 
cues to establish neuronal networks. Guidance cues include the ephrin and semaphorin 
families of repulsive signalling molecules, which cause axonal growth cones to collapse, 
enabling developing axons and dendrites to avoid inappropriate environments. Receptors 
for guidance signals activate the Rho GTPase family of proteins which regulate 
cytoskeleton remodelling. The Rho GTPase Rac1 is essential in the sema 3A growth gone 
collapse pathway (Jin and Strittmatter, 1997). Rac1 activation is also required in driving 
ephrin A1/EphA receptor and sema 3A mediated endocytosis of the plasma membrane 
(Jurney et. al., 2002). The Rac1 GAP, α2-chimaerin was previously found to be involved 
in the sema 3A collapse pathway, associating with other essential components (Brown et. 
al., 2004) and during the course of this study, α2-chimaerin was subsequently shown to 
be important in ephrin/EphA4 collapse (Wegmeyer et. al., Beg et. al., Iwasato et. al. and 
Shi et. al., 2007). The SH2 and GAP domains of α2-chimaerin are both essential in the 
sema 3A collapse process (Brown et. al., 2004), as well as in ephrin /EphA4 signalling 
(Iwasato et. al., 2007; Shi et. al., 2007). 
DAG binding to the C1 domain of chimaerin is known to cause chimaerin activation 
(Caloca et. al., 1997). However, it is unclear how α2-chimaerin is activated by receptor 
signalling in collapse pathways, and it is possible that tyrosine phosphorylation of α2-
chimaerin may be involved. The interactions of the SH2 domain in α2-chimaerin in these 
signalling pathways, possibly involving tyrosine phosphorylated target proteins, are 
unknown. This study aimed to investigate these interactions and to determine whether α2-
chimaerin is itself tyrosine phosphorylated. Additionally, this study aimed to assess 
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whether phosphorylation could be a mechanism of activation for α2-chimaerin in sema 
3A and ephrin A1 collapse pathways or whether C1 domain interactions were required. 
 
3.2 DAG/Phorbol Ester Activation of α2-Chimaerin in COS-7 Cells 
Chimaerin GAP activity is tightly regulated. The phorbol ester, PMA, binding to the C1 
domain is a known mechanism of activation (Ahmed et. al., 1993). A single point 
mutation in the C1 domain of β2-chimaerin blocks phorbol ester/DAG binding and 
therefore, β2-chimaerin activation by phorbol ester (Caloca et. al., 1999).  
The importance of DAG activation in physiological pathways is not fully established. To 
aid investigation of DAG-regulated cellular functions of α2-chimaerin, the equivalent 
cysteine in α2-chimaerin, C239, was mutated to alanine and verified by sequencing, as 
described in Methods (Section 2.4.5). To test whether this mutation was sufficient to 
block α2-chimaerin activation by the phorbol ester PMA, COS-7 cells were transfected 
with wild type α2-chimaerin or the C239A mutant and either untreated or treated with 
PMA.  
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Figure 3.1: C239A mutation of α2-chimaerin is sufficient to 
prevent activation by PMA COS-7 cells were transfected with 
α2-chimaerin or C1 domain mutant α2-chimaerin C239A. Cells 
were untreated, or treated with 1 µM PMA, fixed with 4 % PFA 
and stained for α2-chimaerin with rabbit α2-chimaerin antibody 
and TRITC-secondary antibody (red) and F-actin stained with 
phalloidin-FITC (green).  The scale bar represents 10 µm. 
 
Cells that were transfected with α2-chimaerin and treated with PMA show a collapsed 
state distinctly lacking F-actin, compared with PMA untreated cells (Figure 3.1 A). 
Whereas, the cells transfected with chimaerin C239A and treated with PMA do not 
collapse (B), but appear ruffled indicating that this single point mutation is sufficient to 
prevent PMA from activating α2-chimaerin (Figure 3.1 B). PMA treatment of COS-7 
cells induces cell ruffling, a Rac1 response (Ridley et. al., 1992; Kozma et. al., 1996). 
The Rac1 ruffling response was prevented by exogenous α2-chimaerin activated by PMA 
down regulating Rac1 (Figure 3.1 A). Membrane ruffling in cells expressing α2-
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chimaerin C239A (Figure 3.1 B) is consistent with this mutation preventing RacGAP 
activation by PMA, allowing its use in further experiments. 
Figure 3.1 also shows α2-chimaerin localising to the nucleus (red staining). As this 
localisation was observed with this antibody on occasion throughout this study and by 
other users, it is possible that α2-chimaerin may have some transient movement into the 
nucleus, or that a component of this α2-chimaerin antibody (raised against recombinant 
protein synthesized in E. coli (Hall et. al., 2001)) cross-reacts with a component in the 
cell nucleus.  
 
3.3 Tyrosine Phosphorylation of α2-Chimaerin 
Previous results in the laboratory have shown that the N-terminal region of purified 
recombinant α2-chimaerin can be tyrosine phosphorylated in vitro by Src. Because of the 
auto-inhibited structure of β2-chimaerin, conserved in α2-chimaerin, the N-terminal and 
SH2 domain regulate the GAP activity (Canagarajah et. al, 2004) and it is possible that 
tyrosine phosphorylation of the N-terminal region of chimaerin may be involved in its 
regulation. To determine whether tyrosine phosphorylation of α2-chimaerin occurs in 
vivo, the two known growth cone collapse signalling pathways in which α2-chimaerin is 
essential, sema 3A and ephrin A1/EphA4, were investigated. Initial experiments were 
undertaken with sema 3A because they pre-dated the discovery of chimaerin association 
with EphA4 signalling. 
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3.3.1 Tyrosine Phosphorylation of α2-Chimaerin in Response to Semaphorin 3A 
To investigate α2-chimaerin tyrosine phosphorylation in sema 3A signalling, the 
possibility of a permissive cell system was explored. N1E-115 neuroblastoma cells 
express α2-chimaerin and are one of the best characterised neuronal cell lines in relation 
to morphology and Rho GTPase function (Zhang et. al., 1996; Kozma et. al., 1996). 
N1E-115 neuroblastoma cells are capable of responding to sema 3A (Van Horck et. al., 
2002).  
Figure 3.2 demonstrates a series of preliminary experiments investigating tyrosine 
phosphorylation of α2-chimaerin in N1E-115 neuroblastoma cells. N1E-115 cells were 
treated with a 1:50 dilution of sema 3A-Fc enriched cell media supernatent (Eickholt et. 
al., 2002) over a time course of 0-30 minutes, lysed and total lysates analysed by SDS-
PAGE and immunodetection with a phosphotyrosine antibody (PY20) (Figure 3.2A). 
There was no overall stimulation of protein phosphorylation. To determine whether 
tyrosine phosphorylation of α2-chimaerin in response to sema 3A could be detected, 
N1E-115 neuroblastoma cells were transfected with full length FLAG tagged α2-
chimaerin, Na3VO4 (a tyrosine phosphatase inhibitor) was added to the cells to enhance 
phosphorylation with a sema 3A time course of 0-60 minutes (Figure 3.2B). 
Src family tyrosine kinases are widely involved in many signalling pathways, and Fyn is 
a known component of sema 3A pathways (Sasaki et. al., 2002; Morita et. al., 2006). To 
test whether increased tyrosine phosphorylation of α2-chimaerin was due to Src family 
kinases, N1E-115 neuroblastoma cells were transfected with FLAG-tagged α2-chimaerin 
and treated with Na3VO4 and sema 3A, either in the absence or presence of the Src family 
kinase inhibitor PP2 (Figure 3.2C). 
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In figures 3.2B and C, α2-chimaerin was affinity purified onto FLAG antibody beads and 
analysed by SDS-PAGE and western immunoblotting with a phosphotyrosine antibody 
and subsequently re-blotted with α2-chimaerin antibody. 
 
Figure 3.2: Series of preliminary experiments investigating tyrosine 
phosphorylation of α2-chimaerin in N1E-115 neuroblastoma cells  
(A) N1E-115 neuroblastoma cells were treated with sema 3A at a 1:50 dilution at 
times indicated, cells were lysed, sample buffer added to the total lysate before 
analysis on an SDS-PAGE gel and proteins transferred onto PVDF membrane 
were immunodetected with the phosphotyrosine antibody PY20. 
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(B) N1E-115 neuroblastoma cells were transfected with FLAG tagged α2-
chimaerin and treated with Na3VO4 and with sema 3A at the times indicated. Cells 
were lysed and incubated with FLAG beads, to pull down α2-chimaerin. Samples 
were analysed by SDS-PAGE and western blotted with phosphotyrosine antibody 
PY20 and subsequently re-blotted with α2-chimaerin antibody. 
(C) N1E-115 neuroblastoma cells were transfected with FLAG tagged α2-
chimaerin, treated with Na3VO4 for 20 min, and treated with sema 3A for 40 min, 
either in the absence or presence of PP2. Cells were lysed and α2-chimaerin 
affinity purified using FLAG beads. Samples were analysed by SDS-PAGE and 
western blotted with phosphotyrosine antibody 4G10 and subsequently re-blotted 
with α2-chimaerin antibody. 
 
Although in N1E-115 neuroblastoma cell total lysate there was no net increase in tyrosine 
phosphorylation of total lysate proteins (Figure 3.2A), phosphorylation of α2-chimaerin 
was detected,  highest after 40 minutes of sema 3A treatment (Figure 3.2B). The 
phosphotyrosine level was reduced in the presence of PP2, suggesting that Src family 
tyrosine kinases may be at least partially involved in this tyrosine phosphorylation of α2-
chimaerin (Figure 3.2C), although figure 3.2C is lacking a specific control for PP2 
inhibition. Later experiments showed that the upper band in Figures 3.2B and C is likely 
to be Fyn. 
Overall, this preliminary data shows that it is possible to detect phosphorylated α2-
chimaerin when affinity purified using FLAG beads and that phosphorylation is sensitive 
to PP2. However, sema 3A stimulation produced only slight tyrosine phosphorylation of 
α2-chimaerin, possibly due to low level endogenous receptors. An N1E-115 
neuroblastoma cell line over-expressing the neuropilin 1/plexin A1 receptor complex was 
produced, which did show tyrosine phosphorylation following sema 3A stimulation after 
a short time course, typical of receptor signalling. Vanadate was also not required, 
however, stimulation induced apoptosis and therefore work with this cell line was 
discontinued. 
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3.3.2 α2-Chimaerin is Phosphorylated by Fyn 
To test whether Fyn can directly tyrosine phosphorylate α2-chimaerin, Fyn or kinase 
dead Fyn (K299M) were co-expressed with FLAG-tagged α2-chimaerin in N1E-115 
neuroblastoma cells, and cells were either untreated or treated with PMA. cDNA in 
pCMV5 encoding Fyn and kinase-inactive Fyn K299M were kindly provided by M. Resh 
(Sloane-Kettering Cancer Centre, New York). 
 
 
 
 
Figure 3.3: Wild type Fyn can phosphorylate α2-chimaerin in the presence 
of PMA N1E-115 neuroblastoma cells were transfected with FLAG-α2-
chimaerin and either Fyn or kinase dead Fyn K299M. Cells were untreated or 
treated with 1µM PMA for 1 h. Cells were lysed and α2-chimaerin affinity 
purified onto FLAG antibody beads. Samples were analysed by SDS-PAGE and 
immunodetected with phosphotyrosine antibody PY20 and α2-chimaerin 
antibody. 
 
Results showed that Fyn phosphorylated α2-chimaerin, only after treatment with PMA 
(Figure 3.3). There was no phosphorylation with kinase inactive Fyn or in the absence of 
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PMA. This implies that α2-chimaerin must be in an open conformation (with PMA 
treatment) to become tyrosine phosphorylated. Phosphorylation may therefore be an 
indication of activation. 
 
To test whether sema 3A treatment can activate α2-chimaerin enough to be 
phosphorylated by Fyn, N1E-115 neuroblastoma cells were co-transfected with wild type 
Fyn and α2-chimaerin. Cells were untreated, PMA-treated or sema 3A-treated. α2-
Chimaerin was affinity purified onto FLAG antibody beads and samples analysed via 
SDS-PAGE and western blotting using the anti-phosphotyrosine antibody 4G10. 
 
 
 
Figure 3.4: Fyn phosphorylates α2-chimaerin after cell treatment with 
chimaerin activators PMA and sema 3A N1E-115 neuroblastoma cells were 
transfected with FLAG tagged α2-chimaerin and Fyn. Cells were untreated, 
treated with PMA or treated with sema 3A. Cells were lysed and α2-chimaerin 
affinity purified onto FLAG antibody beads. Samples were analysed by SDS-
PAGE and western blotted with 4G10 phosphotyrosine and α2-chimaerin 
antibodies. 
 
 
In untreated cells no α2-chimaerin phosphorylation was observed, however, after 
treatment either with PMA or sema 3A, α2-chimaerin was phosphorylated by Fyn, 
although to a much lesser extent with sema 3A than with PMA (Figure 3.4). α2-
Chimaerin was affinity purified onto FLAG-antibody beads, the upper tyrosine 
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phosphorylated band was always detected in these experiments along with α2-chimaerin 
tyrosine phosphorylation and has the same mobility as Fyn, suggesting Fyn may bind α2-
chimaerin. 
 
To investigate whether Fyn and α2-chimaerin interact when co-expressed in N1E-115 
neuroblastoma cells, α2-chimaerin was affinity purified onto FLAG antibody beads and 
proteins that were pulled down with α2-chimaerin were probed with anti-Fyn antibody. 
Samples were either untreated or treated with PMA (Figure 3.5). 
 
 
 
Figure 3.5: Fyn interacts with α2-chimaerin N1E-115 neuroblastoma cells 
were transfected with FLAG tagged α2-chimaerin and wild type Fyn. Cells were 
treated with sema 3A and either untreated or treated with PMA. α2-Chimaerin 
was affinity purified onto FLAG-antibody beads. Samples were analysed by 
SDS-PAGE and immunodetected with Fyn and (re-blotted with) α2-chimaerin 
antibodies. 
 
Results showed that Fyn interacted with α2-chimaerin and this was enhanced by PMA 
treatment (Figure 3.5). 
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The region of α2-chimaerin that interacted with Fyn was also investigated, using FLAG-
tagged fragments of α2-chimaerin. The fragments of α2-chimaerin that were available for 
use are shown in figure 3.6.  
 
 
Figure 3.6: Fragments of α2-chimaerin A representation of the 
FLAG-tagged fragments of α2-chimaerin that were used in pull 
down experiments.  
 
 
N1E-115 neuroblastoma cells were co-transfected with Fyn and FLAG-tagged α2-
chimaerin or α2-chimaerin fragments. Cells were subsequently treated with sema 3A and 
subjected to FLAG-pull down assays (Figure 3.7). 
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Figure 3.7: Fyn interacts with α2-chimaerin GAP domain N1E-115 
neuroblastoma cells were transfected with FLAG tagged, α2-chimaerin 
fragments and Fyn. Cells were lysed and incubated with FLAG antibody beads 
to pull down α2-chimaerin. Samples were analysed by SDS-PAGE and 
immunodetected with Fyn and FLAG antibodies. This experiment was repeated, 
producing the same results on three occasions. 
 
Fyn associated strongly with the α2-chimaerin GAP domain, amino acid residues 268-
459. Fyn also pulled down with α2-chimaerin 39-459 (Figure 3.7). The N-terminal 
deletion (1-39) of α2-chimaerin is likely to release the auto-inhibited structure into an 
open conformation and may therefore make the GAP domain more available for binding 
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than wild type α2-chimaerin. Surprisingly, Fyn failed to bind to the fragment containing 
amino acids 196-459, comprising the C1 and GAP domains, perhaps the conformation of 
this fragment prevents Fyn from binding in some way. A small amount of background 
can be seen on the FLAG antibody beads alone. 
 
3.3.3 Tyrosine Phosphorylation of α2-Chimaerin in the EphA4 Pathway 
During the course of this study, collaboration was set up with Nancy Y. Ip in Hong Kong 
(Shi et. al., 2007). Several studies, including this one, described α2-chimaerin in receptor 
tyrosine kinase EphA4 forward signalling (Wegmeyer et. al., 2007; Beg et. al., 2007; 
Iwasato et. al., 2007; Shi et. al., 2007). Ephrin/EphA4 signalling, like sema 3A 
signalling, is a growth cone collapse pathway important in neuronal development and 
axonal guidance. To investigate α2-chimaerin and Fyn in this pathway we obtained 
cDNA clones of the EphA4 receptor and a kinase dead mutant of the EphA4 receptor 
from N. Y. Ip (See Materials and Methods, Chapter 2.0). To be effective, the soluble 
ligand ephrin A1 conjugated to the Fc portion of IgG (R & D Systems) required treatment 
with goat-anti-human IgG (Sigma-Aldrich), for an hour at room temperature, to promote 
clustering; this allowed the study of EphA4 forward signalling. 
 
To investigate whether α2-chimaerin is tyrosine phosphorylated following treatment with 
clustered ephrin A1, N1E-115 neuroblastoma cells were co-transfected with either wild 
type or kinase dead EphA4 and either wild type α2-chimaerin or α2-chimaerin C239A. 
Src family kinases are also a component of the EphA4 pathway (Ellis et. al., 1996; Shi et. 
al., 2007), and earlier results showed Fyn phosphorylated α2-chimaerin only after 
 112 
treatment of α2-chimaerin activators PMA and sema 3A (Figure 3.4). Therefore, the 
effect of over-expressed Fyn was also investigated in ephrin signalling. To induce EphA4 
signalling, cells were treated with pre-clustered ephrin A1 for 10 minutes. FLAG-α2-
chimaerin was affinity purified onto FLAG antibody beads prior to western blot analysis 
with 4G10 phosphotyrosine antibody. 
 
 
Figure 3.8 α2-Chimaerin phosphorylation occurs downstream of 
ephrin A1/EphA4 in N1E-115 cells and is enhanced by co-
expression of Fyn N1E-115 neuroblastoma cells were co-transfected 
with Flag-α2-chimaerin or FLAG-α2-chimaerin C239A and either wild 
type EphA4, Kinase Dead (KD) EphA4 and Fyn as indicated. Cells 
were treated for 10 minutes with pre-clustered ephrin A1 before lysis 
and incubation with FLAG antibody beads to pull down FLAG-tagged 
α2-chimaerin. Samples were immunodetected with phosphotyrosine 
4G10 and subsequently re-blotted with α2-chimaerin antibody. 
 
 
Slight tyrosine phosphorylation of α2-chimaerin occurred in cells co-expressing EphA4 
receptor and α2-chimaerin, following treatment with pre-clustered ephrin A1. Tyrosine 
phosphorylation of α2-chimaerin was enhanced by treatment with PMA or by the 
addition of co-transfected Fyn, where additional bands were co-purified. No tyrosine 
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phosphorylation was observed in cells co-transfected with kinase dead EphA4 and α2-
chimaerin (Figure 3.8). The putative Fyn band was more strongly phosphorylated than 
chimaerin in all samples, with the exception of the kinase-dead EphA4. The C1 mutant 
chimaerin C239A, although expressed at a lower level (lane 5), was also capable of being 
phosphorylated, indicating that a functional DAG binding domain is not essential. 
 
3.3.4 Tyrosine Mutations of α2-Chimaerin 
To investigate sites in α2-chimaerin that are candidates for Fyn tyrosine phosphorylation, 
tyrosine residues were mutated. There are eleven tyrosine residues in the N-terminal 
fragment of α2-chimaerin which was previously Src-phosphorylated in vitro in our 
laboratory, the most likely tyrosine phosphorylation sites were determined using online 
phosphorylation prediction site: http://www.cbs.dtu.dk/services/NetPhos/. Four tyrosine 
residues in the SH2 domain and flanking region, which are conserved between species, 
scored highly as likely sites for tyrosine phosphorylation and therefore they were chosen 
for further study. α2-chimaerin Y70, Y143, Y148 and Y157 were separately mutated to 
phenylalanine to prevent phosphorylation. In addition, Y303 in the GAP domain adjacent 
to the essential arginine R304 was also mutated to phenylalanine. All mutations were 
made by site directed mutagenesis and confirmed by sequencing (see Methods). Figure 
3.9 demonstrates the locations of mutated tyrosines in α2-chimaerin (red) and of 
mutations inactivating each of the domains (blue). The C1 domain inactivating mutation 
C239A was described earlier (Figure 3.1). Mutations inactivating the other two domains 
of α2-chimaerin were already available in our laboratory (Hall et. al., 2001); α2-
chimaerin R73L in the SH2 domain, preventing tyrosine binding and α2-chimaerin 
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R304G in the GAP domain inhibiting GAP activity. The domain inactivating mutations 
were also used in this part of the study investigating activation/ tyrosine phosphorylation 
of α2-chimaerin. 
 
 
Figure 3.9: Mutations of α2-chimaerin Diagram showing the position of tyrosine mutations 
of α2-chimaerin (red text) and domain inactivating mutations of α2-chimaerin (blue text), 
used in this part of the study to investigate tyrosine phosphorylation of α2-chimaerin. 
 
Two different phosphotyrosine antibodies were tested, PY20 and 4G10 (See Antibody 
table in Materials) (Figure 3.10). N1E-115 neuroblastoma cells were co-transfected with 
FLAG-tagged α2-chimaerin and either K299M (kinase dead) or wild type Fyn and treated 
with PMA for 1 hour. α2-Chimaerin was affinity-purified onto FLAG antibody beads and 
samples analysed by western blot using anti-phosphotyrosine antibodies PY20 or 4G10 
as indicated.  
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Figure 3.10: Comparison of phosphotyrosine antibodies N1E-
115 neuroblastoma cells were transfected with FLAG tagged, full 
length α2-chimaerin and either K299M (kinase dead) or wild type 
Fyn. Cells were treated with PMA and α2-chimaerin affinity 
purified onto FLAG-antibody beads. Samples were analysed by 
SDS-PAGE and immunodetected with the phosphotyrosine 
antibodies PY20 or 4G10 and FLAG or α2-chimaerin antibodies. 
 
Both antibodies effectively detected phosphotyrosine, but because the PY20 antibody had 
a generally higher background and strong non-specific detection of size markers (Figure 
3.10), 4G10 phosphotyrosine antibody was used subsequently. 
 
3.4 Identification of Tyrosine Phosphorylation 
To test whether any of the mutated tyrosines are likely candidates for Fyn 
phosphorylation, α2-chimaerin tyrosine mutants and Fyn (or kinase dead Fyn) were co-
transfected into COS-7 or N1E-115 neuroblastoma cells and treated with PMA to fully 
activate α2-chimaerin. α2-Chimaerin was affinity purified onto FLAG antibody beads 
and samples analysed via western blotting using the phosphotyrosine antibody 4G10. 
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Figure 3.11 α2-Chimaerin mutants affect tyrosine phosphorylation 
following PMA treatment in COS-7 cells and N1E-115 neuroblastoma cells 
A: COS-7 cells and B: N1E-115 neuroblastoma cells, were transfected with 
FLAG wild type or mutant α2-chimaerin and wild type Fyn and treated for 1 h 
with 1 µM PMA. Cells were lysed and incubated with FLAG antibody beads to 
pull down α2-chimaerin. Samples were analysed by SDS-PAGE and 
immunodetected with phosphotyrosine 4G10 and α2-chimaerin antibodies.  
C: Analysis of three western blots as shown in 3.11.B of N1E-115 
neuroblastoma cells expressing the various chimaerin mutants and treated with 
PMA using UN-SCAN-IT gel analysis software to quantitate pixels. 
Phosphotyrosine bands were normalised to the corresponding α2-chimaerin 
expression level and then expressed relative to α2-chimaerin Y70 for each 
experiment (normalised to 1 relative protein level), as this had more stable 
expression over all the experiments. Error bars represent standard deviation 
from the mean. 
 
A 
B 
C 
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In COS-7 cells, α2-chimaerin tyrosine phosphorylation was much less than that of the 
upper band (Fyn). Tyrosine phosphorylation of α2-chimaerin Y143F and Y303F 
appeared decreased relative to wild type α2-chimaerin (Figure 3.11 A). Also, in N1E-115 
cells treated with PMA, Y143F and Y303F mutants were less phosphorylated (Figure 
3.11B). These experiments were repeated on three occasions and immunoblots quantified 
using UN-SCAN-IT gel analysis software, where pixels provide a measure of relative 
protein or phosphorylation levels. In these experiments very little tyrosine 
phosphorylation of α2-chimaerin C239A was detected, probably because the α2-
chimaerin C239A mutant is not ‘opened up’ by PMA (see Figure 3.1) and therefore 
tyrosine residues remain obscured from Fyn.  
 
3.5 Semaphorin 3A Treatment of N1E-115 Neuroblastoma Cells 
Expressing Chimaerin Mutants 
To investigate tyrosine phosphorylation in sema 3A signalling, N1E-115 neuroblastoma 
cells were co-transfected with α2-chimaerin tyrosine mutants and Fyn (or kinase dead 
Fyn) and treated with sema 3A. α2-Chimaerin was affinity purified onto FLAG antibody 
beads and samples analysed via western blotting using the phosphotyrosine antibody 
4G10. 
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Figure 3.12 α2-Chimaerin mutants affect tyrosine phosphorylation after 
sema 3A treatment of N1E-115 neuroblastoma cells A: N1E-115 
neuroblastoma cells were transfected with Flag-wild type or mutant α2-
chimaerin and wild type or kinase dead Fyn. Cells were treated for 10 minutes 
with sema 3A. α2-Chimaerin was affinity purified onto FLAG antibody beads. 
Samples were analysed by SDS-PAGE and western blotted with 
phosphotyrosine 4G10, Fyn and α2-chimaerin antibodies. B: Analysis of three 
of the above experiments western blots using UN-SCAN-IT gel analysis 
software. Phosphotyrosine values were measured relative to their respective α2-
chimaerin signal and expressed relative to α2-chimaerin wild type protein level 
(1) in each experiment. Error bars represent standard deviation from the mean. 
 
 
 
In sema 3A treated cells, tyrosine phosphorylation of wild type α2-chimaerin was very 
slight (Figure 3.12, lane 2), but Y70F, Y148F and C239A, were more strongly 
phosphorylated. There was very slightly decreased tyrosine phosphorylation of the 
A 
B 
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Y143F and Y303F mutants compared with wild type α2-chimaerin detectable only in 
some experiments (Figure 3.12A). There was no phosphorylation when kinase dead Fyn 
was co-transfected with α2-chimaerin (Figure 3.12 A). These data suggest that α2-
chimaerin tyrosines 143 and possibly 303 are potential sites of phosphorylation in sema 
3A treated cells expressing Fyn. Increased tyrosine phosphorylation may be due to 
intramolecular interactions being affected by the tyrosine mutations. In contrast to figure 
3.11, where PMA stimulation of α2-chimaerin C239A mutant resulted in less 
phosphorylation, sema 3A stimulation caused increased phosphorylation when compared 
to wild type α2-chimaerin. As shown in figure 3.1, the C239A mutant cannot be activated 
by PMA. This demonstrates that α2-chimaerin activation is a complex process and 
suggests that there are mechanisms other than through the C1 domain for α2-chimaerin 
activation and phosphorylation. 
 
3.6 Ephrin A1 Treatment of N1E-115 Neuroblastoma Cells Permanently 
Expressing EphA4 
α2-Chimaerin interacts with the EphA4 receptor (Wegmeyer et. al., 2007; Beg et. al., 
2007; Iwasato et. al., 2007; Shi et. al., 2007) and Src family kinases are involved 
downstream of ephrin/EphA4 signalling and can bind EphA4 (Ellis et. al., 1996). N1E-
115 neuroblastoma cells did not respond to ephrin A1 treatment and detectable EphA4 
was not present in these cells in western blots (results not shown). An N1E-115 
neuroblastoma cell line permanently expressing EphA4 receptor was therefore produced 
by transfection with EphA4 pcDNA3 and G418 selection. This cell line permanently 
expressing EphA4, was used to investigate Fyn phosphorylation of α2-chimaerin by 
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transient co-transfection with Fyn and FLAG-α2-chimaerin mutants. Cells were treated 
with pre-clustered ephrin A1 for ten minutes before lysis. Chimaerin was affinity purified 
onto FLAG antibody beads, samples were analysed by SDS-PAGE and immunoblotted 
with the 4G10 antibody to examine phosphotyrosine levels. 
 B
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Figure 3.13 α2-Chimaerin mutants affect tyrosine phosphorylation 
downstream of ephrinA1/EphA4 signalling A: N1E-115 neuroblastoma cells 
permanently expressing EphA4 receptor were transfected with FLAG-tagged 
α2-chimaerin and mutants plus wild type Fyn. Cells were treated for 10 minutes 
with pre-clustered ephrin A1 before being lysed and incubated with FLAG 
antibody beads to pull down α2-chimaerin. Samples were immunodetected with 
phosphotyrosine 4G10, Fyn and α2-chimaerin antibodies. This experiment was 
repeated twice. B: Analysis of one experiment was performed using UN-SCAN-
IT gel analysis software. Phosphotyrosine values were measured relative to their 
respective α2-chimaerin signal and expressed relative to α2-chimaerin wild type 
protein level (1).  
 
Figure 3.13 shows tyrosine phosphorylation of α2-chimaerin mutants occurred to 
different extents in ephrin A1/ EphA4 signalling. The Y148F, C239A and possibly Y70F 
A 
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mutants showed increased tyrosine phosphorylation compared with wild type α2-
chimaerin. The R73L mutant was highly phosphorylated in some experiments (up to 10 
times higher than wild type) therefore it was not included in UN-SCAN-IT analysis 
shown in figure 3.13. This could be due to alterations in the SH2 domain caused by the 
R73L mutation allowing more access for the kinase to phosphorylate. Y143F and Y303F 
showed less phosphorylation than wild type, although not reproducibly in the N1E-115 
neuroblastoma cells permanently expressing EphA4. Several other tyrosine mutants 
showed enhanced phosphorylation. Increased tyrosine phosphorylation of some mutants 
is more difficult to explain (see Discussion, Chapter 6.0). However, phosphorylation of 
tyrosine 143 and 303 mutants appeared reduced to some extent in the three cell lines 
tested (N1E-115, N1E-115 expressing EphA4 and COS-7) irrespective of activation 
(sema 3A, ephrin A1 or PMA, respectively), and consistently when PMA treated (Figure 
3.11B). These sites appear to be candidates for Fyn phosphorylation when chimaerin is 
activated/translocated.  
 
3.7 Cell Morphology 
Results in this chapter indicate that α2-chimaerin Y143 is a Fyn site in PMA treated cells, 
but other tyrosines may also be phosphorylated in in vivo signalling, as suggested by Shi 
et. al., 2007 and Wegmeyer et. al., 2007. Since α2-chimaerin influences the morphology 
of neurones (Buttery et. al., 2006), we investigated whether tyrosine mutations altered 
α2-chimaerin function. α2-Chimaerin mutants were transfected into primary hippocampal 
neurones in culture isolated from day 18 rat embryos. After 3-5 div neurones were 
stained with axonal marker Tau antibody, phalloidin and α2-chimaerin antibody, and 
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imaged by confocal microscope. Sholl analysis was used to quantify these results (Sholl, 
1953). This was developed for analysis of the dendritic organisation of cat visual and 
motor cortices (Sholl, 1953). Concentric circles are drawn around the centre of the cell 
soma at fixed step radii. The number of intersections of cell processes crossing the circle 
is counted. The data plotted as the number of intersections, versus the distance from the 
cell soma. For this study, circles at 2 µm intervals between 0 and 250 µm were used. A 
0.5 µm radius span around each radius value was used as a margin to make continuous 
measurements of the intersections and the median calculated for each radius step (Figure 
3.14). 
 
 
Figure 3.14 Diagramatic representation of Sholl analysis A series of 
concentric circles were drawn around the centre of the cell soma with a fixed 
step between them. The number of times the radii is interrupted by a cell process 
was counted, the radius span represents the margin where continuous 
measurements of intersections were made and the median calculated.  
 
Figure 3.15A-D shows typical examples of the controls and mutant α2-chimaerin 
transfected neurones and the quantification of these results by Sholl Analysis. 
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(A) Domain Inactivating Mutants 
 
 
 
(B) Fyn Site α2-Chimaerin Y143F Mutant 
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(C) Potential Fyn Site α2-Chimaerin Y303F Mutant 
 
 
(D) Other Phosphotyrosine Mutants 
 
 
Figure 3.15A-D: α2-Chimaerin mutants affect morphology of developing 
hippocampal neurones E18 primary hippocampal neurones were transfected with 
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Flag wild type or mutant α2-chimaerin cDNAs. Cells were fixed with 4 % 
paraformaldehyde and stained with TRITC-labelled phalloidin (red). A representative 
picture for GFP, α2-chimaerin wild type and each of the α2-chimaerin mutant 
transfected cells is shown for each graph. Scale bars represent 10 µm. Graphs show the 
average of five cell images per GFP, α2-chimaerin wild type or mutant, analysed by 
Sholl analysis.  (A) GFP, α2-chimaerin wild type and the three domain inactivating α2-
chimaerin mutants.  (B) GFP, α2-chimaerin wild type and Y143F mutant. (C) GFP, α2-
chimaerin wild type and Y303F mutant. (D) GFP, α2-chimaerin wild type and three 
tyrosine mutants; Y70F, Y148F and Y157F. 
 
Results showed that FLAG-tagged α2-chimaerin electroporated into E18 hippocampal 
neurones had less dendrites around the cell body, and more branchy axons compared to 
GFP control electroporated neurones (Figure 3.15 A). Expression of α2-chimaerin with 
single point mutations that inactivate the SH2 domain and C1 domain of α2-chimaerin, 
R73L and C239A respectively, both produced similar hippocampal neurone morphology 
to the GFP transfected control, suggesting these mutations prevent the function of α2-
chimaerin. The α2-chimaerin R304G mutant which lacks GAP activity appeared to 
produce more branching on the processes around the cell body and more branching 
further down the processes and spread growth cones, also suggesting that the GAP 
function of α2-chimaerin restricts outgrowth (Figure 3.15A). 
Expression of tyrosine mutants α2-chimaerin-Y143F and Y303F, which are potential Fyn 
sites, shown in previous experiments (Figures 3.11-3.13) resulted in similar hippocampal 
morphology to the GFP control (rather than to wild type α2-chimaerin morphology) 
(Figure 3.15B and C). Conversely, expression of tyrosine mutants α2-chimaerin-Y70F, 
Y148F and Y157F, resulted in much more branching around the cell body, however, 
further down the processes, Y157F appeared to have similar morphology to the GFP 
control and Y70F and Y148F appear to have more similar morphology to wild type α2-
chimaerin (Figure 3.15D).  
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Whilst investigating the morphologies resulting from α2-chimaerin mutants, it was 
observed that α2-chimaerin over-expression promotes the formation of multiple axons 
(Figure 3.16). E18 hippocampal neurones over-expressing GFP control or α2-chimaerin 
or α2-chimaerin Y157F or Y143F were quantified. 
 
 
 
 
 
Figure 3.16 (A) α2-Chimaerin over-expression increases axon 
number in developing hippocampal neurones E18 primary 
hippocampal neurones were transfected with a GFP control or FLAG-
tagged wild type and tyrosine mutant α2-chimaerin cDNAs. Cells were 
fixed with 4 % paraformaldehyde and stained with Cy5-mouse-anti-tau 
(blue), FITC-rabbit-anti-α2-chimaerin antibodies (green) and TRITC-
labelled phalloidin (red). Scale bars represent 10 µm. 
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Figure 3.16 (B) α2-Chimaerin significantly increases axon number in 
developing hippocampal neurones compared to a GFP control The 
number of axons (Tau positive) were quantified from E18 primary 
hippocampal neurones over-expressing a GFP control or FLAG-tagged α2-
chimaerin or FLAG-tagged α2-chimaerin mutants Y157F or Y143F. Error 
bars represent standard deviation from the mean.  
 
Results showed a significant increase in the number of axons produced by E18 primary 
hippocampal neurones over-expressing α2-chimaerin compared to neurones expressing a 
GFP control (Figure 3.16, A and B). Phosphotyrosine mutants had a smaller difference in 
axon number and α2-chimaerin Y143F mutant is significantly different from α2-
chimaerin. Figures 3.15 and 3.16 showed that single point mutations of α2-chimaerin are 
sufficient to affect the morphology of developing hippocampal neurones. 
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3.8 Summary 
The results in chapter 3.0 showed that tyrosine phosphorylation of α2-chimaerin can 
occur in the sema 3A and ephrin A1/EphA4 pathways, which are important in neuronal 
development. It has been reported that α2-chimaerin can be phosphorylated by SFKs (Shi 
et. al., 2007). Chapter 3.0 has demonstrated α2-chimaerin phosphorylation by Fyn 
downstream of activators PMA, sema 3A and ephrin A1. Chapter 3.0 also shows that Fyn 
interacts with α2-chimaerin GAP domain. Single point tyrosine mutations of α2-
chimaerin suggest that Y143 in the SH2-C1linker region (and possibly Y303) are 
possible Fyn phosphorylation sites. The equivalent β2-chimaerin tyrosine, Y153, is 
buried in the inactive β2-chimaerin structure (Canagarajah et. al., 2004), therefore α2-
chimaerin activation must occur before it can be accessed by Fyn for phosphorylation. 
Similarly, α2-chimaerin C239A mutant was only phosphorylated in cells treated with 
upstream receptor ligands, when PMA was not the sole activator of α2-chimaerin, also 
suggesting another route of activation. The treatment of cells with PMA and certain 
mutants (Y70F, Y148F, C239A and R73L) increased tyrosine phosphorylation of α2-
chimaerin with sema 3A or ephrin treatment, suggesting altered accessibility by 
disruption of α2-chimaerin structure or conformation, or affecting other interactions. 
Additionally, the degree of α2-chimaerin activation that can be achieved in N1E-115 
neuroblastoma cells was not particularly high, it may be that neurones would be a more 
physiological reporter system.   
Neurone morphology studies in this chapter suggest that over-expressed single point 
mutations of α2-chimaerin are sufficient to produce morphological changes of 
hippocampal neurones. Over-expression of α2-chimaerin wild type and tyrosine mutants 
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Y70F, Y148F and Y157F appear to increase neurite branching, particularly Y70 and 
Y148 mutants which were also capable of enhanced Fyn phosphorylation. Whereas, α2-
chimaerin domain inactivating mutants along with α2-chimaerin Y143F and Y303F 
mutants showed similar hippocampal neurone morphology to the GFP control. This 
suggests that phosphorylation of Y143 and Y303 (likely by Fyn) could regulate α2-
chimaerin activity in neurones. It has been reported that PKC phosphorylation of serine 
169 in β2-chimaerin is involved in its regulation (Griner et. al., 2010). As this region of 
α2-chimaerin differs slightly from β2-chimaerin (and the S169 residue is not conserved in 
α2-chimaerin) it is possible that they are regulated in slightly different ways. 
Chapter 3.0 demonstrates interesting developments in α2-chimaerin tyrosine 
phosphorylation, but creates more questions over α2-chimaerin regulation and activation. 
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α2-Chimaerin in the ephrin A1/EphA4 Collapse 
Signalling Pathway 
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4.1 α2-Chimaerin in the ephrin A1/EphA4 Collapse Signalling Pathway 
Ephrin/Eph signalling has been implicated in a wide range of processes in neuronal 
development and functions in cell migration and axonal guidance. α2-Chimaerin is a key 
component of EphA4 forward signalling, resulting in growth cone collapse (Wegmeyer 
et. al., 2007; Beg et. al., 2007; Iwasato et. al., 2007; Shi et. al., 2007). Results in the 
previous chapter showed that α2-chimaerin was tyrosine phosphorylated downstream of 
ephrin A1/EphA4 signalling (Figure 3.8) and that α2-chimaerin GAP domain interacts 
with Fyn, possibly acting as a scaffold (Figure 3.7). This part of the study aims to further 
investigate α2-chimaerin interactions in ephrin A1/EphA4 forward signalling.   
 
4.2 EphA4 and α2-Chimaerin Interaction 
The published literature regarding an EphA4 and α2-chimaerin interaction was not 
consistent in relation to the binding sites. One study reported that EphA4 interacts with 
the C-terminal of both α1 and α2-chimaerin (Iwasato et. al., 2007), and two others 
showed an α2-chimaerin SH2 domain interaction with EphA4 and another possible site in 
the remainder of α2-chimaerin (Beg et. al., 2007; Wegmeyer et. al., 2007).  
Chimaerin deletion mutants were used to further map the region of interaction of EphA4 
with α2-chimaerin. COS-7 cells were transfected with the EphA4 receptor and either 
FLAG-tagged α2-chimaerin or truncated α2-chimaerin fragments. Chimaerin was 
purified onto FLAG antibody beads and samples were analysed by SDS-PAGE and 
immunoblotted with EphA4 antibody to identify the binding region. 
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Figure 4.1 EphA4 interacts with α2-chimaerin’s GAP domain COS-7 
cells were transfected with FLAG-tagged α2-chimaerin or fragments and 
wild type EphA4. Cells were lysed and incubated with FLAG antibody 
beads to pull down FLAG α2-chimaerin. Samples were analysed by SDS-
PAGE and immunodetected with EphA4 and FLAG antibodies. The 
above figure is representative of two experiments. 
 
EphA4 interacted with the GAP domain of α2-chimaerin, but not the SH2 domain (Figure 
4.1). However, a background band can be seen in the negative control lane. When cells 
were treated with pre-clustered ephrin A1 for 10 minutes prior to lysis to induce ephrin 
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A1/EphA4 forward signalling, a difference in EphA4 binding of α2-chimaerin was 
observed (Figure 4.2). 
 
 
 
 
Figure 4.2 EphA4 interacts with α2-chimaerin’s SH2 domain when 
stimulated with the ligand ephrin A1 COS-7 cells were transfected with 
EphA4 and FLAG-tagged α2-chimaerin or fragments. Cells were treated 
for 10 minutes with pre-clustered ephrin A1 before lysis and α2-
chimaerin affinity purified onto FLAG antibody beads. Samples were 
analysed with EphA4 and FLAG antibodies. The above figure is 
representative of two experiments. 
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EphA4 bound to the SH2 domain of α2-chimaerin, although binding was quite weak, 
rather than to the GAP domain, which differed from the result without stimulation by 
ephrin A1 as shown in figure 4.1. With ephrin A1 stimulation, EphA4 also associated 
with α2-chimaerin 39-459 (Figure 4.2). The N-terminal deletion, 39-459, construct likely 
releases α2-chimaerin into an open conformation, resulting in other domains becoming 
more available for binding.  
 
4.3 α2-Chimaerin Interacts with the Adaptor Protein Nck1 
Nck1 is an adaptor protein with three SH3 domains and an SH2 domain. Nck interacts 
with RTKs including the ephrins, and links phosphotyrosine signalling to proteins 
involved in regulating the cytoskeleton (Bladt et. al., 2003). Studies have shown Nck to 
interact with EphB1, EphA2 and ephrin B3 in a phosphotyrosine dependant manner via 
its SH2 domain (Stein et. al., 1998; Miura et. al., 2009; Xu and Henkenmeyer 2009). 
Nck1/2 knock out mice have survival defects, but mice lacking one of the two Nck genes 
(Nck1), with conditional knock out of Nck2 in the nervous system, have developmental 
defects of axonal guidance, similar to those of both EphA4 and α2-chimaerin gene 
deletions in mice. Nck has been shown to bind to α2-chimaerin via an SH3 domain 
(Fawcett et. al., 2007). 
To investigate the region of interaction of α2-chimaerin with Nck1, COS-7 cells were co-
transfected with pXJ40 HA-Nck1 (kindly provided by E. Manser, Singapore) and FLAG-
tagged α2-chimaerin or truncated FLAG-tagged α2-chimaerin fragments. Cells were 
untreated or treated with PMA to fully open α2-chimaerin prior to cell lysis. FLAG-
 135 
tagged α2-chimaerin constructs were affinity purified onto FLAG antibody beads and 
samples were analysed via western blotting as indicated in figure 4.3. 
 
 
Figure 4.3: Nck1 interacts with the first 39 amino acid residues of α2-
chimaerin COS-7 cells were transfected with FLAG tagged, full length or 
fragments of α2-chimaerin, and HA tagged Nck1. Cells were untreated or 
treated with 1µM PMA for 1 h before lysis and incubation with FLAG antibody 
beads to pull down α2-chimaerin. Samples were immunodetected with HA and 
FLAG antibodies. The above figure is representative of two experiments. 
 
Results showed that Nck1 bound to α2-chimaerin 1-137 and that deletion of the N-
terminal 1-39 amino acid residues of α2-chimaerin eliminates binding, suggesting that an 
essential binding site lies within the first 39 amino acids. Treatment with PMA had no 
effect on Nck1 binding α2-chimaerin (Figure 4.3), indicating that Nck can interact with 
both active and inactive conformations. Since full length α2-chimaerin was expressed at 
slightly lower levels relative to the α2-chimaerin 1-137 fragment but bound an equivalent 
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amount of Nck1, this result also suggests that 1-39 may not be the only region involved 
in binding. 
 
4.4 Nck1 Interacts with α2-Chimaerin and Promotes Fyn Binding 
Taken together, these results have shown three different regions of α2-chimaerin bind to 
three different protein components of the ephrin/EphA4 signalling pathway; the N-
terminal of α2-chimaerin is involved in binding Nck1, α2-chimaerin SH2 domain appears 
to bind the EphA4 receptor following ephrin A1 stimulation, and α2-chimaerin GAP 
domain binds Fyn. Firstly, to determine whether the α2-chimaerin, Nck1 and Fyn could 
form a complex, COS-7 cells were transfected with α2-chimaerin and either Nck1 or Fyn 
or both. Cells were untreated or treated with PMA 1 h prior to lysis. FLAG-tagged α2-
chimaerin was affinity purified onto FLAG antibody beads and proteins immunodetected 
as indicated in Figure 4.4. 
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Figure 4.4: Nck1 interacts with α2-chimaerin and promotes Fyn 
binding COS-7 cells were transfected with combinations of FLAG-tagged 
α2-chimaerin and Fyn (lanes 1 and 2) or HA-tagged Nck1 (lanes 3 and 4) or 
with all three constructs (lanes 5 and 6). Cells were untreated (lanes 1, 3 and 
5) or treated with 1µM PMA for 1 h before lysis (lanes 2, 4 and 6). FLAG-
α2-chimaerin was affinity purified onto FLAG antibody beads and samples 
analysed with 4G10 phosphotyrosine antibody, Fyn, HA and FLAG 
antibodies. The above figure is representative of two experiments. 
 
 
Results showed that Nck1 binding to α2-chimaerin was sufficient to allow some Fyn 
binding to α2-chimaerin in the absence of PMA (Figure 4.4, compare lanes 1 and 5). 
PMA treatment strongly promoted α2-chimaerin interaction with Fyn and its 
phosphorylation by Fyn (Figures 3.5, 3.8 and 4.4, lanes 1 and 2). However, figure 4.4, 
lanes 5 and 6 showed that when Nck1 is also present, Fyn binding α2-chimaerin is 
detected in the absence of PMA. Thus, Nck1 binding to the N-terminal region of α2-
chimaerin could effectively open α2-chimaerin conformation (or partially relax the 
structure) for Fyn to bind. No enhancement in Fyn binding with the addition of PMA 
treatment was seen, although under these conditions there was an increase in tyrosine 
phosphorylation of α2-chimaerin (lanes 5 and 6). This result may also indicate that α2-
chimaerin can be activated by Nck1 binding, but is further phosphorylated when cells are 
PMA treated.  
Secondly, to explore whether Nck1 and Fyn can interact with each other, COS-7 cells 
were transfected with Fyn alone, Fyn and HA-tagged Nck1, or Fyn, HA-tagged Nck1 and 
FLAG-tagged α2-chimaerin. Cells were lysed and HA-Nck1 affinity purified onto HA 
antibody beads. Proteins were detected as indicated in figure 4.5. 
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Figure 4.5: Nck1 and Fyn do not interact with each other in COS-7 
cells COS-7 cells were transfected with Fyn, lane 1; Fyn and HA-tagged 
Nck1, lane 2, or Fyn, HA-tagged Nck1 and FLAG-tagged α2-chimaerin, 
lane 3. Cells were lysed and incubated with HA antibody beads to pull 
down HA-tagged Nck1. Samples were analysed by SDS-PAGE and 
immunodetected with Fyn, HA and α2-chimaerin antibodies. The above 
figure is representative of two experiments. 
 
 
Results showed that Fyn did not pull down with HA-Nck1 alone in COS-7 cells in the 
absence of α2-chimaerin. When α2-chimaerin, Fyn and Nck1 were co-transfected into 
COS-7 cells, all three proteins could be detected in the pull down (Figure 4.5, lane 3), 
suggesting that α2-chimaerin acts as a scaffold to bind Fyn. However, Nck1 expression 
was much greater in the presence of α2-chimaerin. 
Thirdly, to investigate whether Fyn can tyrosine phosphorylate Nck1 in cells, HA-Nck1 
was affinity purified from COS-7 cells co-expressing Fyn or kinase dead Fyn and HA-
tagged Nck1, and tyrosine phosphorylated proteins were immunodetected with the 4G10 
phosphotyrosine antibody. 
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Figure 4.6: Wild type Fyn can phosphorylate Nck1 COS-7 cells 
were transfected with Fyn or Kinase Dead Fyn and HA-tagged 
Nck1. HA-tagged Nck1 was affinity purified onto HA antibody 
beads. Samples were analysed by SDS-PAGE and western blotted 
with phosphotyrosine 4G10 antibody and with Fyn and HA 
antibodies. The above blot is representative of three experiments. 
 
 
Results showed (Figure 4.6) that in COS-7 cells, wild type Fyn tyrosine phosphorylated 
Nck1. No Fyn or kinase dead Fyn pulled down with HA-Nck1. Figures 4.5 and 4.6 
demonstrate that Fyn can phosphorylate but not bind Nck1. 
These results suggest that the three protein components of the ephrin/EphA4 signalling 
pathway, α2-chimaerin, Fyn and Nck1 could potentially form a complex, with α2-
chimaerin acting as a scaffold for the other two proteins. 
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4.5 α2-Chimaerin in the ephrin A1/EphA4 Signalling Pathway 
4.5.1 α2-Chimaerin shRNA 
To further investigate the ephrinA1/EphA4 signalling pathway, a shRNA approach was 
also undertaken. ShRNA for α2-chimaerin was produced as described in Chapter 2 
Methods. The system used was siSTRIKE U6 Hairpin Cloning System from Promega. To 
test the α2-chimaerin shRNA, N1E-115 neuroblastoma cells were transfected with the 
shRNA sequences for α2-chimaerin or the vector or scrambled sequence controls. G418 
at 800 µg/ml selection was added the next day to select for cells expressing the 
psiSTRIKE vector and the cells lysed five days later. Samples were analysed by SDS-
PAGE and immunoblotted with α2-chimaerin antibody and actin antibody control. 
 
                 
 
 
 
Figure 4.7: α2-Chimaerin shRNA sequence 1 knocks down α2-
chimaerin N1E-115 neuroblastoma cells were untransfected or 
transfected with vector or scrambled shRNA controls or α2-
chimaerin shRNA sequences 1 or 4. Cells were treated with 800 
µg/ml G418 selection 24 hours later. Cells were lysed after five days 
and samples immunodetected with α2-chimaerin and actin antibodies 
(A). The blots from two experiments were subjected to UN-SCAN-
IT analysis, where pixels are measured representing protein level. 
Protein level was then normalised to actin and then the vector control 
A 
B 
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(set to 1). The experiment was repeated on two occasions, error bars 
represent variation from the mean (B). 
 
 
Figure 4.7 shows α2-chimaerin shRNA sequence 1 knocks down α2-chimaerin by up to 
30 % (range 20-30 %). α2-Chimaerin shRNA sequence 4 does not appear to knock down 
α2-chimaerin when normalised to actin. There were consistently less cells and therefore 
less actin with expression of shRNA sequence 4.  
 
The N1E-115 neuroblastoma cell line permanently expressing the EphA4 receptor 
described in Chapter 3 was utilised to investigate α2-chimaerin in ephrin A1/EphA4 
signalling. Following 3-4 hours of serum starvation, N1E-115 neuroblastoma cells 
permanently expressing EphA4 adopted a spread out/flattened morphology. Following 
ten minute treatment of pre-clustered ephrin A1, the cells round up (Figure 4.8).    
 
Serum starved EphA4 
N1E-115 cell
Ephrin A1
Treatment
(10 min)
EphA4 receptor  
 
Figure 4.8 Schematic of N1E-115 neuroblastoma cells permanently 
expressing the EphA4 receptor before and after pre-clustered ephrin A1 
treatment.  
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4.5.2 EphA4 expressing N1E-115 Neuroblastoma Cell Collapse Assay 
It was investigated whether the N1E-115 neuroblastoma cell line permanently expressing 
EphA4 could be used in an assay for chimaerin involvement in ephrin A1 stimulated cell 
collapse. Cells were untransfected or transfected with α2-chimaerin shRNA sequence 1 
or control shRNA cloned in a psiSTRIKE vector expressing hygromycin resistance (see 
Methods) since G418 is used to maintain selection of the EphA4 cell line. Hygromycin 
selection was added at 400 µg/ml to the transfected cells the following day to select for 
cells expressing the psiSTRIKE shRNA vector. (N1E-115 neuroblastoma cells were 
found to be more sensitive to hygromycin compared to G418, therefore a lower 
concentration was required for selection). Five days later cells were serum starved for up 
to 4 hours to induce cell flattening and neurite formation prior to treatment with pre-
clustered ephrin A1. After fixation and phalloidin staining, cell morphology of flattened 
or rounded cells was quantified. 
 
 
 
Figure 4.9 α2-chimaerin shRNA blocks cell rounding of N1E-115 neuroblastoma cells 
permanently expressing the EphA4 receptor N1E-115 neuroblastoma cells permanently 
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expressing the EphA4 receptor were either untransfected or transfected with shRNA controls, 
vector and scrambled or the α2-chimaerin shRNA knockdown sequence 1. The following day 
400 µg/ml hygromycin selection was added, five days later, cells were untreated or treated for 
10 minutes with pre-clustered ephrin A1 prior to being fixed in 4 % PFA/PBS and stained 
with TRITC-phalloidin for F-actin (red). 300 cells were counted for each group, the 
experiment was repeated on two occasions. Error bars represent standard deviation from the 
mean. Scale bars represent 10 µm. 
 
Results showed that following serum starvation and without ephrin A1 treatment, 
untransfected cells have a spread and flattened morphology and when treated with ephrin 
A1 they become rounded up. Expression of α2-chimaerin shRNA (sequence 1) was 
sufficient to prevent cell rounding in the N1E-115 neuroblastoma cell line permanently 
expressing EphA4. Knockdown of α2-chimaerin prevented the ephrin-stimulated cell 
rounding process, which supports that α2-chimaerin participates in ephrin A1/EphA4 
forward signalling. This also demonstrates that this cell line is a useful assay to 
investigate other necessary components in ephrin A1/EphA4 cell rounding. 
Further analyses of domain mutants of α2-chimaerin were carried out to investigate their 
contribution to ephrin A1/EphA4 cell rounding. N1E-115 neuroblastoma cells 
permanently expressing EphA4 were transfected with wild type or the domain 
inactivating mutations of α2-chimaerin.  
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Figure 4.10: α2-Chimaerin domain inactivating mutants block cell rounding of N1E-
115 neuroblastoma cells permanently expressing the EphA4 receptor N1E-115 
neuroblastoma cells permanently expressing the EphA4 receptor were either untransfected 
or transfected with α2-chimaerin mutants. Cells were serum starved for 3-4 h and left 
untreated, or were treated for 10 minutes with pre-clustered ephrin A1 prior to being fixed 
in 4 % PFA/PBS and stained with TRITC-phalloidin for F-actin. The experiment was 
repeated on two occasions. Error bars show average difference. A total 300 cells were 
counted per treatment. 
 
An inactivating mutation in any of α2-chimaerin domains (SH2, C1 or GAP) was 
sufficient to reduce cell rounding by the ligand ephrin A1 (Figure 4.10). Ideally a FLAG 
vector control should have been included in this experiment. Results suggest that the 
function of each α2-chimaerin domain is required for ephrin A1/EphA4 cell collapse. 
In the N1E-115 neuroblastoma cell line permanently expressing EphA4, it was observed 
that α2-chimaerin was unusually found in ‘dot’ like structures, indicative of a possible 
endosomal localisation. To investigate these structures, the N1E-115 neuroblastoma cell 
line permanently expressing EphA4 were fixed in 4 % paraformaldehyde and stained 
with a series of markers for sub cellular organelles. 
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Figure 4.11: α2-Chimaerin co-localises with mitochondrial matrix marker 
HSP60 N1E-115 neuroblastoma cells permanently expressing EphA4 receptor 
were untreated, or treated with pre-clustered ephrin A1, fixed with 4 % PFA and 
stained for α2-chimaerin with rabbit α2-chimaerin antibody and Cy5-secondary 
(red) antibody and FITC (green) conjugated markers were used. Scale bars 
represent 10 µm. 
 
 
Results suggested that α2-chimaerin co-localised with the mitochondrial matrix marker 
HSP60 (Figure 4.11). A small amount of possible co-localisation could also be seen 
between α2-chimaerin and the early endosome marker EEA1 (Figure 4.11). In N1E-115 
cells, over-expressed α2-chimaerin is largely cytoplasmic, although endogenous α2-
chimaerin can have a particulate distribution in neurones (Hall et. al., 2001). N1E-115 
cells permanently expressing EphA4 appear to have some constitutive activity that may 
affect α2-chimaerin distribution irrespective of ephrin A1 stimulation. 
 
4.6 Summary 
The results in chapter 4.0 add to the literature that emerged during this study, 
demonstrating that α2-chimaerin is important in the ephrin/EphA4 signalling pathway 
(Wegmeyer et. al., 2007; Beg et. al., 2007; Iwasato et. al., 2007; Shi et. al., 2007). 
Although knockdown was incomplete, chimaerin shRNA1 inhibited ephrin induced cell 
rounding in EphA4-expressing N1E115 cells. (It is also possible that there is greater 
chimaerin turnover in these cells with ephrin stimulation). It appears that all three α2-
chimaerin domains (SH2, C1 and GAP) are required in ephrin A1/EphA4 induced 
response of cell rounding, as has been reported by Shi et. al., 2007 (for SH2 and GAP 
domains). α2-Chimaerin interacts with the EphA4 receptor (Wegmeyer et. al., 2007; Beg 
et. al., 2007; Iwasato et. al., 2007), with Fyn and with Nck (Wells et. al., 2006), possibly 
acting as a scaffold for a receptor-associated complex containing Fyn and Nck1. 
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However, the precise molecular interactions are not clearly established, since Fyn can 
also interact with EphA4 receptor via its SH2 domain (Ellis et. al., 1996) and Nck SH2 
could also be involved in phosphotyrosine-dependent interactions directly or indirectly 
receptor-associated, as with integrins (Schlaepfer et. al., 1997) and ephrin B3 (Xu and 
Henkemeyer, 2009), whilst its SH3 domain interacts with chimaerin. α2-Chimaerin may 
co-localise with the mitochondrial matrix and early endosomes in the N1E-115 
neuroblastoma cell line permanently expressing EphA4 receptor, in contrast to its largely 
cytoplasmic location in parent N1E-115 cells. This suggests that transfected α2-chimaerin 
may become activated and re-localize in response to EphA4 signalling (see Discussion, 
Chapter 6.0). Overall, this chapter has explored the protein interactions and the 
requirement of α2-chimaerin domains in ephrin A1/EphA4 signalling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 148 
 
 
 
 
Chapter 5.0: 
Results III: 
New Interacting Partners of α2-Chimaerin  
 
 
 
 
 
 
 
 
 
 
 
 149 
5.1 Interacting Partners of α2-Chimaerin 
 
Known α2-chimaerin interacting partners that participate in the sema 3A pathway include 
Rac1, collapsin response mediator protein-2 (CRMP-2) and Cdk5/p35 (Brown et. al., 
2004). CRMP-2 interacts with the SH2 domain of α2-chimaerin. CRMP-2 is one of a 
family of proteins, CRMP-1-5 (CRMP-5 is also known as CRAM (Inatome et. al., 2000; 
Ricard et. al., 2001; Fukata et al., 2002)) involved in collapse pathways, axonal 
outgrowth, tubulin binding and cell division (Schmidt and Strittmatter, 2007). CRMP-2 is 
involved in cell polarity and over-expression of CRMP-2 in neurones produces multiple 
axons (Inagaki et. al., 2001). The Cdk5 activating molecule, p35, and Cdk5, interact with 
the GAP domain of α2-chimaerin and Cdk5/p35 also phosphorylates CRMP-2, priming 
for phosphorylation by GSK-3β (Brown et. al., 2004; Cole et. al., 2004; Yoshimura et. 
al., 2005). 
 
5.2 α2-Chimaerin Interacts with Vps28, a Member of the ESCRT-I 
Complex 
Previously in our laboratory, using a Yeast-2 Hybrid screen, human α2-chimaerin was 
found to interact with human Vacuolar protein sorting 28 (Vps28) protein (C. Monfries). 
A Vps28 mutant in yeast shows a Class E phenotype; accumulation of vesicles consistent 
with early endosomes. Vps28 assembles vacuolar, endocytic and late golgi markers in 
endosome–like Class E compartments (Rieder et. al., 1996). Vps28 is a member of the 
endosomal sorting complex required for transport (ESCRT)-I protein complex. The 
ESCRT-I complex is formed of tumour susceptibility gene 101 (TSG101) (mammalian 
Vps23), Vps37, Mvb12 and Vps28. The complex recognises ubiquitinated multivesicular 
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body (MVB) cargo through a conserved UBC (ubiquitin conjugating)-like domain in 
Vps23 and is required for sorting into MVB vesicles (Katzmann et. al., 2001). The MVB 
pathway involves down regulation of active cell surface receptors and the delivery of 
lysosomal hydrolases degrading active receptors in the lysosome (Katzmann et. al., 
2001). The Vps28 gene is essential; Drosophila homozygous mutants are lethal and 
mutations in Vps28 revealed a link between Vps28 and the actin cytoskeleton 
(Sevrioukov et. al., 2005). Null mutants of Vps28 in Saccharomyces cerevisiae prevent 
golgi to pre-vacuolar compartment transport (Hanson et. al., 2002).   
Vps28 interacts with the conserved C-terminal region of TSG101 (Vps23) (Bishop and 
Woodman, 2001). Structural studies have shown that Mvb12 subunits interact with the 
core region of the TSG101-Vps37 complex (Morita et. al., 2007) and that ESCRT-I is 
assembled with the C-terminal steadiness box of Vps23 (TSG101), the N-terminal of 
Vps28 and the C-terminal of Vps37. The C-terminal half of Vps28 does not directly 
participate in the ESCRT-I complex and interacts with downstream MVB pathway 
components ESCRT-II and ESCRT-III factor Vps20 (Kostelansky et. al., 2006; Pineda-
Molina et. al., 2006). 
Retroviruses such as the human immunodeficiency virus type I (HIV-1) and the equine 
infectious anemia virus (EIAV) can interact with host cellular VPS machinery including 
TSG101 and Vps28 to aid particle release (Martin-Serrano et. al., 2003; Tanzi et. al., 
2003). Vps28 is vital in MVB pathway targeting and sorting. 
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5.3 Vps28 Antibody Characterisation 
Two mouse monoclonal antibodies were characterised. The antibodies were raised to 
Vps28 recombinant protein (C Monfries unpublished results) by T. Jowett (UCL 
Monoclonal Antibody Unit). Further studies on the two antibodies revealed that they each 
recognised a different half of recombinant Vps28, one antibody epitope being in the N-
terminal of Vps28 and the other in the C-terminal half (C. Monfries, unpublished results). 
Investigation of the two antibodies was carried out to test them for further use in western 
blotting of brain extracts and cell staining.  
Western blotting was carried out on sucrose density gradient fractions from E14 and E18 
rat brains, COS-7 cell expressed HA-tagged Vps28 sample was used for comparison as a 
size marker (lower panel, figure 5.1). 
 
 
 
Figure 5.1 Vps28 N- and C-terminal antibody comparisons on E14 and E18 rat 
brain fractions Brain fractions as indicated from E14 and E18 rat brains and a COS-7 
expressed Vps28 sample were analysed via SDS-PAGE. Western blotting with two 
different mouse monoclonal antibodies recognising the N- or C-terminal of Vps28 
allowed comparison of the two antibodies. 
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The Vps28 antibody recognising the C-terminal, detects a single band of around 28 KDa 
in all fractions co-migrating with COS-7 cell expressed Vps28 (Figure 5.1). Whereas the 
antibody recognising the N-terminal of Vps28 detects a band of the expected size in E14 
mitochondria, synaptosome and microsome fractions, although it did not seem to detect 
the COS-7 cell expressed Vps28. The N-terminal antibody also detected a band of the 
expected size in the E14 and E18 microsomal fractions, where numerous additional larger 
bands were also detected. The higher molecular weight bands in the microsome fractions 
were not further investigated, but they could possibly be ubiquitinated products. For 
subsequent western blotting of endogenous Vps28, the antibody recognising the C-
terminal was used. 
 
Both Vps28 antibodies were also tested for endogenous cell staining in N1E-115 cells 
permanently expressing EphA4. 
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Figure 5.2: Vps28 N- and C-terminal antibody comparison on N1E-115 
neuroblastoma cells permanently expressing EphA4 N1E-115 neuroblastoma cells 
permanently expressing EphA4 receptor were fixed with 4 % PFA and stained with the 
N- or C-terminal Vps28 antibody and FITC-secondary antibody (green) and F-actin 
stained with phalloidin-TRITC (red). The scale bar represents 10µm. 
.  
 
As shown in figure 5.2, both the N- and C-terminal Vps28 antibodies detected 
endogenous Vps28 in N1E-115 cells permanently expressing EphA4. Both showed some 
co-localisation with F-actin rich structures. Little difference could be seen between the 
two antibodies for cell staining. 
 
5.4 Vps28 Interacts with the SH2 Domain of α2-Chimaerin  
As previously described, Vps28 was isolated as an interacting partner of α2-chimaerin in 
a Yeast-2 Hybrid screen. To investigate the interaction in mammalian cells and determine 
the region of α2-chimaerin interaction with Vps28, COS-7 cells were transfected with 
HA-tagged Vps28 and either FLAG-tagged α2-chimaerin or truncated α2-chimaerin 
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fragments. Chimaerin was affinity purified onto FLAG antibody beads and samples were 
analysed by SDS-PAGE and immunoblotted with HA antibody to identify the binding 
region. 
 
Figure 5.3 Vps28 interacts with α2-chimaerin’s SH2 domain COS-7 cells 
were transfected with FLAG-tagged α2-chimaerin or fragments and HA-tagged 
Vps28. Cells were lysed and incubated with FLAG antibody beads to pull down 
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FLAG α2-chimaerin. Samples were analysed by SDS-PAGE and 
immunodetected with HA and FLAG antibodies. The figure is a representative 
blot from two experiments. 
 
Vps28 pulls down with the α2-chimaerin SH2 domain, amino acid residues 1-137. Vps28 
also pulls down with the 39-459 construct (Figure 5.3). As described previously, the 39-
459 N-terminal deletion construct, alters α2-chimaerin into an open conformation and 
makes it more available for binding than the wild type. Because α2-chimaerin 39-459 
binds Vps28 more strongly, there may be other residues contributing to the interaction 
than in the α2-chimaerin 1-137 SH2 fragment and this interaction was not tested for 
phosphotyrosine dependence. 
 
To investigate whether Vps28 and α2-chimaerin co-localise within neurones, 3 div 
hippocampal neurones from E18 rat brains were fixed with 4 % paraformaldehyde and 
stained for endogenous α2-chimaerin and endogenous Vps28, imaged using an LSM510 
confocal microscope. 
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Figure 5.4 Vps28 co-localises with α2-chimaerin in hippocampal 
neurones 3 div hippocampal neurones from E18 rat brains were fixed in 4 
% paraformaldehyde and stained with monoclonal Vps28 and rabbit 
polyclonal α2-chimaerin antibodies for endogenous proteins and secondary 
antibodies conjugated to FITC (green) and Cy5 (red) respectively and F-
actin stained with phalloidin-TRITC. The scale bar represents 10 µm. 
 
Results suggested that endogenous Vps28 and α2-chimaerin co-localise in hippocampal 
neurones (Figure 5.4). 
To investigate Vps28 function in cells, shRNA for Vps28 was produced as described in 
Chapter 2.0 Methods, using the siSTRIKE U6 Hairpin Cloning System (Promega). To 
test the Vps28 shRNA, N1E-115 neuroblastoma cells were transfected with the three 
shRNA sequences for Vps28 or the vector or scrambled sequence controls, after 24 h 
expression, cells were selected (5 d) with G418 (800 µg/ml). Samples were analysed by 
SDS-PAGE and immunoblotted with Vps28 antibody and actin antibody as an equalising 
control. 
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Figure 5.5 Vps28 shRNA sequence 1 knocks down Vps28 N1E-
115 neuroblastoma cells were transfected with vector or scrambled 
shRNA controls or Vps28 shRNA sequences 1, 2 or 3. Cells were 
treated with 800 µg/ml G418 selection 24 hours later. Cells were 
lysed after five days and samples were analysed by SDS-PAGE and 
immunodetected with Vps28 and actin antibodies. 
 
 
Figure 5.5 shows, all three shRNAs reduced Vps28 levels, with sequence 1 being the 
most effective. 
To investigate whether Vps28 plays a role in endocytosis in the ephrin A1/EphA4 
pathway, the Vps28 shRNA sequence 1 was transfected into N1E-115 neuroblastoma 
cells permanently expressing EphA4.  
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Figure 5.6: Ephrin A1-treated N1E-115 neuroblastoma cells permanently expressing 
EphA4 transfected with scrambled or Vps28 shRNA N1E-115 neuroblastoma cells 
permanently expressing EphA4 receptor were transfected with scrambled or Vps28 
shRNA sequence 1. Cells were treated for 10 minutes with pre-clustered ephrin A1 prior 
to being fixed with 4 % PFA and stained with the α2-chimaerin-Cy5 (blue) and ESCRT-I 
component, Tsg101-FITC (green) antibodies and F-actin stained with phalloidin-TRITC 
(red). The scale bar represents 10 µm. 
 
Expression of Vps28 shRNA-1 caused extensive cell death and loss of polymerised actin 
in the few remaining cells, in keeping with an essential role in cell function (Sevrioukov 
et. al., 2005) (Figure 5.6). Time constraints prevented this from being further 
investigated. 
 
5.5 Endogenous Associations of α2-Chimaerin in Cortical Neurones 
To confirm endogenous associations of α2-chimaerin found in this study, an 
immunoprecipitation (as described in Chapter 2.0 methods) was carried out using rabbit 
polyclonal anti-α2-chimaerin antibody that was produced ‘in house’ (Hall et. al., 2001). 
Three 10 cm plates of approximately 2 x 106 cortical neurones at 7 days in vitro were 
used for each sample. Pre-clustered ephrin A1 treatment was used on one sample to 
investigate whether ephrin A1/EphA4 forward signalling affected interactions with α2-
chimaerin, especially considering the domain shift of EphA4 binding shown in figures 
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4.1 and 4.2. Neurones were lysed and lysates immunoprecipitated as described in 
Methods. Samples were subsequently analysed by immunoblotting with antibodies for; 
(1) α2-chimaerin, to confirm its selective immunoprecipitation; (2) Fyn; (3) EphA4 and 
(4) Vps28. 
                
Figure 5.7 α2-Chimaerin immunoprecipitation from 
cortical neurones 7 div cortical neurones were untreated or 
treated with 10 minutes of pre-clustered ephrin A1 prior to 
lysis. Control IgG or rabbit-anti-α2-chimaerin antibody was 
used to IP α2-chimaerin. Samples were analysed by SDS-
PAGE and target antibodies, as indicated, tested to 
investigate α2-chimaerin endogenous interacting partners. 
 
 
Results confirmed (Figure 5.7) that α2-chimaerin immunoprecipitated with the rabbit-
anti-α2-chimaerin antibody but not the IgG control. Endogenous α2-chimaerin was 
shown to interact with EphA4, which was only detectable after ephrin A1 treatment. Fyn 
was also shown to interact endogenously with α2-chimaerin regardless of ephrin A1 
treatment. The endogenous association of Vps28 with α2-chimaerin was slightly 
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increased with ephrin A1 treatment suggesting a possible involvement in receptor 
stimulated endocytosis. These results demonstrate that EphA4, Fyn and Vps28 are all 
associated with endogenous α2-chimaerin in cortical neurones. Fyn appears to be a 
constitutive partner, whilst EphA4 was only detectable as a binding partner after ephrin 
A1 stimulation. These results are consistent with the over-expression interactions from 
this study for α2-chimaerin with Fyn and EphA4 (Figures 3.8 and 4.1/2 respectively). 
 
5.6 Identification of α2-Chimaerin Binding Partners in Brain 
To identify new α2-chimaerin interacting partners in brain extracts, dual tagged His-
Biotin vectors were used. The N-terminal and SH2 domain of α2-chimaerin (1-137) was 
cloned into the tap-tag vectors as described in Methods.  Recombinant α2-chimaerin-SH2 
domain His-Biotin was grown in BL-21 cells and the protein purified on a nickel column 
and subsequently further affinity purified on a streptavidin column (see Methods Chapter 
2.0). Synaptosomal membrane extracts (in triton-X100 extraction buffer, see Methods) 
from 10 d rat brains were used as a source of brain protein. After washing, bound proteins 
were eluted from the column and analysed by SDS-PAGE as shown in figure 5.8. 
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Figure 5.8 α2-Chimaerin pull down from rat synaptosomal brain fraction α2-
Chimaerin pHIS-BIOTIN was used as bait, to pull down interacting proteins from rat 
synaptosomal brain fraction. Samples were analysed by SDS-PAGE and coomassie 
staining. Bands (numbered) were cut out of the gel to be sent off for mass 
spectrometry, to investigate α2-chimaerin interacting partners. 
 
 
 
After extensive washing and elution with desthiobiotin which did not release bound 
protein, elution with 1 % SDS at 37 °C was required to elute the protein from the 
streptavidin column (Figure 5.8). Numbers show bands which were excised from the gel 
and sent for mass spectrometry analysis.  
 
See appendix for identified proteins, which included;  
Band   6    62KD; CRMP 2 (62 kDa); 
Band   8    30KD; Prohibitin (2 peptides); 
Band   9    26KD; Rabs 2A, 6B, 11B, and 7A; 
Tubulin and several mitochondrial proteins were also bound. 
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5.7 Summary 
The results in Chapter 5.0 identify a novel interacting partner of α2-chimaerin, Vps28. 
Vps28, a member of the ESCRT-I complex, binds active α2-chimaerin, via the SH2 
domain (Figure 5.3). Two mouse monoclonal ‘in house’ antibodies recognising the N-
terminal and C-terminal of Vps28 were shown to be suitable for use in cell staining and 
western blotting. Vps28 shRNA-1 knocks down Vps28 very effectively and caused cell 
death in N1E-115 neuroblastoma cells permanently expressing EphA4. It may be that 
Vps28 shRNA sequences 3 and 4 which only partially knocked down Vps28 may be 
more useful for further studying the function of the Vps28 interaction with α2-chimaerin. 
The immunoprecipitation from cortical neurones (Figure 5.7) confirmed Fyn (Shi et. al., 
2007), EphA4 (Wegmeyer et. al., 2007; Beg et. al., 2007; Iwasato et. al., 2007) and 
Vps28 as endogenous α2-chimaerin binding partners. Ephrin A1 treatment enhanced the 
association with EphA4. The His-Biotin pull down identified the known α2-chimaerin 
partner CRMP-2 (Brown et. al., 2004) and has also suggested some novel possible α2-
chimaerin partners, such as Prohibitin and several Rab proteins. Prohibitin is a 
mitochondrial protein that has been shown to associate with the plasma membrane, 
become tyrosine phosphorylated and interact with phosphatidylinositol 3,4,5-triphosphate 
(Ande and Mishra, 2009).  Therefore it is possible that prohibitin could come into contact 
with α2-chimaerin at the plasma membrane. Rab proteins serve as master regulators in 
membrane trafficking (Hutagalung and Novik, 2011), thus their interaction with α2-
chimaerin implicates some kind of α2-chimaerin involvement in cell trafficking. 
Since α2-chimaerin partners include Vps28 and some Rab proteins, it may be involved in 
endocytosis and vesicle recycling, not previously reported. Unfortunately due to time 
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restraints the preliminary results in this chapter were unable to be followed up. Interesting 
future work for chimaerin would include an investigation into the significance of its 
interaction with Vps28. This is could be the key to downregulation of α2-chimaerin or 
possible involvement of chimaerin in endocytosis. 
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6.0 Discussion 
In the developing nervous system the formation of neuronal networks requires the 
accurate navigation of axons and dendrites in response to attractive or repulsive guidance 
signals. The RhoGTPases regulate changes in the actin cytoskeleton downstream of these 
signalling molecules, enabling outgrowth and navigation of axons and dendrites (and in 
cell migration). RhoGAPs (and RhoGEFs), which out-number the GTPases they regulate, 
are linked with other signal transduction proteins via multiple domains, and function in 
response to different signals (Bernards, 2003). α-Chimaerins are a major Rac down 
regulator in neurones and regulators of neuronal morphology, but how they function in 
pathways linking membrane receptors to the cytoskeleton is only partly understood. At 
the outset of this study the two isoforms, α1 and α2, had been shown to be involved 
respectively in pruning of dendrites (Van de Ven et. al., 2005; Buttery et. al., 2006) and 
in growth cone collapse in sema 3A axonal guidance signalling (Brown et. al., 2004). α2-
Chimaerin has subsequently been shown to participate in ephrin signalling, with 
locomotor defects in mice lacking a functional chimaerin gene (Wegmeyer et. al., 2007; 
Beg et. al., 2007; Iwasato et. al., 2007; Shi et. al., 2007), and coding mutations in the 
human gene impeding eye movement (Miyake et. al., 2008). 
This study aimed to investigate α2-chimaerin regulation and interactions in neuronal 
signalling pathways. This led to the identification of α2-chimaerin tyrosine 143 as a Fyn 
phosphorylation site, and highlighted the importance of Fyn and α2-chimaerin in the 
sema 3A and ephrin/EphA4 neuronal signalling pathways. As well as Fyn, other novel 
α2-chimaerin binding partners emerged during and as part of this study, including the 
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scaffold protein Nck, (Wells et. al., 2006; Chapter 4.0) and Vps28, a component of the 
ESCRT-I complex. 
The RhoGTPases, including Rac, play a vital part in the regulation of the actin 
cytoskeleton in developing neurones. Rac is essential in guidance signalling, such as in 
the sema 3A and ephrin/Eph pathways, in which Rac is transiently activated and 
subsequently downregulated and involved in endocytosis (Jurney et. al,. 2002). Rac 
exchange factor Vav is also involved in endocytosis in ephrin signalling (Cowan et. al., 
2005) (and Vav2 regulates EGF receptor endocytosis (Thalappilly et. al., 2010)). The 
regulation of the RacGAP α2-chimaerin in neuronal signalling is tightly controlled, 
which is essential for regulating neuronal development and outgrowth. The conformation 
of chimaerins, DAG-binding and involvement of phosphorylation may all play a role in 
this regulation of chimaerin activity and of its cellular location.  
 
6.1 Biological Function and Regulation of Chimaerin  
The crystal structure of β2-chimaerin was determined in 2004 and provided a possible 
mechanism for chimaerin allosteric activation by lipids (Canagarajah et. al., 2004). β2-
Chimaerin is held in an autoinhibited, inactive conformation with the C1 domain 
occluded by the N-terminal, SH2 domain, the linker between the SH2 and C1 domains 
and the GAP domain (Canagarajah et. al., 2004). The activation of chimaerin by the 
phorbol ester PMA has been well described (Ahmed et. al., 1993). PMA promotes 
translocation of α2-chimaerin from a predominantly cytosolic location to membranes 
(Brown et al 2004), although higher concentrations of PMA are required than for the 
translocation of PKC (Caloca, et. al., 1997). However, DAG although necessary for 
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chimaerin translocation to membranes, may not be sufficient for its activation (Colón-
González et. al., 2008), and in T-cells, translocation of β2-chimaerin is not solely 
dependant on the C1 domain (Caloca et. al., 2008).  
The C1 domain is not accessible to DAG when β2-chimaerin is in an inactive state, and 
this has also been suggested for other non-kinase phorbol ester receptors such as Munc-
13, as well as kinase MRCK (Shen et. al., 2005; Choi et. al., 2008). Their activities are 
tightly controlled and other factors such as post-translational modifications or protein-
protein interactions may contribute to exposure of the C1 domain prior to DAG binding. 
Possibilities explored in this study and suggested by the work of others for chimaerin 
activation include tyrosine phosphorylation of α2-chimaerin (Wegmeyer et. al., 2007) 
and β2-chimaerin (Kai et. al., 2007) and also Nck1 binding to α2-chimaerin (Wegmeyer 
et. al., 2007; Fawcett et. al., 2007). 
In EphA4 signalling, tyrosine phosphorylation of α2-chimaerin may be direct, by the 
EphA4 receptor (Wegmeyer et. al., 2007), which can phosphorylate a2-chimaerin 
peptides in vitro at Y21, Y143 and Y202 (Warner et. al., 2008), and/or indirect, by the 
non-RTK SFKs (Shi et. al., 2007). EphA4 stimulation by ephrin A1 resulted in tyrosine 
phosphorylation of α2-chimaerin and increased activity towards Rac1. SFKs were 
implicated as a2-chimaerin phosphorylation was reduced with the addition of PP2, a SFK 
inhibitor (Shi et. al., 2007). Results described in this study suggest that whilst tyrosine 
phosphorylation of α2-chimaerin occurs in the sema 3A and ephrin/EphA4 pathways, it is 
unlikely that tyrosine phosphorylation alone activates α2-chimaerin. Moreover, EphA4 
mediates signalling through PLCγ activation (Zhou et. al., 2007), thereby producing 
DAG, which may activate α2-chimaerin in this pathway. 
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Results described also suggest that α2-chimaerin Y143 and possibly Y303 are Fyn 
phosphorylation sites in vivo. The other tyrosine residues investigated by mutation are 
unlikely phosphorylation sites for Fyn, but it is conceivable that other kinases may 
phosphorylate at these sites. In neurones additional sites may be phosphorylated based on 
the reduced phosphorylation of mutants in ephrin-stimulated neurones Y202, Y303 and 
Y333 could be phosphosphorylation sites as well as tyrosines in the N-terminal region 
(Wegmeyer et. al., 2007). Wegmeyer et. al., (2007); and Shi et. al., (2007) also reported 
multiple likely sites that included Y70, Y143 and Y148 in Hek293 cells expressing 
EphA4.  
Protein sequence homology shows that α2-chimaerin Y143 corresponds to Y153 in β2-
chimaerin. Similarly to the findings in this study, β2-chimaerin has been shown to be 
phosphorylated by the SFK Lck (Kai et. al., 2007; Siliceo and Mérida, 2009) at Y153 
and/or Y21. Phosphorylation of Y21 inhibited GAP activity and phosphorylation of Y153 
had little effect (Kai et. al., 2007), or showed slight inhibition of levels of active Rac 
(Siliceo and Mérida, 2009). SFKs phosphorylate β2-chimaerin Y21 in response to cell 
stimulation with EGF, which appears to negatively regulate β2-chimaerin RacGAP 
activity (Kai et. al., 2007). This site corresponds to Y11 in α2-chimaerin which was not 
tested in this study, as it did not score as highly as some other tyrosine sites in the online 
phosphorylation prediction website used (http://www.cbs.dtu.dk/services/NetPhos/). It 
would therefore be interesting to investigate whether phosphorylation of α2-chimaerin 
Y11 would have similar effects to that of β2-chimaerin Y21. 
In response to T-cell receptor signalling β2-chimaerin Y153 can be phosphorylated by 
Lck, regulating β2-chimaerin membrane stabilisation and reportedly, negatively 
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regulating its GAP activity (Siliceo and Mérida, 2009). Whether Fyn phosphorylation 
could lead to negative regulation of α2-chimaerin could not be reliably determined. The 
use of a consistent GAP assay would have helped to investigate this possibility, but 
physiological chimaerin activation in cells would be required (and its possible inhibition 
in the case of mutated chimaerin) and this would have been difficult to interpret due to 
the variable expression levels of transfected chimaerin and chimaerin mutants and so was 
not included.  
Some of the tyrosine mutants produced resulted in α2-chimaerin becoming hyper-
phosphorylated on co-expression with Fyn in cells stimulated with sema 3A or ephrin A1. 
This suggests either that their modification could inhibit association with another protein 
such as a phosphatase for example or that the amino acid substitutions resulted in 
disruption of α2-chimaerin structure, allowing increased accessibility to Fyn kinase. This 
is supported by the results in chapter 4.0 showing that phosphorylation of α2-chimaerin 
was greatly increased on PMA treatment of cells and without any stimulation, little if any 
phosphorylation occured. This is also consistent with a study that showed certain 
mutations of β2-chimaerin caused increased lipid association and GAP activity due to 
irregular C1 and RacGAP domain exposure (Sosa et. al., 2009).  
DAG interaction with the C1 domain is clearly an important control mechanism for α2-
chimaerin. The generation of DAG in signalling pathways will have an impact on the 
membrane location of chimaerin and other C1 domain proteins (Caloca et. al., 1999; 
Caloca et. al., 2001; Giorgione et. al., 2006). Rac can itself act upstream of some 
isoforms of PLC, in generating DAG, suggesting a possible feedback loop on Rac 
inactivation (El-Sibai and Backer, 2007). Phorbol ester treatment promoted stabilisation 
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of endogenous α1-chimaerin, degradation of which involves the unique N-terminal 
(Marland et. al., 2011), and DAG may also stabilise α2-chimaerin. This suggests a role 
for DAG in chimaerin stabilisation as well as the already known potential for chimaerin 
activation (Ahmed et. al., 1993). 
 
6.2 Fyn as a regulator of RhoGAPS 
Fyn, a member of the SFKs, can be myristoylated and palmitoylated, anchoring it to the 
plasma membrane and is involved in trafficking (Resh, 1999; Sandilands et. al., 2007; 
Sato et. al., 2009). This study demonstrated Fyn binding to α2-chimaerin GAP domain 
and tyrosine phosphorylation of α2-chimaerin by Fyn. These actions of Fyn may regulate 
α2-chimaerin in terms of stability, membrane or receptor localisation or GAP activity. 
Fyn regulates a number of proteins involved in actin dynamics and is involved in 
oligodendroglial maturation and process outgrowth (Osterhout et. al., 1999; Sperber et. 
al., 2001). Fyn has been shown to modulate actin dynamics by activating Cdk5, which in 
turn phosphorylates WAVE2, downstream of platelet derived growth factor in migrating 
oligodendrocyte precursor cells (Miyamoto et. al., 2008).  
Fyn is known to regulate the activity of other RhoGTPases. Fyn SH2 domain binds 
p190RhoGAP, found via a yeast two hybrid screen (Wolf et. al., 2001). Fyn activity 
regulates phosphorylation of p190RhoGAP, leading to an increase in GAP activity and in 
RhoGDP. Down-regulation of Rho signalling, which is involved in contractility and 
neurite retraction, via activation of p190RhoGAP, promotes neurite formation (Liang et. 
al., 2004; Govek et. al., 2005). This also regulates morphological changes in 
oligodendrocyte differentiation (Wolf et. al., 2001).  
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Additionally, Fyn can phophorylate p250RhoGAP enhancing its GAP activity and 
therefore inactivating Rho (Taniguchi et. al., 2003). Conversely, the GAP activity of 
TCGAP, a Cdc42 GAP and a regulator of insulin-induced glucose transport in 
adipocytes, is suppressed by Fyn phosphorylation (Liu et. al., 2006). Fyn activity 
produces a response aiding process outgrowth due to Cdc42 and Rac1 binding GTP and 
becoming activated (Krämer-Albers and White, 2011). The precise role that Fyn 
phosphorylation plays in α2-chimaerin function would be an interesting avenue for 
further study. α2-Chimaerin direct interaction with Fyn may scaffold other interactions in 
the EphA4 pathway. 
 
6.3 Nck  
The adaptor proteins Nck1 and Nck2, comprising of three SH3 domains and an SH2 
domain, interact with Eph receptors, including EphA4 (Holland et. al., 1997; Bisson et. 
al., 2007). Nck1 and 2 also link phosphotyrosine signalling to actin cytoskeleton 
regulating proteins, (Bladt et. al., 2003) such as N-WASP and the WAVE1 complex 
(Rivero-Lezcano et. al., 1995; Eden et. al., 2002). Nck1 has been shown to bind α2-
chimaerin (Wells et. al., 2006). In addition, α2-chimaerin, but not α1-chimaerin was 
demonstrated to bind both Nck1 and Nck2, requiring α2-chimaerin SH2 domain (N-
terminal 1-183 amino acids) and one of the three SH3 domains of Nck (Wegmeyer et. al., 
2007). This study established that the first 1-39 amino acid residues of α2-chimaerin 
contain a Nck1 binding site.  The SH3 domain of Nck1 that binds α2-chimaerin was not 
mapped during this study, but was determined at the same time by collaborators (Sit Soon 
Tuck and Ed Manser, Singapore, personal communication). 
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Results also suggested that Nck may function as a complex with α2-chimaerin and Fyn 
since all three proteins, α2-chimaerin, Fyn and Nck, were able to associate (Chapter 4.0). 
In addition, when Nck was present, α2-chimaerin could bind Fyn effectively in the 
absence of PMA. This is in concurrence with Wegmeyer et. al., (2007) who suggested 
that α2-chimaerin and Nck may act together to balance Rac activity. Within the 
limitations of the RacGTP assay and variable expression levels of the different proteins, 
these results indicated that Nck may either limit chimaerin RacGAP activity or act 
downstream of EphA4 in promoting Rac activity, counterbalanced by chimaerin 
(Wegmeyer et. al., 2007). Nck2 is also involved in ephrin B3 reverse signalling, 
regulating interactions with Dock180 and PAK, altering actin reorganization and axon 
pruning (Xu and Henkemeyer, 2009). Nck adaptors are implicated in linking 
phosphotyrosine signals to cytoskeleton reorganization and are required for the 
development of normal limb movement, since Nck1 (-/-) mice with Nck2 knockout in the 
nervous system showed a similar phenotype to EphA4 (-/-) mice (Fawcett et al, 2007; 
Kullander et. al., 2003). Nck may also be involved in EphA4-induced loss of adhesion 
required in cell sorting in development (Bisson et. al., 2007), and interact with EphA3 
phosphotyrosine residues in cell migration and process retraction (Hu et. al., 2009). The 
mounting supporting evidence suggests that Nck adaptors are vital in neuronal signalling 
pathways and development. 
It has been reported that in T-cell receptor activity, Nck binding to the CD3 subunits of 
T-cell receptors inhibits phosphorylation by Lck or Fyn, thereby acting as a down 
regulator of receptor signalling (Takeuchi et. al., 2009). Currently there is no evidence 
for Nck inhibiting EphA4 or α2-chimaerin phosphorylation by Fyn, however, it is 
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possible that similar regulatory mechanisms could be involved in ephrin/EphA4 
signalling. Results in this study demonstrated that Nck could be phosphorylated by Fyn, 
which could alter its subsequent interactions. 
Further studies would be of interest to determine whether Nck1, Nck2 or both are 
involved in ephrin A1/EphA4 signalling and whether regulation by tyrosine 
phosphorylation is involved. This could be done using selective Nck1 and 2 knock-down 
in neurones or in the N1E-115 neuroblastoma cell line permanently expressing EphA4 
and testing the response in an ephrin A1 induced collapse assay. Single point mutations 
of predicted phosphorylation sites would aid investigation into its regulation by tyrosine 
phosphorylation. Nck1 and 2 are adaptor proteins that interact with integrins and GIT1 
(Zhao et. al., 2000; Buday et. al., 2002), and are involved in the activation of N-WASP 
and related proteins, promoting the polymerization of F-actin (Tomasevic et. al., 2007). 
Nck SH3 domains are important in these functions and interaction with chimaerin may 
conceivably down-regulate this function of Nck. 
 
6.4 Role of α2-chimaerin Domains 
The role of α2-chimaerin SH2 domain is as yet undefined. Several binding partners of 
α2-chimaerin have been identified that interact with the SH2 domain. These include 
CRMP-2, as well as Vps28 which was identified as a binding partner during the course of 
this study. EphA4 under certain conditions (such as ephrin stimulation (Figure 4.2; Beg 
et. al., 2007; Wegmeyer et. al., 2007)) may also bind α2-chimaerin SH2 domain. The 
results in chapter 4.0 are consistent with the other reports suggesting that there are 2 
binding sites for EphA4 in chimaerin (Beg et. al., 2007; Wegmeyer et. al., 2007). Nck1 
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was thought to bind α2-chimaerin SH2 region (and was unaffected by a mutation 
abolishing phosphotyrosine binding), however, pull down experiments with α2-chimaerin 
fragments in this study have shown that it more likely binds the N-terminal region 
adjacent to the SH2 domain, a region not present in α1-chimaerin. This further 
demonstrates the importance of the unique N-terminal as well as other domains in control 
mechanisms for chimaerin, as with other tightly regulated small GTPase GAPs. It has 
been suggested that the N-terminal GTP binding domain of p190RhoGAP plays an auto 
regulatory role (Tatsis et. al., 1998). 
As previously described, the C1 domain is very important in altering conformation and in 
membrane translocation of α2-chimaerin, affecting the accessibility of α2-chimaerin 
binding and phosphorylation sites. It has recently been reported that phosphorylation by 
PKCδ of serine 169 in the linker region between the SH2 and C1 domains of β2-
chimaerin, prevents membrane translocation, thus keeping β2-chimaerin in the cytosol 
and away from membrane-associated Rac (Griner et. al., 2010). Since PKC is also 
regulated by DAG, it would be interesting to investigate whether PKC or other 
serine/threonine phosphorylation in α2-chimaerin had the same inhibiting effect. 
However, this site is not conserved in the α2-chimaerin linker region suggesting that the 
two proteins may be differently regulated. 
The GAP domain of chimaerin regulates Rac1 function, which affects morphology. 
Binding of α1-chimaerin to the NMDA receptor NR2A subunit in a phorbol ester-
dependent manner, has been shown in neuronal dendrites to inhibit new spine formation 
and prune existing spines. This process was shown to require a functional α1-chimaerin 
GAP domain and is therefore mediated by Rac1 activity, which regulates F-actin in these 
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structures (Van de Ven et. al., 2005; Buttery et. al., 2006). Additionally, α1-chimaerin 
protein levels were reported to be controlled by synaptic activity and an increase in 
expression resulted in pruning of dendritic spines and branches in cultured Purkinje and 
hippocampal neurones, requiring both DAG binding and RacGAP activity. Results in 
chapter 3.0 show over-expression of α2-chimaerin mutated to inactivate the GAP domain 
(R304G) in rat hippocampal neurones (Chapter 3.0), which resulted in altered 
morphology, with some spread growth cones. Over-expression of wild type α2-chimaerin 
promoted increased branching and axon number, whilst α2-chimaerin SH2 domain 
inactivating mutant (R73L) appeared to be without any effect, and surprisingly some 
phosphotyrosine mutants strongly promoted branching. This may indicate that α2-
chimaerin is regulated by multiple interactions and modifications involving all three 
domains and with subtle effects on development of neuronal structure. 
 
6.5 Other Functions 
In addition to the roles of chimaerin already mentioned, during the course of this study 
other emerging functions have become apparent. α2-Chimaerin has been demonstrated to 
be important in ocular motor neurone axon path finding, where gain-of-function missense 
mutations in CHN1 cause a variant form of the congenital eye movement disorder 
Duane’s retraction syndrome (Miyake et. al., 2008). Very recently α-chimaerin has been 
identified as having a possible role in the postnatal period of visual cortical plasticity in 
cats (Yang et. al., 2011). This evidence supports the notion that conformational changes 
of chimaerins, such as possibly occurs with the hyperphosphorylated tyrosine mutants, 
can lead to functional changes or disruption. 
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Results from this study suggest a possible new role for α2-chimaerin in endocytosis. 
Ectopic expression of the GAP domain of α2-chimaerin was previously shown to inhibit 
cytoskeletal response to the chemotactic peptide formyl-methionyl-leucyl-phenylalanine 
and colony stimulating factor-1, thereby preventing phagocytosis, in which Rac is a key 
regulator (Cox et. al., 1997). Interestingly, Fyn is present in RhoD (an endosomal 
marker) positive endosomes (Sandilands et. al., 2007). The mass spectrometry data from 
this study indicates that some Rabs, small G-proteins highly involved in regulating 
vesicular transport, are also likely to be associated with α2-chimaerin. These potential α2-
chimaerin partners function in neurones (Ng and Tang, 2008); Rabs 2A and 6A are 
involved in golgi transport (Ayala et. al., 1990; Shetty et. al., 1998), and Rabs 7A and 
11A are involved in endosomal sorting (Saxena et. al., 2005; Satoh et. al., 2005; Shirane 
and Nakayama, 2006). 
Results from this study also suggest a role for α2-chimaerin in the ubiquitin proteasome 
system, with the SH2 domain associating with Vps28, a component of the ESCRT-I 
complex. This is a novel finding not yet supported by other studies, Vps28 was isolated 
as a yeast two hybrid partner of α2-chimaerin (C. Monfries, C. Hall, personal 
communication) and endogenous Vps28 could be immunoprecipitated with chimaerin 
(Chapter 5.0).  Vps28 interacts with Tsg101 and in cells the interaction stabilises its 
expression levels (Bishop and Woodman, 2001). Vps28 C-terminal connects with 
ESCRT-II (Kostelansky et. al., 2006)  
In Drosophila Vps28 knockdown has been shown to alter the actin cytoskeleton 
(Sevrioukov et. al., 2005) and interestingly another RhoGAP, BCR interacts with Tsg101 
(Olabisi et. al., 2006). Thus RhoGAPs may link regulation of the actin cytoskeleton 
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through Rac and Rabs to vesicle formation and trafficking, as reported for P50RhoGAP 
(Sirokmany et. al., 2006). Additionally, it has been suggested that Eps8 protein also 
connects receptor signalling through Rac to cell trafficking through Rab5 (Lanzetti et. al., 
2000), suggesting a common link between the two processes, possibly involving Rac-
dependent actin rearrangements and/or receptor recycling. In addition, Rab35 has been 
reported to regulate cell shape and neurite outgrowth, indicating a wider role for Rabs 
other than in cell trafficking (Chevallier et. al., 2009).   
 
6.6 Models for α2-Chimaerin in Neuronal Collapse Pathways 
The results from this study, taken together with published research have enabled models 
to be developed of how α2-chimaerin may function in growth cone collapse in axonal 
guidance signalling pathways. The SH2 and GAP domains of α2-chimaerin were shown 
to be essential in the sema 3A growth cone collapse pathway (Brown et. al., 2004). The 
model in figure 6.1 illustrates how α2-chimaerin may act in the pathway stimulated by 
sema 3A through interaction with Cdk5 and its substrate CRMP2 (Brown et. al., 2004). 
In this study, α2-chimaerin was shown to be phosphorylated by Fyn, also a component of 
this pathway (Sasaki et. al., 2002). Phosphorylation of Cdk5 primes for phosphorylation 
of CRMP2 by GSK3β, a central kinase in the sema 3A pathway (Eickholt et. al., 2002), 
regulating activity of microtubule associated proteins (Gu and Ihara, 2000). This 
transmits the signal to affect microtubule dynamics, whilst regulation of Rho GTPases 
and associated proteins also alter the actin cytoskeleton. It is possible that elements from 
this model may also function downstream of EphA4, but this is yet to be demonstrated. 
Fyn participates in sema 3A guidance and activates Cdk5 by phosphorylating N-terminal 
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Y15 (Sasaki et. al., 2002; Morita et. al., 2006) and most likely phosphorylates α2-
chimaerin in this pathway. However, since phosphorylation is greatly enhanced on PMA 
treatment, which would allow access to buried tyrosine residues, Fyn phosphorylation 
alone is unlikely to activate α2-chimaerin in the pathway and DAG probably has a key 
role in activating α2-chimaerin prior to phosphorylation. 
 
 
Figure 6.1: Model for α2-chimaerin in the sema 3A pathway Sema 3A 
signals across the plasma membrane though the NP1/PlexA1 receptor. Fyn 
and DAG may play a role in the pathway; Fyn activates Cdk5. Rac1 and 
p35/Cdk5 bind the GAP domain of α2-chimaerin. p35/Cdk5 phosphorylates 
CRMP-2 causing phosphorylation by GSK3-β. CRMP-2 binds α2-
chimaerin SH2 domain. The signal is then cascaded down to affect 
microtubule and actin dynamics, possibly involving Tau, PAK, LIM Kinase 
and Cofilin. 
 
α2-Chimaerin was more recently shown to be involved in EphA4 signalling (Wegmeyer 
et. al., 2007; Beg et. al., 2007; Iwasato et. al., 2007; Shi et. al., 2007). The chimaerin 
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interactions previously identified in the sema 3A pathway may also be involved in 
EphA4 signalling. However, results from this study combined with the work of others 
have indicated that other partners may play a key role, including Nck and Fyn 
(Wegmeyer et. al., 2007; Shi et. al., 2007). Possible mechanisms are shown in figure 6.2, 
of how α2-chimaerin may function in growth cone collapse pathways in neurones 
downstream of EphA4.    
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Figure 6.2: Model for α2-chimaerin in the ephrin A1/EphA4 pathway This model for α2-
chimaerin proposes that following stimulation of EphA4 by the ligand ephrin A1, α2-chimaerin 
translocates from the cytosol to membranes, stimulated either by DAG and/or interaction with 
proteins such as Nck, EphA4 receptor, Fyn, or another mechanism. α2-Chimaerin C1 domain 
interacts with the membrane and SH2 domain may directly bind EphA4. Activated α2-chimaerin 
down-regulates Rac1-GTP initiating a collapse response. Fyn binds the GAP domain and 
phosphorylates α2-chimaerin SH2-C1 linker altering further interactions (or marking it for 
degradation). EphA4 may also bind to α2-chimaerin GAP domain to inhibit further signalling, 
leaving the SH2 domain open for new interactions. On termination of signalling, the receptor 
complex may enter the endocytosis pathway and pass into the ESCRT sorting pathway. ESCRT 1 
component Vps28 binds the SH2 domain of α2-chimaerin linking it with associated actin 
remodelling. The receptor complex may be degraded or recycled back to the plasma membrane. 
 
 180 
α2-Chimaerin may translocate from the cytosol to the membrane, stimulated either by 
DAG and/or another interaction. For example, Nck1 binding to α2-chimaerin N-terminal 
in response to receptor stimulation at the plasma membrane, involving tyrosine 
phosphorylation and SH2 interaction. Whether the SH2 domains of Nck, Fyn or α2-
chimaerin interact directly with EphA4 is not established. The C1 domain interacts with 
the membrane, and α2-chimaerin SH2 domain may directly bind EphA4. α2-Chimaerin 
becomes activated and down regulates Rac1 to initiate a collapse response. 
Subsequently/concurrently Fyn may bind and phosphorylate α2-chimaerin Y143 in C1-
SH2 linker (and possibly the GAP domain at Y303) altering its interactions, activity or to 
mark it for degradation. EphA4 may bind to α2-chimaerin GAP domain to inhibit 
signalling, leaving the SH2 domain open for binding. The whole receptor complex 
including α2-chimaerin could then enter the endocytosis pathway where it may be 
degraded or recycled back to the plasma membrane.  
The ESCRT-I component Vps28 can bind α2-chimaerin SH2 domain. Whilst chimaerin 
may also be a cargo protein, it is more likely that it mediates regulation of Rac and co-
ordination with Rab proteins (which are also chimaerin binding targets (Chapter 5.0)) 
affecting vesicle formation at the plasma membrane and trafficking as early endosomes. 
Although this remains to be investigated, the results described here and several key 
papers published during this study have contributed to a greater understanding of α2-
chimaerin in axonal guidance signalling and its involvement in ephrin/EphA4 neuronal 
growth cone collapse (Wegmeyer et. al., 2007; Beg et. al., 2007; Iwasato et. al., 2007; 
Shi et. al., 2007; Fawcett, et. al., 2007). 
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6.7 Future work 
There are many possible areas of investigation which could be expanded upon. The 
tyrosine mutants constructed in this study and available deletion mutants of α2-chimaerin 
were very useful for mapping sites of α2-chimaerin modification and its interactions with 
the binding partners identified during this study. However, time constraints prevented 
cloning of deletion or domain inactivating mutants of all the α2-chimaerin partners, to 
map the regions of binding, especially of Fyn, Nck and EphA4. Equivocal results were 
obtained for the latter (Beg et. al., 2007; Wegmeyer et. al., 2007) It is not established 
whether the kinase domain, SH2 or SH3 domain of Fyn binds chimaerin GAP domain. 
The role of Fyn phosphorylation of α2-chimaerin is also an interesting area which 
requires further investigation. A workable assay for assessing GAP activity may help to 
establish whether and how Fyn phosphorylation regulates α2-chimaerin activity. This 
would require a sensitive and rapid assay, and the conventional RacGTP binding assays 
have not proved to be as sensitive for down-regulation by GAP activity as for GEFs.  
It was unfortunate that the Vps28 section of this study came so near to the end, as 
investigating the function of this novel α2-chimaerin binding partner would be of real 
interest. A role in endocytosis has not been reported for α2-chimaerin. In view of the 
links between Rac and Rab small GTPases in endocytosis (Bhattacharya et. al., 2004), 
this interaction should be pursued. Ideally a cell assay would need to be established with 
fluorescent tags which could enable visualisation of α2-chimaerin localisation in 
endocytosis. The effects of chimaerin knockdown and chimaerin mutants on the 
formation of MVB and cargo trafficking could also be investigated. Although the Vps28 
shRNA which most effectively eliminated Vps28 led to cell apoptosis, there were other 
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shRNA sequences which only caused a partial knockdown of Vps28, which may be of 
some use for future investigations. Interestingly, Tsg101 knockdown is also lethal and 
these two proteins interact directly (Ruland et. al., 2001; Bishop and Woodman, 2001). 
Further investigation of the interaction of chimaerin with the rab proteins identified by 
the proteomic approach in chapter 5.0 and their role in endocytosis and vesicle trafficking 
would be interesting in relation to this. 
A key issue highlighted by the number of binding partners investigated, is under what 
circumstances chimaerin interacts with these potential multiple endogenous partners. 
Chimaerin is expressed as 2 isoforms and some partners may interact with only α2-
chimaerin via the N-terminal and SH2 domains, but α2-chimaerin is expressed in adult 
neurones as well as throughout development, and in testis (Hall et. al., 1993). Further 
studies involving primary neurones, including dendritic morphology and mass 
spectrometry of interacting partners, would help to investigate phosphorylation, 
endogenous interactions and functions of α2-chimaerin within specific neuronal 
signalling pathways and during development. 
The signalling transducers that link membrane receptors and the RhoGTPases and co-
ordinate their activities are still under much investigation. For example, the GEF 
ephexin1 has been shown to be an essential mediator for EphA-dependent growth cone 
collapse through the activation of RhoA and the inhibition of Rac1 (Shamah et. al., 2001; 
Sahin et. al., 2005). The regulation of ephexin1 by EphA4 is dependent, among others, 
upon SFKs and Cdk5, both of which are also involved in signalling with α2-chimaerin 
(Qi et. al., 2004), further supporting their roles together in the EphA4 pathway. 
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6.8 Conclusions 
This study has identified α2-chimarin Y143 as a Fyn phosphorylation site and that Fyn 
interacts with α2-chimaerin GAP domain. These findings have added to the evidence that 
Fyn has a key role in signalling pathways, including the sema 3A and ephrin A1/EphA4 
pathways looked at in this study. This investigation has also demonstrated that Nck binds 
to α2-chimaerin N-terminal and that a complex may be formed with α2-chimaerin acting 
as a scaffolding protein for Nck and Fyn. EphA4 may interact with α2-chimaerin at two 
different sites dependent upon its activation status, which could explain the differences 
found in other studies as mentioned above (Chapter 4.0). Fyn may generate 
phosphotyrosine binding sites for other interactions in EphA4 signalling and since Fyn, 
Nck and α2-chimaerin all have SH2 domains and Nck also has three SH3 domains (and 
Fyn has an SH3), multiple interactions may participate in the receptor complex.  Novel 
binding partners of α2-chimaerin identified in this study, Vps28 and Rab proteins, 
suggest a possible role or method of degradation/recycling for α2-chimaerin in 
endocytosis.  
This study investigated α2-chimaerin as a piece of this complex puzzle and has tried to 
demonstrate where existing and novel α2-chimaerin partners may fit into neuronal 
collapse pathways. Chimaerins are fascinating proteins with many emerging functions. 
This study contributes in a small way to aiding the understanding of the complex 
signalling pathways involved in neuronal development. 
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Appendix- Mass Spectrometry Data 
 
 
Crmp-2 
gi|40254595 (100%), 62,277.9 Da
dihydropyrimidinase-like 2 [Mus musculus], gi|157786744|ref|NP_001099187.1| dihydropyrimidinase-like 2 [Rattus norvegicus], gi|1351260|sp|P47942.1|DPYL2_RAT RecName: Full=Dihydropyrimidinase-related protein 2; Short=DRP-2; AltName: Full=Turned on after division, 64 kDa protein; Short=TOAD-64; AltName: Full=Collapsin response mediator protein 2; Short=CRMP-2, gi|94730376|sp|O08553.2|DPYL2_MOUSE RecName: Full=Dihydropyrimidinase-related protein 2; Short=DRP-2; AltName: Full=ULIP 2 protein, gi|599966|emb|CAA86981.1| TOAD-64 [Rattus rattus], gi|38614412|gb|AAH62955.1| Dihydropyrimidinase-like 2 [Mus musculus],  gi|148704041|gb|EDL35988.1| dihydropyrimidinase-like 2 [Mus musculus], gi|149030338|gb|EDL85394.1| dihydropyrimidinase-like 2 [Rattus norvegicus]
2 unique peptides, 2 unique spectra, 2 total spectra, 23/572 amino acids (4% coverage)
M S Y Q G K K N I P R I T S D R L L I K G G K I V N D D Q S F Y A D I Y M E D G
L I K Q I G E N L I V P G G V K T I E A H S R M V I P G G I D V H T R F Q M P D
Q G M T S A D D F F Q G T K A A L A G G T T M I I D H V V P E P G T S L L A A F
D Q W R E W A D S K S C C D Y S L H V D I T E W H K G I Q E E M E A L V K D H G
V N S F L V Y M A F K D R F Q L T D S Q I Y E V L S V I R D I G A I A Q V H A E
N G D I I A E E Q Q R I L D L G I T G P E G H V L S R P E E V E A E A V N R S I
T I A N Q T N C P L Y V T K V M S K S A A E V I A Q A R K K G T V V Y G E P I T
A S L G T D G S H Y W S K N W A K A A A F V T S P P L S P D P T T P D F L N S L
L S C G D L Q V T G S A H C T F N T A Q K A V G K D N F T L I P E G T N G T E E
R M S V I W D K A V V T G K M D E N Q F V A V T S T N A A K V F N L Y P R K G R
I S V G S D A D L V I W D P D S V K T I S A K T H N S A L E Y N I F E G M E C R
G S P L V V I S Q G K I V L E D G T L H V T E G S G R Y I P R K P F P D F V Y K
R I K A R S R L A E L R G V P R G L Y D G P V C E V S V T P K T V T P A S S A K
T S P A K Q Q A P P V R N L H Q S G F S L S G A Q I D D N I P R R T T Q R I V A
P P G G R A N I T S L G  
 
 
 
Prohibitin 
gi|62664759 (100%), 27,717.2 Da
PREDICTED: similar to prohibitin [Rattus norvegicus], gi|109508393|ref|XP_001060250.1| PREDICTED: similar to prohibitin [Rattus norvegicus]
2 unique peptides, 2 unique spectra, 2 total spectra, 20/253 amino acids (8% coverage)
M A A K V F E S I G K F G L A L A V A G G V V N S A L Y N V D A A T D R F R G V
Q D I V V G E G T H F L I P W V Q K P I I F D C R S R P R K V P V I T G S K D L
Q N V N I T L R I L F R P V A S Q L P R I Y T S I G E D Y D E R V L P S I T T E
I L K S V V A R F D A G E L I T Q R E L V S R Q V S D D L T E R A A T F G L I L
D D V S L T H L T F G K E F T E A V E A K Q V A Q Q E A E R A R F V V E K A E Q
Q K K A A I I S A E G D S K A A E L I A N S L A T A G D G L I E L R K L E A A E
D I A Y Q L S R S R N I T
 
Rabs 
gi|157817539 (100%), 19,878.0 Da
RAB6B, member RAS oncogene family [Rattus norvegicus], gi|194221614|ref|XP_001496020.2| PREDICTED: similar to RAB6B, member RAS oncogene family [Equus caballus], gi|149018752|gb|EDL77393.1| RAB6B, member RAS oncogene family (predicted) [Rattus norvegicus]
4 unique peptides, 4 unique spectra, 4 total spectra, 41/175 amino acids (23% coverage)
M Y D S F D N T Y Q A T I G I D F L S K T M Y L E D R T V R L Q L W D T A G Q E
R F R S L I P S Y I R D S T V A V V V Y D I T N L N S F Q Q T S K W I D D V R T
E R G S D V I I M L V G N K T D L A D K R Q I T I E E G E Q R A K E L S V M F I
E T S A K T G Y N V K Q L F R R V A S A L P G M E N V Q E K S K E G M I D I K L
D K P Q E P P A S E G G C S C
 
 218 
gi|14249144 (100%), 24,489.0 Da
RAB11B, member RAS oncogene family [Rattus norvegicus], gi|78369332|ref|NP_001030468.1| RAB11B, member RAS oncogene family [Bos taurus], gi|190358517|ref|NP_004209.2| RAB11B, member RAS oncogene family [Homo sapiens],  gi |109123235|ref|XP_001093925.1| PREDICTED: RAB11B, member RAS oncogene family [Macaca mulatta],  gi|38258938|sp|Q15907.4|RB11B_HUMAN RecName: Full=Ras-related protein Rab-11B; AltName: Full=GTP-binding protein YPT3, gi|50403673|sp|O35509.4|RB11B_RAT RecName: Full=Ras-related protein Rab-11B, gi|108860922|sp|Q3MHP2.3|RB11B_BOVIN RecName: Full=Ras-related protein Rab-11B, gi |9837357|gb|AAG00542.1|AF286534_1 GTP-binding protein RAB11B [Rattus norvegicus], gi|20379070|gb|AAM21095.1|AF498947_1 small GTP binding protein RAB11B [Homo sapiens], gi|38303833|gb|AAH62041.1| RAB11B, member RAS oncogene family [Rattus norvegicus], gi|54695942|gb|AAV38343.1| RAB11B, member RAS oncogene family [Homo sapiens], gi|61355645|gb|AAX41161.1| RAB11B member RAS oncogene family [synthetic construct], gi|75773827|gb|AAI05163.1| RAB11B, member RAS oncogene family [Bos taurus], gi|82414868|gb|AAI10082.1| RAB11B, member RAS oncogene family [Homo sapiens], gi|90085246|dbj|BAE91364.1| unnamed protein product [Macaca fascicularis], gi |119589331|gb|EAW68925.1|  RAB11B, member RAS oncogene family, isoform CRA_a [Homo sapiens], gi|119589333|gb|EAW68927.1| RAB11B, member RAS oncogene family, isoform CRA_a [Homo sapiens], gi|149031659|gb|EDL86622.1|  RAB11B, member RAS oncogene family [Rattus norvegicus], gi|189066581|dbj|BAG35831.1| unnamed protein product [Homo sapiens], gi|194707448|gb|ACF87808.1| unknown [Zea mays]
2 unique peptides, 2 unique spectra, 2 total spectra, 19/218 amino acids (9% coverage)
M G T R D D E Y D Y L F K V V L I G D S G V G K S N L L S R F T R N E F N L E S
K S T I G V E F A T R S I Q V D G K T I K A Q I W D T A G Q E R Y R A I T S A Y
Y R G A V G A L L V Y D I A K H L T Y E N V E R W L K E L R D H A D S N I V I M
L V G N K S D L R H L R A V P T D E A R A F A E K N N L S F I E T S A L D S T N
V E E A F K N I L T E I Y R I V S Q K Q I A D R A A H D E S P G N N V V D I S V
P P T T D G Q K P N K L Q C C Q N L
 
gi|13027392 (100%), 23,504.0 Da
RAB7A, member RAS oncogene family [Rattus norvegicus], gi |1710001|sp|P09527.2|RAB7A_RAT RecName: Full=Ras-related protein Rab-7a; AltName: Full=Ras-related protein p23; AltName: Full=Ras-related protein BRL-RAS, gi|51247924|pdb|1VG0|B Chain B, The Crystal Structures Of The Rep-1 Protein In Complex With Monoprenylated Rab7 Protein, gi|51247926|pdb|1VG8|A Chain A, Gppnhp-Bound Rab7, gi|51247927|pdb|1VG8|B Chain B, Gppnhp-Bound Rab7, gi |51247928|pdb|1VG8|C Chain C, Gppnhp-Bound Rab7, gi |51247929|pdb|1VG8|D Chain D, Gppnhp-Bound Rab7, gi|9837359|gb|AAG00543.1|AF286535_1 GTP-binding protein RAB7 [Rattus norvegicus], gi|505565|emb|CAA31053.1| unnamed protein product [Rattus rattus], gi|47938948|gb|AAH72470.1| RAB7, member RAS oncogene family [Rattus norvegicus], gi|71891601|dbj|BAE16999.1| RAB7 [Rattus norvegicus], gi |71891603|dbj|BAE17000.1| RAB7 [Rattus norvegicus], gi|149036684|gb|EDL91302.1| RAB7, member RAS oncogene family, isoform CRA_a [Rattus norvegicus]
2 unique peptides, 2 unique spectra, 2 total spectra, 23/207 amino acids (11% coverage)
M T S R K K V L L K V I I L G D S G V G K T S L M N Q Y V N K K F S N Q Y K A T
I G A D F L T K E V M V D D R L V T M Q I W D T A G Q E R F Q S L G V A F Y R G
A D C C V L V F D V T A P N T F K T L D S W R D E F L I Q A S P R D P E N F P F
V V L G N K I D L E N R Q V A T K R A Q A W C Y S K N N I P Y F E T S A K E A I
N V E Q A F Q T I A R N A L K Q E T E V E L Y N E F P E P I K L D K N E R A K A
S A E S C S C
 
Tubulin 
gi|21746161 (100%), 49,953.1 Da
tubulin, beta [M us musculus], gi|29788768|ref|NP_821080.1| tubulin,  beta 2B [Homo sapiens], gi|110347600|ref|NP_001013908.2| tubulin, beta 2b [Rattus norv egicus], gi|74003816|ref|XP_848443.1| PREDICTE D: similar to tubulin, beta isoform 1 [Canis familiaris],  gi|74003822|ref|XP_856242.1| PREDICTED: similar to tubulin, beta isoform 4 [Canis familiaris], gi|109069455|ref|XP_001092807.1| PREDICTED: sim ilar to tubulin, beta isoform 4 [M acaca mulatta], gi|109069457|ref|XP_001092923.1| PREDICTED: similar to tubulin, beta isoform 5 [Macaca mulatta], gi|114605266|ref|XP_001162039.1| PREDICTED: hypothetical protein isoform 6 [Pan troglodytes],  gi|126322056|ref|XP_001368194.1|  PREDICTED: similar to Tubulin, beta 2B [Monodelphis domestica], gi|74761283|sp|Q9BVA1.1|TBB2B_HUMAN RecName: Full=Tubulin beta-2B chain, gi|81904211|sp|Q9CWF2.1|TBB2B_MOUSE RecName: Full=Tubulin beta-2B chain, gi|118573906|sp|Q6B856.2|TBB2B_BOVIN RecName: Full=Tubulin beta-2B chain,  gi|118573907|sp|Q3KRE8.1|TBB2B_RAT RecName: Full=Tubulin beta-2B chain; AltName: Full=T beta-15, gi|12655009|gb|AAH01352.1| Tubulin, beta 2B [Homo sapiens],  gi|12846474|dbj |BAB27182.1| unnamed protein product [Mus musculus], gi|39645753|gb|AAH63610.1| Tubulin, beta 2B [Homo sapiens], gi|48145693|emb|CAG33069.1| M GC8685 [Homo sapiens], gi|54696722|gb|AAV38733.1| tubulin,  beta polypeptide paralog [Homo sapiens], gi|57209349|emb|CAI40952.1| novel protein similar to tubulin beta polypeptide TUBB [Homo sapiens],  gi|76779404|gb|AAI05755.1| Tubulin, beta 2b [Rattus norvegicus], gi|119575529|gb|EAW55125.1| tubulin,  beta 2B, isoform CRA_a [Homo sapiens], gi|148708940|gb|EDL40886.1| mCG1395 [Mus musculus], gi|149045229|gb|EDL98315.1| rCG44217 [Rattus norv egicus], gi|158259889|dbj|BAF82122.1| unnamed protein product [Homo sapiens], gi |187951269|gb|AAI38936.1| Tubulin, beta 2b [Mus musculus], gi |187953053|gb|AAI38937.1| Tubulin, beta 2b [Mus musculus]
10 unique peptides, 10 unique spectra, 12 total spectra, 106/445 amino acids (24% cov erage)
M R E I V H I Q A G Q C G N Q I G A K F W E V I S D E H G I D P T G S Y H G D S
D L Q L E R I N V Y Y N E A T G N K Y V P R A I L V D L E P G T M D S V R S G P
F G Q I F R P D N F V F G Q S G A G N N W A K G H Y T E G A E L V D S V L D V V
R K E S E S C D C L Q G F Q L T H S L G G G T G S G M G T L L I S K I R E E Y P
D R I M N T F S V M P S P K V S D T V V E P Y N A T L S V H Q L V E N T D E T Y
C I D N E A L Y D I C F R T L K L T T P T Y G D L N H L V S A T M S G V T T C L
R F P G Q L N A D L R K L A V N M V P F P R L H F F M P G F A P L T S R G S Q Q
Y R A L T V P E L T Q Q M F D S K N M M A A C D P R H G R Y L T V A A I F R G R
M S M K E V D E Q M L N V Q N K N S S Y F V E W I P N N V K T A V C D I P P R G
L K M S A T F I G N S T A I Q E L F K R I S E Q F T A M F R R K A F L H W Y T G
E G M D E M E F T E A E S N M N D L V S E Y Q Q Y Q D A T A D E Q G E F E E E E
G E D E A  
 
 
gi|12963615 (100%), 50,418.7 Da
tubulin, beta 3 [Mus musculus], gi|145966774|ref|NP_640347.2| tubulin, beta 3 [Rattus norv egicus], gi|20455323|sp|Q9ERD7.1|TBB3_MOUSE RecName: Full=Tubulin beta-3 chain, gi|81918226|sp|Q4QRB4.1|TBB3_RAT RecName: Full=Tubulin beta-3 chain; AltName: Full=Neuron-specific class III beta-tubulin, gi|10998840|gb|AAG26010.1|AF312873_1 tubulin beta-3 [M us musculus], gi|12849331|dbj |BAB28299.1| unnamed protein product [Mus musculus], gi|21595026|gb|AAH31357.1| Tubulin, beta 3 [Mus musculus], gi |26341868|dbj |BAC34596.1| unnamed protein product [Mus musculus], gi |56972196|gb|AAH88749.1| Tubulin, beta 3 [Mus musculus], gi|67677915|gb|AAH97281.1|  Tubb3 protein [Rattus norv egicus], gi|148679795|gb|EDL11742.1| tubulin, beta 3 [Mus musculus], gi|149038450|gb|EDL92810.1| rCG51321, isoform CRA_a [Rattus norv egicus]
5 unique peptides, 5 unique spectra, 5 total spectra, 127/450 amino acids (28% cov erage)
M R E I V H I Q A G Q C G N Q I G A K F W E V I S D E H G I D P S G N Y V G D S
D L Q L E R I S V Y Y N E A S S H K Y V P R A I L V D L E P G T M D S V R S G A
F G H L F R P D N F I F G Q S G A G N N W A K G H Y T E G A E L V D S V L D V V
R K E C E N C D C L Q G F Q L T H S L G G G T G S G M G T L L I S K V R E E Y P
D R I M N T F S V V P S P K V S D T V V E P Y N A T L S I H Q L V E N T D E T Y
C I D N E A L Y D I C F R T L K L A T P T Y G D L N H L V S A T M S G V T T S L
R F P G Q L N A D L R K L A V N M V P F P R L H F F M P G F A P L T A R G S Q Q
Y R A L T V P E L T Q Q M F D A K N M M A A C D P R H G R Y L T V A T V F R G R
M S M K E V D E Q M L A I Q S K N S S Y F V E W I P N N V K V A V C D I P P R G
L K M S S T F I G N S T A I Q E L F K R I S E Q F T A M F R R K A F L H W Y T G
E G M D E M E F T E A E S N M N D L V S E Y Q Q Y Q D A T A E E E G E M Y E D D
D E E S E A Q G P K  
 219 
gi|223556 (100%), 50,241.8 Da
tubulin alpha
12 unique peptides, 13 unique spectra, 14 total spectra, 159/451 amino acids (35% cov erage)
M R E C I S I H V G Q A G V Q I G N A C W E L Y C L E H G I Q P D G Q M P S D K
T I G G G D D S F N T F F S E T G A G K H V P R A V F V D L E P T V I D E V R T
G T Y R Q L F H P E Q L I T G K E D A A N N Y A R G H Y T I G K E I I D L V L D
R I R K L A D Q C T G L Q G F L V F H S F G G G T G S G F T S L L M E R L S V D
Y G K K S K L E F S I Y P A P Q V S T A V V E P Y N S I L T T H T T L E H S D C
A F M V D N E A I Y D I C R R N L D I E R P T Y T N L N R L I G Q I V S S I T A
S L R F D G A L N V D L T E F Q T N L V P Y P R I H F P L A T Y A P V I S A E K
A Y H E Q L S V A E I T N A C F E P A N Q M V K C D P R H G K Y M A C C L L Y R
G D V V P K D V N A A I A T I K T K R T I Q F V D W C P T G F K V G I N Y Q P P
T V V P G G D L A K V Q R A V C M L S N T T A I A E A W A R L D H K F D L M Y A
K R A F V H W Y V G E G M E E G E F S E A R E D M A A L E K D Y E E V G V D S V
E Y E G E E E G E E Y  
 
 
Mitochondrial 
gi|13324704 (100%), 24,297.4 Da
GrpE-like 1, mitochondrial [Rattus norvegicus], gi|6226823|sp|P97576.2|GRPE1_RAT RecName: Full=GrpE protein homolog 1,  mitochondrial; AltName: Full=Mt-GrpE#1; Flags: Precursor,  gi|2804584|gb|AAC53534.1| mt-GrpE#1 precursor, gi|67678103|gb|AAH97312.1| GrpE-like 1, mitochondrial [Rattus norvegicus], gi |149047377|gb|EDM00047.1|  GrpE-like 1, mitochondrial [Rattus norvegicus]
12 unique peptides, 13 unique spectra, 15 total spectra, 120/217 amino acids (55% coverage)
M A A R C V R L A R R S L P A L A L S F R P S P R L L C T A T K Q K N N G Q N L
E E D L G H C E P K T D P S S A D K T L L E E K V K L E E Q L K E T M E K Y K R
A L A D T E N L R Q R S Q K L V E E A K L Y G I Q G F C K D L L E V A D I L E K
A T Q S V P K E E V S N N N P H L K S L Y E G L V M T E V Q I Q K V F T K H G L
L R L D P I G A K F D P Y E H E A L F H T P V E G K E P G T V A L V S K V G Y K
L H G R T L R P A L V G V V K D A
 
 
